[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20210107981A1 - Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies - Google Patents

Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies Download PDF

Info

Publication number
US20210107981A1
US20210107981A1 US17/068,477 US202017068477A US2021107981A1 US 20210107981 A1 US20210107981 A1 US 20210107981A1 US 202017068477 A US202017068477 A US 202017068477A US 2021107981 A1 US2021107981 A1 US 2021107981A1
Authority
US
United States
Prior art keywords
sequence
seq
aspects
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/068,477
Inventor
Alice Yam
Ryan Stafford
Aaron Sato
John Lee
Avinash Gill
Junhao Yang
Heather Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutro Biopharma Inc
Original Assignee
Sutro Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc filed Critical Sutro Biopharma Inc
Priority to US17/068,477 priority Critical patent/US20210107981A1/en
Publication of US20210107981A1 publication Critical patent/US20210107981A1/en
Priority to US18/110,114 priority patent/US20230203165A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • antibodies with binding specificity for PD-1 and compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions and kits. Also provided are methods of using anti-PD-1 antibodies for therapeutic and diagnostic purposes.
  • PD-1 Programmed cell death protein 1
  • CD279 is a cell surface protein molecule that belongs to the immunoglobulin superfamily. It is expressed on T and B lymphocytes and macrophages, and plays a role in cell fate and differentiation. See Ishida et al., EMBO J., 1992, 11:3887-3895, incorporated by reference in its entirety. Activation of PD-1 is thought to negatively regulate the immune response. See Blank et al., Cancer Immunol. Immunother., 2007, 56:739-745; and Freeman et al., J. Exp. Med., 2000, 192:1027-1034, each of which is incorporated by reference in its entirety.
  • PD-1 has two known ligands, PD-L1 and PD-L2, which are both members of the B7 family. See Freeman et al., supra; and Latchman et al., Nat. Immunol., 2001, 2:261-268, each of which is incorporated by reference in its entirety. The interaction between PD-1 and these ligands is thought to play a role in a variety of diseases, including cancer (see Ribas and Tumeh, Clin. Cancer Res., 2014, Jun.
  • the antibodies that selectively bind PD-1.
  • the antibodies bind human PD-1.
  • the antibodies also bind homologs of human PD-1.
  • the homolog is a cynomolgus monkey homolog.
  • the homolog is a murine homolog.
  • the antibodies bind to human PD-1, a cynomolgus monkey homolog, and a murine homolog.
  • the antibodies comprise at least one CDR sequence defined by a consensus sequence provided in this disclosure. In some embodiments, the antibodies comprise an illustrative CDR, V H , or V L sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions.
  • compositions and kits comprising the antibodies.
  • the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used.
  • the pharmaceutical composition is a composition for parenteral administration.
  • the method is a method of treatment. In some embodiments, the method is a diagnostic method. In some embodiments, the method is an analytical method. In some embodiments, the method is a method of purifying and/or quantifying PD-1.
  • the antibodies are used to treat a disease or condition.
  • the disease or condition is selected from a cancer, autoimmune disease, and infection.
  • FIG. 1 provides a comparison of the Kabat and Chothia numbering systems for CDR-H1. Adapted from Martin A. C. R. (2010). Protein Sequence and Structure Analysis of Antibody Variable Domains. In R. Kontermann & S. Dübel (Eds.), Antibody Engineering vol. 2 (pp. 33-51). Springer-Verlag, Berlin Heidelberg.
  • FIG. 2 provides a chart of tumor volume over 17-days of treatment with various anti-PD-1 antibodies, as described in Example 15.
  • FIG. 3 provides a chart of interferon gamma (IFN-g) secretion in a cytomegalovirus (CMV) recall assay, as described in Example 16.
  • IFN-g interferon gamma
  • CMV cytomegalovirus
  • FIG. 4 provides a chart of interferon gamma (IFN-g) secretion in a mixed lymphocyte response (MLR) assay, as described in Example 17.
  • IFN-g interferon gamma
  • MLR mixed lymphocyte response
  • FIG. 5 provides a chart of mouse survival in a model of graft versus host disease, as described in Example 18.
  • the term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ⁇ 10%, ⁇ 5%, or ⁇ 1%. In certain embodiments, the term “about” indicates the designated value ⁇ one standard deviation of that value.
  • a sentence stating that “if ⁇ 2 is A, then ⁇ 3 is not D; ⁇ 5 is not S; or ⁇ 6 is not S; or combinations thereof” includes the following combinations when ⁇ 2 is A: (1) ⁇ 3 is not D; (2) ⁇ 5 is not S; (3) ⁇ 6 is not S; (4) ⁇ 3 is not D; as is not S; and ⁇ 6 is not S; (5) ⁇ 3 is not D and ⁇ 5 is not S; (6) ⁇ 3 is not D and ⁇ 6 is not S; and (7) ⁇ 5 is not S and ⁇ 6 is not S.
  • PD-1 and “PD-1 antigen” are used interchangeably herein. Unless specified otherwise, the terms include any variants, isoforms and species homologs of human PD-1 that are naturally expressed by cells, or that are expressed by cells transfected with a PD-1 gene.
  • PD-1 proteins include full-length PD-1 (e.g., human PD-1; GI: 167857792; SEQ ID NO: 1; extracellular domain: Pro21-Gln167), as well as alternative splice variants of PD-1, such as PD-1 ⁇ ex2, PD-1 ⁇ ex3, PD-1 ⁇ ex2,3, and PD-1 ⁇ ex2,3,4.
  • PD-1 proteins include murine PD-1 (e.g., SEQ ID NO: 299; extracellular domain: Leu25-Gln167).
  • PD-1 proteins include cynomolgus PD-1 (e.g., SEQ ID NO: 300; extracellular domain: Pro21-Gln167).
  • immunoglobulin refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, Pa. Briefly, each heavy chain typically comprises a heavy chain variable region (V H ) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, C H1 , C H2 , and C H3 . Each light chain typically comprises a light chain variable region (V L ) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
  • antibody describes a type of immunoglobulin molecule and is used herein in its broadest sense.
  • An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), and antibody fragments.
  • Antibodies comprise at least one antigen-binding domain.
  • One example of an antigen-binding domain is an antigen binding domain formed by a V H -V L dimer.
  • a “PD-1 antibody,” “anti-PD-1 antibody,” “PD-1 Ab,” “PD-1-specific antibody” or “anti-PD-1 Ab” is an antibody, as described herein, which binds specifically to the antigen PD-1. In some embodiments, the antibody binds the extracellular domain of PD-1.
  • the V H and V L regions may be further subdivided into regions of hypervariability (“hypervariable regions (HVRs);” also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved.
  • the more conserved regions are called framework regions (FRs).
  • Each V H and V L generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
  • the CDRs are involved in antigen binding, and confer antigen specificity and binding affinity to the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, Md., incorporated by reference in its entirety.
  • the light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
  • the heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • the IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
  • the amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997 , J. Mol. Biol., 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996 , J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated by reference in its entirety.
  • Kabat numbering scheme
  • Al-Lazikani et al. 1997 , J. Mol. Biol., 273:927-948
  • Chothia numbering scheme
  • Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes.
  • residue numbering is provided using both the Kabat and Chothia numbering schemes.
  • FIG. 1 provides a comparison of the Kabat and Chothia numbering schemes for CDR-H1. See Martin (2010), supra.
  • the numbering scheme used for identification of a particular CDR herein is the Kabat/Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge, the numbering scheme is specified as either Kabat or Chothia.
  • EU numbering scheme is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
  • antibody fragment comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody.
  • Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab′) 2 fragments, Fab′ fragments, scFv (sFv) fragments, and scFv-Fc fragments.
  • “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.
  • Fab fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (Cm) of the heavy chain.
  • Fab fragments may be generated, for example, by papain digestion of a full-length antibody.
  • F(ab′) 2 ” fragments contain two Fab′ fragments joined, near the hinge region, by disulfide bonds.
  • F(ab′) 2 fragments may be generated, for example, by pepsin digestion of an intact antibody.
  • the F(ab′) fragments can be dissociated, for example, by treatment with ß-mercaptoethanol.
  • Single-chain Fv or “sFv” or “scFv” antibody fragments comprise a VII domain and a V L domain in a single polypeptide chain.
  • the V H and V L are generally linked by a peptide linker.
  • scFv-Fc” fragments comprise an scFv attached to an Fc domain.
  • an Fc domain may be attached to the C-terminal of the scFv.
  • the Fc domain may follow the V H or V L , depending on the orientation of the variable domains in the scFv (i.e., V H -V L or V L -V H ). Any suitable Fc domain known in the art or described herein may be used.
  • the Fc domain is an IgG1 Fc domain (e.g., SEQ ID NO: 295).
  • the linker is (G 4 S) 3 (see SEQ ID NO: 298).
  • a monoclonal antibody refers to an antibody from a population of substantially homogeneous antibodies.
  • a population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts.
  • a monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies.
  • the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones.
  • the selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and/or to reduce its immunogenicity in a subject.
  • chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
  • “Humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody.
  • a humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody).
  • the donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect.
  • selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody.
  • Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function.
  • a “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.
  • an “isolated antibody” is one that has been separated and/or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials.
  • an isolated antibody is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator.
  • an isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain.
  • An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody's natural environment is not present.
  • an isolated antibody is prepared by at least one purification step.
  • an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by weight of an antibody, the remainder of the weight comprising the weight of other solutes dissolved in the solvent.
  • Binding affinity refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K D ). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument.
  • SPR surface plasmon resonance
  • the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction.
  • Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule.
  • Specific binding can also be determined by competition with a control molecule that is similar to the target, such as an excess of non-labeled target. In that case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by the excess non-labeled target.
  • k d (sec ⁇ 1 ), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the k off value.
  • k a (M ⁇ 1 ⁇ sec ⁇ 1 ), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the k on value.
  • K D K d /k a .
  • an “affinity matured” antibody is one with one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen, compared to a parent antibody which does not possess the alteration(s).
  • an affinity matured antibody has nanomolar or picomolar affinity for the target antigen.
  • Affinity matured antibodies may be produced using a variety of methods known in the art. For example, Marks et al. ( Bio/Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by V H and V L domain shuffling. Random mutagenesis of CDR and/or framework residues is described by, for example, Barbas et al. ( Proc. Nat. Acad.
  • the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (e.g., PD-1).
  • an antigen e.g., PD-1
  • PD-1 is coated on a plate and allowed to bind a first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces binding of the second antibody, then the antibodies compete.
  • the term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of the order in which they are added. In some embodiments, one antibody reduces binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
  • epitope means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and/or sugar side chains and may have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to PD-1 variants with different point-mutations.
  • Percent “identity” between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, or CLUSTAL OMEGA software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • a “conservative substitution” or a “conservative amino acid substitution,” refers to the substitution of one or more amino acids with one or more chemically or functionally similar amino acids. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as “conservatively modified variants.” Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. By way of example, the following groups of amino acids are considered conservative substitutions for one another.
  • amino acid refers to the twenty common naturally occurring amino acids.
  • Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).
  • Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), as
  • Treating” or “treatment” of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder that exists in a subject.
  • “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject.
  • “treating” or “treatment” includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both.
  • “treating” or “treatment” includes delaying or preventing the onset of the disease or disorder.
  • terapéuticaally effective amount refers to an amount of an antibody or composition that when administered to a subject is effective to treat a disease or disorder.
  • the term “subject” means a mammalian subject. Exemplary subjects include, but are not limited to humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, avians, goats and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has cancer, an autoimmune disease or condition, and/or an infection that can be treated with an antibody provided herein. In some embodiments, the subject is a human that is suspected to have cancer, an autoimmune disease or condition, and/or an infection.
  • antibodies that selectively bind human PD-1 are provided herein.
  • the antibody selectively binds to the extracellular domain of human PD-1.
  • the antibody selectively binds to one or more of full-length human PD-1, PD-1 ⁇ ex2, PD-1 ⁇ ex3, PD-1 ⁇ ex2,3, and PD-1 ⁇ ex2,3,4. See Nielsen et al., Cellular Immunology, 2005, 235:109-116, incorporated by reference in its entirety.
  • the antibody binds to homologs of human PD-1. In some aspects, the antibody binds to a homolog of human PD-1 from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats and sheep. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a murine homolog.
  • the antibody has one or more CDRs having particular lengths, in terms of the number of amino acid residues.
  • the Chothia CDR-H1 of the antibody is 6, 7, 8, or 9 residues in length.
  • the Kabat CDR-H1 of the antibody is 4, 5, 6, or 7 residues in length.
  • the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length.
  • the Kabat CDR-H2 of the antibody is 15, 16, 17, or 18 residues in length.
  • the Kabat/Chothia CDR-H3 of the antibody is 5, 6, 7, 8, 9, 10, 11, or 12 residues in length.
  • the Kabat/Chothia CDR-L1 of the antibody is 9, 10, 11, 12, 13, 14, 15, or 16 residues in length. In some aspects, the Kabat/Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some aspects, the Kabat/Chothia CDR-L3 of the antibody is 8, 9, 10, 11, or 12 residues in length.
  • the antibody comprises a light chain.
  • the light chain is a kappa light chain.
  • the light chain is a lambda light chain.
  • the antibody comprises a heavy chain.
  • the heavy chain is an IgA.
  • the heavy chain is an IgD.
  • the heavy chain is an IgE.
  • the heavy chain is an IgG.
  • the heavy chain is an IgM.
  • the heavy chain is an IgG1.
  • the heavy chain is an IgG2.
  • the heavy chain is an IgG3.
  • the heavy chain is an IgG4.
  • the heavy chain is an IgA1. In some aspects, the heavy chain is an IgA2.
  • the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab′) 2 fragment. In some aspects, the antibody fragment is a Fab′ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.
  • the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.
  • the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.
  • the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure.
  • the antibody inhibits the binding of PD-1 to its ligands. In some aspects, the antibody inhibits the binding of PD-1 to PD-L1. In some aspects, the antibody inhibits the binding of PD-1 to PD-L2. In some aspects, the antibody inhibits the binding of PD-1 to PD-L1 and PD-L2.
  • the antibodies provided herein may be useful for the treatment of a variety of diseases and conditions, including cancers, autoimmune diseases, and infections.
  • the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115.
  • the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120.
  • the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125.
  • the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130.
  • the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 309. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 310. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 311. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 312.
  • the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 313. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 314. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 315.
  • the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the CDR-H3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 132-136. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 132. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 133. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 134. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 135. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 136.
  • the antibody comprises a V H sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in this disclosure, and variants thereof.
  • the antibody comprises a V H sequence comprising one or more Kabat CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-H sequences provided in this disclosure, and variants thereof.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126.
  • the antibody comprises a VII sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 309. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 310. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 311.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 312. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 313. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 314. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 315.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331.
  • the antibody comprises a VII sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 91. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. In some aspects, the antibody comprises a VII sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 331.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 31. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 32. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 33.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 34 In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 35. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 36. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 37.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 38. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 39. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 40. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 41.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 42. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 43. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 44. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 45.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 46. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 47. In some aspects, the antibody comprises a VII sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 48. In some aspects, the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 49.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331.
  • the Kabat CDR-H3 sequence and the Kabat CDR-H2 sequence are both from a single illustrative V H sequence provided in this disclosure.
  • the Kabat CDR-H3 and Kabat CDR-H2 are both from a single illustrative V H sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49.
  • the Kabat CDR-H3 sequence and the Kabat CDR-H1 sequence are both from a single illustrative V H sequence provided in this disclosure.
  • the Kabat CDR-H3 and Kabat CDR-H1 are both from a single illustrative VII sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49 and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331.
  • the Kabat CDR-H1 sequence and the Kabat CDR-H2 sequence are both from a single illustrative V H sequence provided in this disclosure.
  • the Kabat CDR-H1 and Kabat CDR-H2 are both from a single illustrative V H sequence selected from SEQ ID NOs: 246-264. 2.2.1.7. Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3
  • the antibody comprises a V H sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315.
  • the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 sequence are all from a single illustrative VII sequence provided in this disclosure.
  • the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative V H sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • the V H sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
  • the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the V H sequences provided herein do not comprise certain Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequences.
  • the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 108-112 or 132-136. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 108. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 109. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 110. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 111.
  • the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 112. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 132. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 133. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 134. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 135. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 136.
  • the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 55-59 or 103-107. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 55. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 56. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 57. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 58.
  • the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 59. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 103. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 104. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 105. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 106. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 107.
  • the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 2-6 or 50-54. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 2. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 3. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 4. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 5.
  • the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 6. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 50. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 51. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 52. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 53. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 54.
  • the antibody comprises a V H sequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in this disclosure, and variants thereof.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a VII sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 309. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 310. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 311.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 312. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 313. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 314. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 315.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 60. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 61. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 62.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 63. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 64. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 65. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 66.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 67. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 68. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 69. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 70.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 71. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 72. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 73. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 74.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 75. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 76. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 78.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 7. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 8. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 9.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 10 In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 11. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 12. In some aspects, the antibody comprises a VII sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 13.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 14. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 15. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 16. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 17.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 18. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 19. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 20. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 21.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 22. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 23. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 24. In some aspects, the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 25.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78.
  • the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence are both from a single illustrative V H sequence provided in this disclosure.
  • the Chothia CDR-H3 and Chothia CDR-H2 are both from a single illustrative V H sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25.
  • the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence are both from a single illustrative V H sequence provided in this disclosure.
  • the Chothia CDR-H3 and Chothia CDR-H1 are both from a single illustrative VII sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25 and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78.
  • the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence are both from a single illustrative V H sequence provided in this disclosure.
  • the Chothia CDR-H1 and Chothia CDR-H2 are both from a single illustrative V H sequence selected from SEQ ID NOs: 246-264.
  • the antibody comprises a V H sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315.
  • the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR-H3 sequence are all from a single illustrative V H sequence provided in this disclosure.
  • the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative V H sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • the V H sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
  • the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the V H sequences provided herein do not comprise certain Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequences.
  • the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 108-112 or 132-136. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 108. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 109. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 110. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 111.
  • the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 112. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 132. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 133. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 134. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 135. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 136.
  • the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 79-83. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 79. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 80. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 81. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 82. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 83.
  • the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 26-30. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 26. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 27. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 28. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 29. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 30.
  • the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 246-264 and 316-322. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 246. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 247. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 248. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 249.
  • the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 250. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 251. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 252. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 253. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 254.
  • the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 255 (with or without a serine prepended to the sequence). In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 256. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 257. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 258. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 259.
  • the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 260. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 261. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 262. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 263. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 264.
  • the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 316. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 317. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 318. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 319. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 320.
  • the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 321. In some aspects, the antibody comprises a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 322.
  • V H sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative V H sequence provided in this disclosure.
  • the V H sequence comprises, consists of, or consists essentially of a variant of an illustrative V H sequence provided in this disclosure. In some aspects, the V H sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative V H sequences provided in this disclosure.
  • the V H sequence comprises, consists of, or consists essentially of any of the illustrative V H sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions.
  • the amino acid substitutions are conservative amino acid substitutions.
  • the V H sequences provided herein do not comprise certain V H sequences.
  • the V H sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 265-269. In some aspects, the V H sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 265. In some aspects, the V H sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 266. In some aspects, the V H sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 267. In some aspects, the V H sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 268. In some aspects, the V H sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 269.
  • the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 200. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 201. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 202. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 203.
  • the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 204. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 205. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 206. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 207. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 208.
  • the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 209. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 210. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 211. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 212. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 213.
  • the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 214. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 215. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 216. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 217. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 218.
  • the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the CDR-L3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 195-199 or 219-223. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 195. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 196. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 197. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 198.
  • the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 199. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 219. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 220. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 221. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 222. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 223.
  • the antibody comprises a V L sequence comprising one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-L sequences provided in this disclosure, and variants thereof.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 200. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 201. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 202.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 203. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 204. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 205. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 206.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 207. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 208. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 209. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 210.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 211. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 212. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 213. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 214.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 215. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 216. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 217. In some aspects, the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 218.
  • the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 171. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 172. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 173.
  • the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 174. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 175. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 176. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 177.
  • the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 178. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 179. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 180. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 181.
  • the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 182. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 183. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 184. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 185.
  • the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 186. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 187. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 188. In some aspects, the antibody comprises a V L sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 189.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 145. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 146. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 147. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 148.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. In some aspects, the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189.
  • the CDR-L3 sequence and the CDR-L2 sequence are both from a single illustrative V L sequence provided in this disclosure.
  • the CDR-L3 and CDR-L2 are both from a single illustrative V L sequence selected from SEQ ID NOs: 270-288.
  • the antibody comprises a V L sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218 and a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160.
  • the CDR-L3 sequence and the CDR-L1 sequence are both from a single illustrative V L sequence provided in this disclosure.
  • the CDR-L3 and CDR-L1 are both from a single illustrative V L sequence selected from SEQ ID NOs: 270-288.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189.
  • the CDR-L1 sequence and the CDR-L2 sequence are both from a single illustrative V L sequence provided in this disclosure.
  • the CDR-L1 and CDR-L2 are both from a single illustrative V L sequence selected from SEQ ID NOs: 270-288.
  • the antibody comprises a V L sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218.
  • the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all from a single illustrative V L sequence provided in this disclosure.
  • the CDR-L1, CDR-L2, and CDR-L3 are all from a single illustrative V L sequence selected from SEQ ID NOs: 270-288.
  • the V L sequences provided herein comprise a variant of an illustrative CDR-L3, CDR-L2, and/or CDR-L1 sequence provided in this disclosure.
  • the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the V L sequences provided herein do not comprise certain CDR-L3, CDR-L2, and/or CDR-L1 sequences.
  • the CDR-L3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 195. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 196. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 197. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 198.
  • the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 199. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 219. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 220. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 221. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 222. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 223.
  • the CDR-L2 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 166-170 or 190-194. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 190. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 166. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 167. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 168.
  • the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 169. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 170. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 191. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 192. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 193. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 194.
  • the CDR-L1 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 137-141 or 161-165. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 137. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 138. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 139. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 140.
  • the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 141. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 161. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 162. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 163. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 164. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 165.
  • the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 270-288. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 270. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 281. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 282. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 283.
  • the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 284. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 285. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 286. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 287. In some aspects, the antibody comprises a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 288.
  • V L sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative V L sequence provided in this disclosure.
  • the V L sequence comprises, consists of, or consists essentially of a variant of an illustrative V L sequence provided in this disclosure. In some aspects, the V L sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity with any of the illustrative V L sequences provided in this disclosure.
  • the V L sequence comprises, consists of, or consists essentially of any of the illustrative V L sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions.
  • the amino acid substitutions are conservative amino acid substitutions.
  • the V L sequences provided herein do not comprise certain V L sequences.
  • the V L sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 289-293. In some aspects, the V L sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 289. In some aspects, the V L sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 290. In some aspects, the V L sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 291. In some aspects, the V L sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 292. In some aspects, the V L sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 293.
  • the antibody comprises a CDR-H3 sequence and a CDR-L3 sequence.
  • the CDR-H3 sequence is part of a VII and the CDR-L3 sequence is part of a V L .
  • the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 113-131 and 309-315
  • the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 200-218.
  • the CDR-H3 sequence is SEQ ID NO: 113, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 114, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 115, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 116, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 117, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 118, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 119, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 120, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 121, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 122, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 123, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 124, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 125, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 126, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 127, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 128, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 129, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 130, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 131, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 309, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 310, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 311, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 312, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 313, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 314, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3 sequence is SEQ ID NO: 315, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218.
  • the CDR-L3 sequence is SEQ ID NO: 200.
  • the CDR-L3 sequence is SEQ ID NO: 201.
  • the CDR-L3 sequence is SEQ ID NO: 202.
  • the CDR-L3 sequence is SEQ ID NO: 203.
  • the CDR-L3 sequence is SEQ ID NO: 204.
  • the CDR-L3 sequence is SEQ ID NO: 205.
  • the CDR-L3 sequence is SEQ ID NO: 206.
  • the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • the CDR-H3-CDR-L3 pairs provided herein comprise a variant of an illustrative CDR-H3 and/or CDR-L1 sequence provided in this disclosure.
  • the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • the CDR-H3-CDR-L3 pairs provided herein do not comprise certain CDR-H3-CDR-L3 pairs.
  • the CDR-H3 sequence is not selected from SEQ ID NOs: 108-112 or 132-136, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-H3 sequence is not SEQ ID NO: 108, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 109, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 110, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 111, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 112, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 132, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 133, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 134, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 135, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the CDR-H3 sequence is not SEQ ID NO: 136, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • the CDR-L3 sequence is not SEQ ID NO: 195.
  • the CDR-L3 sequence is not SEQ ID NO: 196.
  • the CDR-L3 sequence is not SEQ ID NO: 197.
  • the CDR-L3 sequence is not SEQ ID NO: 198.
  • the CDR-L3 sequence is not SEQ ID NO: 199.
  • the CDR-L3 sequence is not SEQ ID NO: 219.
  • the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • the antibody comprises a V H sequence and a V L sequence.
  • the V H sequence is a V H sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 246-264 and 316-322
  • the V L sequence is a V L sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 270-288.
  • the V H sequence is SEQ ID NO: 246, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 247, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 248, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 249, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 250, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 251, and the V L sequence is selected from SEQ ID NOs: 270-288. In some aspects, the V L sequence is SEQ ID NO: 270. In some aspects, the V L sequence is SEQ ID NO: 271. In some aspects, the V L sequence is SEQ ID NO: 272. In some aspects, the V L sequence is SEQ ID NO: 273. In some aspects, the V L sequence is SEQ ID NO: 274. In some aspects, the V L sequence is SEQ ID NO: 275. In some aspects, the V L sequence is SEQ ID NO: 276. In some aspects, the V L sequence is SEQ ID NO: 277. In some aspects, the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 252, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 253, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 254, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 255 (with or without a serine prepended to the sequence), and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278. In some aspects, the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 256, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 257, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 258, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 259, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 260, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 261, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 262, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 263, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 264, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 316, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 317, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 318, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 319, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 320, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 321, and the V L sequence is selected from SEQ ID NOs: 270-288. In some aspects, the V L sequence is SEQ ID NO: 270. In some aspects, the V L sequence is SEQ ID NO: 271. In some aspects, the V L sequence is SEQ ID NO: 272. In some aspects, the V L sequence is SEQ ID NO: 273. In some aspects, the V L sequence is SEQ ID NO: 274. In some aspects, the V L sequence is SEQ ID NO: 275. In some aspects, the V L sequence is SEQ ID NO: 276. In some aspects, the V L sequence is SEQ ID NO: 277. In some aspects, the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • the V H sequence is SEQ ID NO: 322, and the V L sequence is selected from SEQ ID NOs: 270-288.
  • the V L sequence is SEQ ID NO: 270.
  • the V L sequence is SEQ ID NO: 271.
  • the V L sequence is SEQ ID NO: 272.
  • the V L sequence is SEQ ID NO: 273.
  • the V L sequence is SEQ ID NO: 274.
  • the V L sequence is SEQ ID NO: 275.
  • the V L sequence is SEQ ID NO: 276.
  • the V L sequence is SEQ ID NO: 277.
  • the V L sequence is SEQ ID NO: 278.
  • the V L sequence is SEQ ID NO: 279. In some aspects, the V L sequence is SEQ ID NO: 280. In some aspects, the V L sequence is SEQ ID NO: 281. In some aspects, the V L sequence is SEQ ID NO: 282. In some aspects, the V L sequence is SEQ ID NO: 283. In some aspects, the V L sequence is SEQ ID NO: 284. In some aspects, the V L sequence is SEQ ID NO: 285. In some aspects, the V L sequence is SEQ ID NO: 286. In some aspects, the V L sequence is SEQ ID NO: 287. In some aspects, the V L sequence is SEQ ID NO: 288.
  • V H -V L pairs provided herein comprise a variant of an illustrative V H and/or V L sequence provided in this disclosure.
  • the V H sequence comprises, consists of, or consists essentially of a variant of an illustrative V H sequence provided in this disclosure. In some aspects, the V H sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity with any of the illustrative V H sequences provided in this disclosure.
  • the V H sequence comprises, consists of, or consists essentially of any of the illustrative V H sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions.
  • the amino acid substitutions are conservative amino acid substitutions.
  • the V L sequence comprises, consists of, or consists essentially of a variant of an illustrative V L sequence provided in this disclosure. In some aspects, the V L sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity with any of the illustrative V L sequences provided in this disclosure.
  • the V L sequence comprises, consists of, or consists essentially of any of the illustrative V L sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions.
  • the amino acid substitutions are conservative amino acid substitutions.
  • the V H -V L pairs provided herein do not comprise certain V H -V L pairs.
  • the V H sequence is not selected from SEQ ID NOs: 265-269, and the V L sequence is not selected from SEQ ID NOs: 289-293.
  • the V H sequence is not SEQ ID NO: 265, and the V L sequence is not selected from SEQ ID NO: 289-293. In some aspects, the V L sequence is not SEQ ID NO: 289. In some aspects, the V L sequence is not SEQ ID NO: 290. In some aspects, the V L sequence is not SEQ ID NO: 291. In some aspects, the V L sequence is not SEQ ID NO: 292. In some aspects, the V L sequence is not SEQ ID NO: 293.
  • the V H sequence is not SEQ ID NO: 266, and the V L sequence is not selected from SEQ ID NO: 289-293. In some aspects, the V L sequence is not SEQ ID NO: 289. In some aspects, the V L sequence is not SEQ ID NO: 290. In some aspects, the V L sequence is not SEQ ID NO: 291. In some aspects, the V L sequence is not SEQ ID NO: 292. In some aspects, the V L sequence is not SEQ ID NO: 293.
  • the V H sequence is not SEQ ID NO: 267, and the V L sequence is not selected from SEQ ID NO: 289-293. In some aspects, the V L sequence is not SEQ ID NO: 289. In some aspects, the V L sequence is not SEQ ID NO: 290. In some aspects, the V L sequence is not SEQ ID NO: 291. In some aspects, the V L sequence is not SEQ ID NO: 292. In some aspects, the V L sequence is not SEQ ID NO: 293.
  • the V H sequence is not SEQ ID NO: 268, and the V L sequence is not selected from SEQ ID NO: 289-293. In some aspects, the V L sequence is not SEQ ID NO: 289. In some aspects, the V L sequence is not SEQ ID NO: 290. In some aspects, the V L sequence is not SEQ ID NO: 291. In some aspects, the V L sequence is not SEQ ID NO: 292. In some aspects, the V L sequence is not SEQ ID NO: 293.
  • the V H sequence is not SEQ ID NO: 269, and the V L sequence is not selected from SEQ ID NO: 289-293. In some aspects, the V L sequence is not SEQ ID NO: 289. In some aspects, the V L sequence is not SEQ ID NO: 290. In some aspects, the V L sequence is not SEQ ID NO: 291. In some aspects, the V L sequence is not SEQ ID NO: 292. In some aspects, the V L sequence is not SEQ ID NO: 293.
  • anti-PD-1 antibodies comprising one or more sequences defined by consensus sequences.
  • Each consensus sequence is based, at least in part, on one or more alignments of two or more useful anti-PD-1 CDR sequences provided in this disclosure. Based on such alignments, a person of skill in the art would recognize that different amino acid residues may useful in certain positions of the CDRs. Accordingly, each consensus sequence encompasses two or more useful anti-PD-1 CDR sequences.
  • the antibody comprises a CDR-H3 sequence defined by the consensus sequence D- ⁇ 2 - ⁇ 3 -Y- ⁇ 5 - ⁇ 6 -G-S-G-Y, where ⁇ 2 is A, V, or S; ⁇ 3 is D or E; ⁇ 5 is S or G; and ⁇ 6 is S, L, or T.
  • ⁇ 2 is A, V, or S
  • ⁇ 3 is D or E
  • ⁇ 5 is S or G
  • ⁇ 6 is S, L, or T.
  • S, G, or R Sequencing of individual clones isolated from the output of the antibody selection process revealed that R occurred at position as at nearly the same frequency as G.
  • ⁇ 2 is A
  • ⁇ 3 is not D
  • ⁇ 5 is not S
  • ⁇ 6 is not S; or combinations thereof.
  • ⁇ 2 is V or S; ⁇ 3 is E; as is G; or ⁇ 6 is L or T; or combinations thereof.
  • ⁇ 2 is not A; ⁇ 3 is not D; ⁇ 5 is not S; or ⁇ 6 is not S; or combinations thereof.
  • the antibody comprises a CDR-H3 sequence defined by the consensus sequence ß 1 -G-Y-ß 4 -ß 5 -Y-ß 7 - ⁇ 8 -F-ß 10 -ß 11 , where ß 1 is not present or Q; ß 4 is G or D; ß 5 is N or V; ß 7 is L or S; ß 8 is Y or W; ß 10 is D or A; and ß 11 is V or Y.
  • the antibody comprises a Chothia CDR-H1 sequence defined by the consensus sequence G- ⁇ 2 - ⁇ 3 - ⁇ 4 - ⁇ 5 - ⁇ 6 - ⁇ 7 , where ⁇ 2 is Y or F; ⁇ 3 is T, R or I; ⁇ 4 is F or L; ⁇ 5 is S, E, T, P, or R; ⁇ 6 is T, S, H, Q, R, or W; and ⁇ 7 is F, Y, or Q.
  • ⁇ 5 is T
  • ⁇ 6 is not S.
  • ⁇ 5 is S, E, P, or R; or ⁇ 6 is T, H, Q, R, or W; or combinations thereof.
  • ⁇ 2 is not Y; ⁇ 3 is not T or R; ⁇ 5 is not T; ⁇ 6 is not S; or ⁇ 7 is not Y; or combinations thereof.
  • the antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence W- ⁇ 2 -S-A- ⁇ 5 -N-G-N-T- ⁇ 10 -Y-A-Q-K-L-Q-G, where ⁇ 2 is I or V; ⁇ 5 is Y or H; and ⁇ 10 is K or N.
  • the antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence ⁇ 1 -I-S-G- ⁇ 5 -G- ⁇ 7 - ⁇ 8 -T-Y-Y- ⁇ 12 -D-S-V- ⁇ 16 -G, where ⁇ 1 is T or A; ⁇ 5 is S or G; ⁇ 7 is S or G; ⁇ 8 is S, D or N; ⁇ 12 is A, P or S; and ⁇ 16 is K or Q.
  • ⁇ 1 is A
  • ⁇ 5 is not S
  • ⁇ 7 is not G
  • ⁇ 8 is not S
  • ⁇ 12 is not A
  • ⁇ 16 is not K; or combinations thereof.
  • the antibody comprises a Kabat CDR-H1 sequence defined by the consensus sequence ⁇ 1 - ⁇ 2 -G- ⁇ 4 -S, where ⁇ 1 is T, R, W, Q, H, or S; ⁇ 2 is Y, F, or Q; and ⁇ 4 is M or I.
  • ⁇ 1 is T, R, W, Q, or H; ⁇ 2 is F or Q; or ⁇ 4 is M; or combinations thereof.
  • the antibody comprises a CDR-L3 sequence defined by the consensus sequence Q-Q- ⁇ 3 - ⁇ 4 - ⁇ 5 - ⁇ 6 -P- ⁇ 8 -T, where ⁇ 3 is N, S, or W; ⁇ 4 is Y, K, or I; ⁇ 5 is N, E, or S; ⁇ 6 is S, V, D, or T; and ⁇ 8 is Y or W.
  • ⁇ 4 is Y
  • ⁇ 3 is not S
  • ⁇ 5 is not S
  • ⁇ 6 is not T
  • ⁇ 8 is not W; or combinations thereof.
  • ⁇ 3 is not S; ⁇ 4 is not Y; ⁇ 5 is not S; ⁇ 6 is not T; or ⁇ 8 is not W; or combinations thereof.
  • the antibody comprises a CDR-L1 sequence defined by the consensus sequence S-G-D-A-L- ⁇ 6- ⁇ 7-Q-Y- ⁇ 10-Y, where ⁇ 6 is P, T, or S; ⁇ 7 is M, T, E, or K; and ⁇ 10 is G or A.
  • ⁇ 6 is P
  • ⁇ 7 is not K
  • ⁇ 10 is not A, or combinations thereof.
  • the antibody comprises a CDR-L1 sequence defined by the consensus sequence R-A-S-E- ⁇ 5 -V-D- ⁇ 8 - ⁇ 9 -G- ⁇ 11 -S-F-M- ⁇ 15 , where ⁇ 5 is S or N; ⁇ 8 is N or D; ⁇ 9 is S or Y; ⁇ 11 is I or V; and ⁇ 15 is S or N.
  • the antibody that specifically binds PD-1 is an antibody comprising a variable region that is encoded by a particular germline gene, or a variant thereof.
  • the illustrative antibodies provided herein comprise variable regions that are encoded by the heavy chain variable region germline genes VH1-18, VH3-21, VH3-7, and VH3-15, or variants thereof; and the light chain variable region germline genes V ⁇ 3-25, V ⁇ 1-9, V ⁇ 3-11, V ⁇ 3-20, and V ⁇ 4-1, or variants thereof.
  • the CDR sequences provided herein may also be useful when combined with variable regions encoded by other variable region germline genes, or variants thereof.
  • the CDR sequences provided herein may be useful when combined with variable regions encoded by variable region germline genes, or variants thereof, that are structurally similar to the variable region germline genes recited above.
  • a CDR-H sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the VH1 or VH3 family, or a variant thereof.
  • a CDR-L sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the V ⁇ 3, V ⁇ 1, V ⁇ 3, and V ⁇ 4 families, or a variant thereof.
  • the affinity of the antibody for PD-1 is less than about 10 ⁇ 5 M, less than about 10 ⁇ 6 M, less than about 10 ⁇ 7 M, less than about 10 ⁇ 8 M, less than about 10 ⁇ 9 M, less than about 10 ⁇ 10 M, less than about 10 ⁇ 11 M, or less than about 10 ⁇ 12 M.
  • the affinity of the antibody is between about 10 ⁇ 7 M and 10 ⁇ 11 M.
  • the affinity of the antibody is between about 10 ⁇ 7 M and 10 ⁇ 10 M.
  • the affinity of the antibody is between about 10 ⁇ 7 M and 10 ⁇ 9 M.
  • the affinity of the antibody is between about 10 ⁇ 7 M and 10 ⁇ 8 M. In some embodiments, the affinity of the antibody is between about 10 ⁇ 8 M and 10 ⁇ 11 M. In some embodiments, the affinity of the antibody is between about 10 ⁇ 8 M and 10 ⁇ 10 M. In some embodiments, the affinity of the antibody is between about 10 ⁇ 9 M and 10 ⁇ 11 M. In some embodiments, the affinity of the antibody is between about 10 ⁇ 10 M and 10 ⁇ 11 M.
  • the affinity of the antibody for human PD-1 is between about 3.85 ⁇ 10 ⁇ 8 M and 2.52 ⁇ 10 ⁇ 10 M. In some embodiment, the affinity of the antibody for human PD-1 is about 2.55 ⁇ 10 ⁇ 8 M, about 1.52 ⁇ 10 ⁇ 8 M, about 9.52 ⁇ 10 ⁇ 9 M, about 1.09 ⁇ 10 ⁇ 8 M, about 4.50 ⁇ 10 ⁇ 9 M, about 1.90 ⁇ 10 ⁇ 9 M, about 4.76 ⁇ 10 ⁇ 9 M, about 4.5 ⁇ 10 ⁇ 9 M, about 1.04 ⁇ 10 ⁇ 8 M, about 9.90 ⁇ 10 ⁇ 9 M, about 9.13 ⁇ 10 ⁇ 10 M, about 2.52 ⁇ 10 ⁇ 10 M, about 2.58 ⁇ 10 ⁇ 9 M, about 3.85 ⁇ 10 ⁇ 8 M, about 3.66 ⁇ 10 ⁇ 9 M, about 3.15 ⁇ 10 ⁇ 9 M, about 5.14 ⁇ 10 ⁇ 9 M, about 2.47 ⁇ 10 ⁇ 9 M, about 2.79 ⁇ 10 ⁇ 9 M, about 1.20 ⁇ 10 ⁇ 9 M, or about 1.28
  • the affinity of the antibody for human PD-1 expressed on the surface of a cell is between about 3.2 and about 0.2 nM. In some embodiment, the affinity of the antibody for human PD-1 expressed on the surface of a cell is about 0.2 nM, about 0.4 nM, about 0.9 nM, about 1 nM, about 0.3 nM, about 0.7 nM, about 0.2 nM, about 0.8 nM, about 3.2 nM, about 2.9 nM, about 1.39 nM, or about 1.34 nM.
  • the affinity of the antibody for murine PD-1 is between about 6.09 ⁇ 10 ⁇ 8 M and 9.08 ⁇ 10 ⁇ 9 M. In some embodiment, the affinity of the antibody for murine PD-1 is about 6.09 ⁇ 10 ⁇ 8 M, about 6.22 ⁇ 10 ⁇ 8 M, or about 9.08 ⁇ 10 ⁇ 9 M.
  • the affinity of the antibody for cynomolgus PD-1 is between about 2.43 ⁇ 10 ⁇ 8 M and 1.95 ⁇ 10 ⁇ 10 M. In some embodiment, the affinity of the antibody for cynomolgus PD-1 is about 2.43 ⁇ 10 ⁇ 8 M, about 1.55 ⁇ 10 ⁇ 8 M, about 2.22 ⁇ 10 ⁇ 8 M, about 2.56 ⁇ 10 ⁇ 9 M, about 2.54 ⁇ 10 ⁇ 9 M, about 5.61 ⁇ 10 ⁇ 10 M, or about 1.95 ⁇ 10 ⁇ 10 M
  • the antibody has a k a of at least about 10 4 M ⁇ 1 ⁇ sec ⁇ 1 . In some embodiments the antibody has a k a of at least about 10 5 M ⁇ 1 ⁇ sec ⁇ 1 . In some embodiments the antibody has a k a of at least about 10 6 M ⁇ 1 ⁇ sec ⁇ 1 . In some embodiments the antibody has a k a of between about 10 4 M ⁇ 1 ⁇ sec ⁇ 1 and about 10 5 M ⁇ 1 ⁇ sec ⁇ 1 . In some embodiments the antibody has a k a of between about 10 5 M ⁇ 1 ⁇ sec ⁇ 1 and about 10 6 M ⁇ 1 ⁇ sec ⁇ 1 .
  • the antibody has a k a when associating with human PD-1 of between about 4.74 ⁇ 10 4 M ⁇ 1 ⁇ sec ⁇ 1 and about 1.23 ⁇ 10 6 M ⁇ 1 ⁇ sec ⁇ 1 . In some embodiments the antibody has a k a when associating with human PD-1 of about 4.88 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 1.23 ⁇ 10 6 M ⁇ 1 ⁇ sec ⁇ 1 , about 7.37 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 6.87 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 5.63 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 5.16 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 2.48 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 7.98 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 1.82 ⁇ 10 5 M ⁇ 1 ⁇ sec ⁇ 1 , about 4.74 ⁇ 10 4 M ⁇ 1
  • the antibody has a k d of about 10 ⁇ 5 sec ⁇ 1 or less. In some embodiments the antibody has a k d of about 10 4 sec ⁇ 1 or less. In some embodiments the antibody has a k d of about 10 ⁇ 3 sec ⁇ 1 or less. In some embodiments the antibody has a k d of between about 10 ⁇ 2 sec ⁇ 1 and about 10 ⁇ 5 sec ⁇ 1 . In some embodiments the antibody has a k d of between about 10 ⁇ 2 sec ⁇ 1 and about 10 ⁇ 4 sec ⁇ 1 . In some embodiments the antibody has a k d of between about 10 ⁇ 3 sec ⁇ 1 and about 10 ⁇ 5 sec ⁇ 1 .
  • the antibody has a k d when dissociating from human PD-1 of between about 1.87 ⁇ 10 ⁇ 2 sec ⁇ 1 and about 4.17 ⁇ 10 ⁇ 4 sec ⁇ 1 . In some embodiments the antibody has a k d when dissociating from human PD-1 of about 1.24 ⁇ 10 ⁇ 2 sec ⁇ 1 , about 1.87 ⁇ 10 ⁇ 2 sec ⁇ 1 , about 7.01 ⁇ 10 ⁇ 3 sec ⁇ 1 , about 7.74 ⁇ 10 ⁇ 3 sec ⁇ 1 , about 2.54 ⁇ 10 ⁇ 3 sec ⁇ 1 , about 9.80 ⁇ 10 ⁇ 4 sec ⁇ 1 , about 1.18 ⁇ 10 ⁇ 3 sec ⁇ 1 , about 3.59 ⁇ 10 ⁇ 3 sec ⁇ 1 , about 4.68 ⁇ 10 ⁇ 4 sec ⁇ 1 , about 1.82 ⁇ 10 ⁇ 3 sec ⁇ 1 , about 6.79 ⁇ 10 ⁇ 4 sec ⁇ 1 , about 6.28 ⁇ 10 ⁇ 4 sec ⁇ 1 , about 4.17 ⁇ 10 ⁇ 4 sec ⁇ 1 .
  • the K D , k a , and k d are determined at 25° C. In some embodiments, the K D , k a , and k d are determined by surface plasmon resonance. In some embodiments, the K D , k a , and k d are determined according to the methods described in Examples 4 and 6.
  • the antibody inhibits binding of one or more of PD-L1 and PD-L2 to PD-1.
  • the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1 to about 7 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1.99, about 2.53, about 5.86, or about 5.96 nM.
  • the antibody inhibits binding of PD-L2 to PD-1 with an IC 50 of about 0.01 to about 1 nM. In some aspects, the antibody inhibits binding of PD-L2 to PD-1 with an IC 50 of about 0.01, about 0.18, about 0.56, or about 0.58 nM.
  • the antibody inhibits binding of PD-L1 to PD-1 with an IC 50 of about 5.96 nM, and inhibits binding of PD-L2 to PD-1 with an IC 50 of about 0.56 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC 50 of about 5.86 nM, and inhibits binding of PD-L2 to PD-1 with an IC 50 of about 0.58 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC 50 of about 1.99 nM, and inhibits binding of PD-L2 to PD-1 with an IC 50 of about 0.01 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC 50 of about 2.53 nM, and inhibits binding of PD-L2 to PD-1 with an IC 50 of about 0.18 nM.
  • the anti-PD-1 antibodies induce the secretion of interferon gamma when added to a peripheral blood mononuclear cell (PBMC) two-way mixed lymphocyte reaction (MLR) assay, as described in Examples 8 and 16.
  • PBMC peripheral blood mononuclear cell
  • MLR mixed lymphocyte reaction
  • the anti-PD-1 antibodies induce the secretion of interferon gamma when added to a PBMC cytomegalovirus recall assay, as described in Example 16.
  • the anti-PD-1 antibodies accelerate the onset of graft versus host disease, as shown in Example 18.
  • an antibody may be altered to increase, decrease or eliminate the extent to which it is glycosylated. Glycosylation of polypeptides is typically either “N-linked” or “O-linked.”
  • N-linked glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue.
  • the tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
  • X is any amino acid except proline
  • O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
  • Addition or deletion of N-linked glycosylation sites to the antibody may be accomplished by altering the amino acid sequence such that one or more of the above-described tripeptide sequences is created or removed.
  • Addition or deletion of O-linked glycosylation sites may be accomplished by addition, deletion, or substitution of one or more serine or threonine residues in or to (as the case may be) the sequence of an antibody.
  • amino acid modifications may be introduced into the Fc region of an antibody provided herein to generate an Fc region variant.
  • the Fc region variant possesses some, but not all, effector functions.
  • Such antibodies may be useful, for example, in applications in which the half-life of the antibody in vivo is important, yet certain effector functions are unnecessary or deleterious.
  • effector functions include complement-dependent cytotoxicity (CDC) and antibody-directed complement-mediated cytotoxicity (ADCC). Numerous substitutions or substitutions or deletions with altered effector function are known in the art.
  • Fc receptor (FcR) binding assays can be conducted to measure Fc ⁇ R binding.
  • FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Ann. Rev. Immunol., 1991, 9:457-492.
  • Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are provided in U.S. Pat. Nos. 5,500,362 and 5,821,337; Hellstrom et al., Proc. Natl. Acad. Sci. USA., 1986, 83:7059-7063; Hellstrom et al., Proc. Natl. Acad. Sci. USA., 1985, 82:1499-1502; and Bruggemann et al., J. Exp. Med., 1987, 166:1351-1361.
  • Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
  • PBMC peripheral blood mononuclear cells
  • NK Natural Killer
  • ADCC activity of the molecule of interest may be assessed in vivo, using an animal model such as that disclosed in Clynes et al. Proc. Natl. Acad. Sci. USA., 1998, 95:652-656.
  • C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity.
  • Examples of C1q binding assays include those described in WO 2006/029879 and WO 2005/100402.
  • Complement activation assays include those described, for example, in Gazzano-Santoro et al., J. Immunol. Methods, 1996, 202:163-171; Cragg et al., Blood, 2003, 101:1045-1052; and Cragg and Glennie, Blood, 2004, 103:2738-2743.
  • FcRn binding and in vivo clearance can also be measured, for example, using the methods described in Petkova et al., Intl. Immunol., 2006, 18:1759-1769.
  • the PD-1 antigen to be used for production of antibodies may be intact PD-1 or a fragment of PD-1.
  • the intact PD-1, or fragment of PD-1 may be in the form of an isolated protein or expressed by a cell.
  • Other forms of PD-1 useful for generating antibodies will be apparent to those skilled in the art.
  • Monoclonal antibodies may be obtained, for example, using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-497, and/or by recombinant DNA methods (see e.g., U.S. Pat. No. 4,816,567). Monoclonal antibodies may also be obtained, for example, using phage or yeast-based libraries. See e.g., U.S. Pat. Nos. 8,258,082 and 8,691,730.
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
  • a suitable fusing agent such as polyethylene glycol
  • the hybridoma cells are seeded and grown in a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • Useful myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive media conditions, such as the presence or absence of HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and MC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, Calif.), and SP-2 or X63-Ag8-653 cells (available from the American Type Culture Collection, Rockville, Md.).
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. See e.g., Kozbor, J. Immunol., 1984, 133:3001.
  • hybridoma cells After the identification of hybridoma cells that produce antibodies of the desired specificity, affinity, and/or biological activity, selected clones may be subcloned by limiting dilution procedures and grown by standard methods. See Goding, supra. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • DNA encoding the monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • the hybridoma cells can serve as a useful source of DNA encoding antibodies with the desired properties.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as bacteria (e.g., E. coli ), yeast (e.g., Saccharomyces or Pichia sp.), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody, to produce the monoclonal antibodies.
  • Humanized antibodies may be generated by replacing most, or all, of the structural portions of a monoclonal antibody with corresponding human antibody sequences. Consequently, a hybrid molecule is generated in which only the antigen-specific variable, or CDR, is composed of non-human sequence.
  • Methods to obtain humanized antibodies include those described in, for example, Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. USA., 1998, 95:8910-8915; Steinberger et al., J. Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl. Acad. Sci. USA., 1989, 86:10029-10033; and U.S. Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6,180,370.
  • Human antibodies can be generated by a variety of techniques known in the art, for example by using transgenic animals (e.g., humanized mice). See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA., 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258; Bruggermann et al., Year in Immuno., 1993, 7:33; and U.S. Pat. Nos. 5,591,669, 5,589,369 and 5,545,807. Human antibodies can also be derived from phage-display libraries (see e.g., Hoogenboom et al., J. Mol.
  • Human antibodies may also be generated by in vitro activated B cells (see e.g., U.S. Pat. Nos. 5,567,610 and 5,229,275). Human antibodies may also be derived from yeast-based libraries (see e.g., U.S. Pat. No. 8,691,730).
  • the invention also provides isolated nucleic acids encoding anti-PD-1 antibodies, vectors and host cells comprising the nucleic acids, and recombinant techniques for the production of the antibodies.
  • the nucleic acid encoding it may be isolated and inserted into a replicable vector for further cloning (i.e., amplification of the DNA) or expression.
  • the nucleic acid may be produced by homologous recombination, for example as described in U.S. Pat. No. 5,204,244.
  • the vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, for example as described in U.S. Pat. No. 5,534,615.
  • Suitable host cells include any prokaryotic (e.g., bacterial), lower eukaryotic (e.g., yeast), or higher eukaryotic (e.g., mammalian) cells.
  • Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia ( E. coli ), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella ( S. typhimurium ), Serratia ( S. marcescans ), Shigella , Bacilli ( B. subtilis and B. licheniformis ), Pseudomonas ( P.
  • eubacteria such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia ( E. coli ), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella ( S. typ
  • E. coli 294 One useful E. coli cloning host is E. coli 294, although other strains such as E. coli B, E. coli X1776, and E. coli W3110 are suitable.
  • eukaryotic microbes such as filamentous fungi or yeast are also suitable cloning or expression hosts for anti-PD-1 antibody-encoding vectors.
  • Saccharomyces cerevisiae or common baker's yeast, is a commonly used lower eukaryotic host microorganism.
  • Schizosaccharomyces pombe Kluyveromyces ( K. lactis, K. fragilis, K. bulgaricus K. wickeramii, K. waltii, K. drosophilarum, K. thermotolerans , and K.
  • Useful mammalian host cells include COS-7 cells, HEK293 cells; baby hamster kidney (BHK) cells; Chinese hamster ovary (CHO); mouse sertoli cells; African green monkey kidney cells (VERO-76), and the like.
  • the host cells used to produce the anti-PD-1 antibody of this invention may be cultured in a variety of media.
  • Commercially available media such as, for example, Ham's F10, Minimal Essential Medium (MEM), RPMI-1640, and Dulbecco's Modified Eagle's Medium (DMEM) are suitable for culturing the host cells.
  • MEM Minimal Essential Medium
  • RPMI-1640 RPMI-1640
  • DMEM Dulbecco's Modified Eagle's Medium
  • any of the media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal. Biochem., 1980, 102:255; and U.S. Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, and 5,122,469, or WO 90/03430 and WO 87/00195 may be used.
  • any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics, trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • growth factors such as insulin, transferrin, or epidermal growth factor
  • salts such as sodium chloride, calcium, magnesium, and phosphate
  • buffers such as HEPES
  • nucleotides such as adenosine and thymidine
  • antibiotics such as adenosine and thymidine
  • trace elements defined as inorganic compounds usually present at final concentrations in the micromolar range
  • the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration.
  • the particulate debris either host cells or lysed fragments
  • the particulate debris is removed, for example, by centrifugation or ultrafiltration.
  • Carter et al. Bio/Technology, 1992, 10:163-167 describes a procedure for isolating antibodies which are secreted to the periplasmic space of E. coli . Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation.
  • sodium acetate pH 3.5
  • EDTA EDTA
  • PMSF phenylmethylsulf
  • the antibody is produced in a cell-free system.
  • the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety.
  • the cell-free system utilizes a cell-free extract from a eukaryotic cell or from a prokaryotic cell.
  • the prokaryotic cell is E. coli .
  • Cell-free expression of the antibody may be useful, for example, where the antibody accumulates in a cell as an insoluble aggregate, or where yields from periplasmic expression are low.
  • supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon® or Millipore® Pellcon® ultrafiltration unit.
  • a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • the antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a particularly useful purification technique.
  • the suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
  • Protein A can be used to purify antibodies that are based on human ⁇ 1 , ⁇ 2 , or ⁇ 4 heavy chains (Lindmark et al., J. Immunol. Meth., 1983, 62:1-13).
  • Protein G is useful for all mouse isotypes and for human ⁇ 3 (Guss et al., EMBO J., 1986, 5:1567-1575).
  • the matrix to which the affinity ligand is attached is most often agarose, but other matrices are available.
  • Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose.
  • the antibody comprises a C H3 domain
  • the BakerBond ABX® resin is useful for purification.
  • the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5 to about 4.5, generally performed at low salt concentrations (e.g., from about 0 to about 0.25 M salt).
  • Suitable routes of administration include, but are not limited to, the inhalation, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary, and subcutaneous routes.
  • the pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients , Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
  • the pharmaceutical composition comprises an anti-foaming agent.
  • Any suitable anti-foaming agent may be used.
  • the anti-foaming agent is selected from an alcohol, an ether, an oil, a wax, a silicone, a surfactant, and combinations thereof.
  • the anti-foaming agent is selected from a mineral oil, a vegetable oil, ethylene bis stearamide, a paraffin wax, an ester wax, a fatty alcohol wax, a long chain fatty alcohol, a fatty acid soap, a fatty acid ester, a silicon glycol, a fluorosilicone, a polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2-ethyl-hexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof.
  • the pharmaceutical composition comprises a cosolvent.
  • cosolvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, and propylene glycol.
  • the pharmaceutical composition comprises a buffer.
  • buffers include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, and monosodium glutamate.
  • the pharmaceutical composition comprises a carrier or filler.
  • carriers or fillers include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, and guar gum.
  • the pharmaceutical composition comprises a surfactant.
  • surfactants include d-alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, and vitamin E polyethylene(glycol) succinate.
  • the pharmaceutical composition comprises an anti-caking agent.
  • anti-caking agents include calcium phosphate (tribasic), hydroxymethyl cellulose, hydroxypropyl cellulose, and magnesium oxide.
  • excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, and sugars. Specific examples of each of these agents are described, for example, in the Handbook of Pharmaceutical Excipients , Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, incorporated by reference in its entirety.
  • the pharmaceutical composition comprises a solvent.
  • the solvent is saline solution, such as a sterile isotonic saline solution or dextrose solution.
  • the solvent is water for injection.
  • the pharmaceutical compositions are in a particulate form, such as a microparticle or a nanoparticle.
  • Microparticles and nanoparticles may be formed from any suitable material, such as a polymer or a lipid.
  • the microparticles or nanoparticles are micelles, liposomes, or polymersomes.
  • a composition provided herein is a pharmaceutical composition or a single unit dosage form.
  • Pharmaceutical compositions and single unit dosage forms provided herein comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic antibodies.
  • anhydrous pharmaceutical compositions and dosage forms comprising an antibody, since water can facilitate the degradation of some antibodies.
  • Anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine can be anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • parenteral dosage forms can be administered to subjects by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses subjects' natural defenses against contaminants, parenteral dosage forms are typically, sterile or capable of being sterilized prior to administration to a subject. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • Excipients that increase the solubility of one or more of the antibodies disclosed herein can also be incorporated into the parenteral dosage forms.
  • the doctor will determine the posology which he considers most appropriate according to a preventive or curative treatment and according to the age, weight, condition and other factors specific to the subject to be treated.
  • the amount of the antibody or composition which will be effective in the prevention or treatment of a disorder or one or more symptoms thereof will vary with the nature and severity of the disease or condition, and the route by which the antibody is administered.
  • the frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject.
  • Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • exemplary doses of a composition include milligram or microgram amounts of the antibody per kilogram of subject or sample weight (e.g., about 10 micrograms per kilogram to about 50 milligrams per kilogram, about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 microgram per kilogram to about 10 milligrams per kilogram).
  • the dosage of the antibody provided herein, based on weight of the antibody, administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, or 15 mg/kg or more of a subject's body weight.
  • the dosage of the composition or a composition provided herein administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is 0.1 mg to 200 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 10 mg, 0.1 mg to 7.5 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 mg to 7.5 mg, 0.25 mg to 5 mg, 0.25 mg to 2.5 mg, 0.5 mg to 20 mg, 0.5 to 15 mg, 0.5 to 12 mg, 0.5 to 10 mg, 0.5 mg to 7.5 mg, 0.5 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 7.5 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.
  • the dose can be administered according to a suitable schedule, for example, once, two times, three times, or for times weekly. It may be necessary to use dosages of the antibody outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with subject response.
  • dosage amounts and dose frequency schedules are also encompassed by the herein described dosage amounts and dose frequency schedules.
  • the dosage administered to the subject may be increased to improve the prophylactic or therapeutic effect of the composition or it may be decreased to reduce one or more side effects that a particular subject is experiencing.
  • treatment or prevention can be initiated with one or more loading doses of an antibody or composition provided herein followed by one or more maintenance doses.
  • a dose of an antibody or composition provided herein can be administered to achieve a steady-state concentration of the antibody in blood or serum of the subject.
  • the steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age.
  • administration of the same composition may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.
  • administration of the same prophylactic or therapeutic agent may be repeated and the administration may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.
  • the antibodies of the invention are administered to a mammal, generally a human, in a pharmaceutically acceptable dosage form such as those known in the art and those discussed above.
  • the antibodies of the invention may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, or intratumoral routes.
  • the antibodies also are suitably administered by peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects.
  • the intraperitoneal route may be particularly useful, for example, in the treatment of ovarian tumors.
  • the antibodies provided herein may be useful for the treatment of any disease or condition involving PD-1, such as cancer, autoimmune disease, and infection.
  • any suitable cancer may be treated with the antibodies provided herein.
  • suitable cancers include, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone cancer, breast cancer, bronchial tumor, Burkitt Lymphoma, carcinoma of unknown primary origin, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, fibrous histiocytoma, Ewing sar
  • any suitable autoimmune disease may be treated with the antibodies provided herein.
  • suitable autoimmune diseases, or diseases with an autoimmune component include, for example, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticarial, axonal &
  • any suitable infection may be treated with the antibodies provided herein.
  • suitable infections include, for example, hepatitis A virus, hepatitis B virus, hepatitis C virus (HCV), human immunodeficiency virus (HIV), and other viral infections.
  • the antibodies provided herein are used in diagnostic applications.
  • an ant-PD-1 antibody may be useful in assays for PD-1 protein.
  • the antibody can be used to detect the expression of PD-1 in various cells and tissues. These assays may be useful, for example, evaluating cancer and autoimmune disease.
  • the antibody may be labeled with a detectable moiety. Suitable detectable moieties include, but are not limited to radioisotopes, fluorescent labels, and enzyme-substrate labels.
  • the anti-PD-1 antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which specifically binds to the anti-PD-1 antibody.
  • the antibodies of the invention may be used as affinity purification agents.
  • the antibodies may be immobilized on a solid phase such a resin or filter paper, using methods well known in the art.
  • the immobilized antibody is contacted with a sample containing the PD-1 protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PD-1 protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the PD-1 protein from the antibody.
  • an anti-PD-1 antibody provided herein is provided in the form of a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing a procedure.
  • the procedure is a diagnostic assay. In other embodiments, the procedure is a therapeutic procedure.
  • the kit further comprises a solvent for the reconstitution of the anti-PD-1 antibody.
  • the anti-PD-1 antibody is provided in the form of a pharmaceutical composition.
  • Antibody Fab or scFv libraries were constructed using a standard overlap extension PCR protocol with mutagenic primers targeting CDRs. See Heckman and Pease, Nat. Protoc., 2007, 2:924-932, incorporated by reference in its entirety. Selections for novel antibodies were performed using standard ribosome display protocols. See Dreir and Plückthun, Methods Mol. Biol., 2011, Clifton, N.J., 687:283-306, incorporated by reference in its entirety. Specifically, scFv-based selection formats were performed according to published protocols. See Hanes and Plückthun, Proc. Natl. Acad. Sci. USA., 1997, 94:4937-4942, incorporated by reference in its entirety.
  • cell-free extracts were treated with 50 ⁇ M iodoacetamide for 30 minutes at room temperature (RT; 20° C.) and added to a premix containing cell-free reaction components (see Groff et al., mAbs, 2014, 6:671-678, incorporated by reference in its entirety) and 10% (v/v) RCA DNA template (approximately 10 ⁇ g/mL DNA) for variants of interest.
  • Cell free reactions at a final volume of 604, were incubated at 30° C. for 12 h on a shaker at 650 rpm in 96-well plates. Four hundred to one-thousand-five-hundred colonies were screened, depending on the predicted diversity of the libraries used in the different selection campaigns.
  • each reaction was diluted 1:50 into PBST (PBS at pH 7.4 with 0.2% Tween-20+0.2% BSA) and the variants expressed in each reaction were tested for functional activity via ELISA-based binding to recombinant human PD-1 (ACROBiosystems, Inc., Catalog No. PD1-H5221 or SINO Biological Inc. Catalog No. 10377-H08H).
  • PBST PBS at pH 7.4 with 0.2% Tween-20+0.2% BSA
  • Standard ELISA-based methods were employed. Specifically, 384-well plates were coated with 2 ⁇ g/mL recombinant PD-1 diluted in bicarbonate buffer, and then blocked with BSA. Antibody variants of interest were allowed to bind to the PD-1-coated plates, and detected with secondary antibodies (e.g., HRP-conjugated anti-human Fc or anti-FLAG) and then detected with chemiluminescent substrate (Pierce ELISA SuperSignalTM Substrate). Plates were analyzed on a Molecular Devices SpectraMax® M5 plate reader. Top hits were selected based on ELISA signal or signal/noise ratio and sequenced. Based on functional activity and sequence analysis, a subset of variants was selected for further scale-up and characterization.
  • secondary antibodies e.g., HRP-conjugated anti-human Fc or anti-FLAG
  • chemiluminescent substrate Pierce ELISA SuperSignalTM Substrate
  • the top leads from the initial round of screening were cultured and plasmids encoding the antibody genes of interest were isolated using a QIAprep 96 Turbo® Miniprep Kit (Qiagen) according to the manufacturer's instructions. DNA was added to 4 mL of cell-free reaction medium to achieve a final concentration of 10 ⁇ g/mL. The cell-free reaction medium was then incubated overnight for 12 hr at 30° C., at 650 rpm.
  • the expressed variants from clarified cell-free reactions were purified via immobilized metal ion affinity chromatography (IMAC) using a semi-automated high throughput batch purification method. Briefly, purifications were performed in a 96-well plate format where 50 ⁇ L/well of IMAC resin (Ni Sepharose® High Performance, GE Healthcare) was equilibrated in IMAC binding buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole), incubated with 1 mL cell-free reaction for 15 minutes, followed by two washes in IMAC binding buffer.
  • IMAC binding buffer 50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole
  • His-tagged antibody variants were then eluted using 200 ⁇ L IMAC elution buffer (50 mM Tris pH 8.0, 300 mM NaCl, 500 mM imidazole), and buffer exchanged into PBS using a 96-well ZebaTM plate (7 kDa MWCO, Thermo Fisher). Purified antibodies were quantified via high throughput capillary electrophoresis using the LabChip GXII® (Perkin Elmer) against a trastuzumab standard curve, according to the manufacturer's instructions.
  • mice were immunized with the extracellular domain of human PD-1 fused with human Fc (R&D Systems, supra) using standard immunization methods.
  • the spleens and/or lymph nodes of the mice were harvested and fused with P3X cells to generate the hybridomas (Aragen Biosciences, Morgan Hill, Calif.), similar to what has been previously described. See Chronopoulou et al., Methods Mol. Biol., 2014, 1131:47-70; and Kim et al., Methods Mol. Biol., 2014, 1131:33-45, each of which is incorporated by reference in its entirety.
  • Mouse single-chain antibodies were constructed by using total gene synthesis using codons optimized for E. coli .
  • the genes encoding the antibodies were cloned into a standard cell-free expression vector. See Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety.
  • the CDRs from m1E9 were grafted onto human antibody frameworks VH3-21, VH3-7, V ⁇ 1-9, and V ⁇ 3-11 by standard methodology to yield humanized antibodies h1E9-1, h1E9-2, h1E9-4, and h1E9-5. See Kuramochi et al., Methods Mole. Biol., 2014, 1060:123-137, incorporated by reference in its entirety. The same method was used to graft the CDRs from m4B10 onto human antibody frameworks VH3-15, V ⁇ 3-11, V ⁇ 3-20, and V ⁇ 4-1 to yield humanized antibodies h4B10-1, h4B10-2, and h4B10-3.
  • Human PD-1 (ACROBiosystems, Inc., Catalog No. PD1-H5221), cynomolgus PD-1 (ACROBiosystems, Inc., Catalog No. PD1-H5254), and murine PD-1 (R&D Systems Inc., Catalog No. 1021-PD-100) were used, as indicated, for kinetic analysis.
  • Monoclonal anti-FLAG M2 IgG (Sigma-Aldrich #F9291) was immobilized onto a CMS chip (GE Life Sciences) using amine coupling chemistry (from Amine Coupling Kit, GE Life Sciences). The immobilization steps were carried out at a flow rate of 25 ⁇ l/min in 1 ⁇ HBS-EP+ buffer (GE Life Sciences; 10 ⁇ Stock diluted before use). The sensor surfaces were activated for 7 min with a mixture of NHS (0.05 M) and EDC (0.2 M). The Anti-FLAG M2 IgG was injected over all 4 flow cells at a concentration of 25 ⁇ g/ml in 10 mM sodium acetate, pH 4.5, for 7 min. Ethanolamine (1 M, pH 8.5) was injected for 7 min to block any remaining activated groups. An average of 12,000 response units (RU) of capture antibody was immobilized on each flow cell.
  • RU response units
  • the analyte (huPD1-His) was bound at 50, 25, 12.5, 6.25 and 0 nM for 180 seconds, followed by a 600 second dissociation phase at a flow rate of 50 ⁇ l/min. Between each ligand capture and analyte binding cycle, regeneration was carried out using 2 injections of 10 mM glycine pH 2.0 for 30 seconds at 30 ⁇ L/min, followed by a 30 second buffer wash step.
  • K D affinity, nM
  • Anti-PD1 antibodies were tested for their ability to block a PD-1/PD-L1 interaction.
  • PD-1 ACROBiosystems, Inc.
  • PD-1 ACROBiosystems, Inc.
  • the plate was washed 3 times with PBS pH 7.4 with 0.05% Tween20 and blocked with 2% bovine serum albumin (BSA) in PBS pH 7.4+0.1% Tween20 for 1 hour at 30° C.
  • BSA bovine serum albumin
  • the blocking solution was aspirated, and a dilution series of antibody was mixed with 100 nM PD-L1-Fc (ACROBiosystems, Inc.) in 0.2% BSA in PBS pH 7.4+0.1% Tween20 (diluent buffer) and incubated at 30° C. for 1 hour.
  • the plate was washed, and 10 nM anti-PD-L1 antibody (BioLegend, clone 29E.2A3) in diluent buffer was added to all wells.
  • Antibodies with expression levels >250 nM and mouse IgGs from hybridomas were tested in a fluorescence-activated cell sorting (FACS) cell-binding assay.
  • FACS fluorescence-activated cell sorting
  • Chinese Hamster Ovary (or CHO) Cells stably expressing the human target molecule PD-1 on the cell surface (CHO-PD1) were used to screen for binding.
  • Parental CHO cells were used as a negative control to determine background-binding levels.
  • Parental CHO cells and CHO-PD1 cells were cultured in RPMI w/10% FCS penicillin/streptomycin (Pen/Strep) and glutamine (or Gln) and split every 3-4 days at 10 5 cells/mL.
  • a mix of parental CHO cells and CHO-PD1 cells was prepared as follows: Parental CHO cells were washed 2 ⁇ in PBS then incubated in PBS containing 1 ⁇ M CellTraceTM Oregon Green488® (Life Technologies) at 37° C. for 30 minutes. Cells were then washed 2 ⁇ with RPMI w/10% fetal calf serum (FCS), washed 2 ⁇ with FACS buffer (PBS w/2% FCS), suspended thoroughly in ice-cold FACS buffer at a final concentration of 2 ⁇ 10 6 cells/mL and kept on ice. CHO-PD1 cells were similarly washed with FACS buffer and kept on ice at 2 ⁇ 10 6 cells/mL.
  • CHO cells and CHO-PD1 cells were then mixed to obtain a 1:1 cell suspension and seeded at 100 ⁇ L per well on 96 well polypropylene plates. Plates were spun at 1500 rpm for 5 minutes and cell pellets were suspended in 50 ⁇ L FACS buffer containing 6-12 point dilutions of anti-PD-1 variants starting from concentrations of ⁇ 100-200 nM antibody, dispensed using BioMek FX (Beckman Coulter).
  • Variants that showed cell-binding activity were tested in a fluorescence-activated cell sorting (FACS) cell-based competition assay.
  • FACS fluorescence-activated cell sorting
  • CHO-PD1 cells were cultured in RPMI with 10% FCS Pen/Strep and Gln and split every 3-4 days at 10 5 cells/ml.
  • Cells were washed 2 ⁇ with FACS buffer (PBS w/2% FCS), thoroughly in ice-cold FACS buffer at a final concentration of 1 ⁇ 10 6 cells/ml and seeded at 1004 per well on 96 well polypropylene plates. Plates were spun at 1500 rpm for 5 minutes and cell pellets were suspended in 50 ⁇ L FACS buffer containing 8 point 1:3 dilutions (2 ⁇ concentrated) of anti-PD-1 antibody variants, starting from high concentration of ⁇ 200 nM.
  • FACS buffer containing a fixed amount of either 6 ⁇ g/ml rhPDL2-Fc or 50 ⁇ g/ml rhPDL1-Fc proteins were then added to the cells.
  • Cell were then incubated on ice for 1 hr, washed with FACS buffer and incubated for 1 hr on ice with 50 ⁇ l FACS buffer containing 2.5 ⁇ g/ml R-phycoerythrin-conjugated anti-human IgG (Jackson ImmunoResearch). Cells were then washed 2 ⁇ with FACS buffer and fixed for 10 minutes in 200 ⁇ l PBS with 2% PFA prior to acquisition. Samples were acquired using a Becton Dickinson LSRII FACS. Mean Fluorescence Intensity of rhPDL1 or rhPDL2 protein binding was analyzed using FlowJo® software (Tree Star, Inc.).
  • Anti-PD-1 antibodies were functionally tested for potency in blocking the PD-1 pathway in a peripheral blood mononuclear cell (PBMC) two-way mixed lymphocyte reaction (MLR) assay by measuring interferon gamma (IFN-g) secretion in cell culture medium.
  • PBMC peripheral blood mononuclear cell
  • MLR mixed lymphocyte reaction
  • IFN-g interferon gamma secretion in cell culture medium.
  • 1 ⁇ 10 5 human PBMC from 2 allogeneic donors were co-cultured in RPMI media+10% FBS in a total volume of 150 ⁇ l in a 96-well U-bottom plate.
  • Anti-PD-1 antibodies were added at specific concentrations to each well. Isotype control antibody, non-PD-1 targeting antibody, or nothing were used as a negative controls.
  • Cells were cultured for 5 days at 37° C. At day 5, conditioned media was collected and levels of IFN-g were measured using DuoSet® ELISA kits (R&D Systems).
  • Table 1 shows the characteristics of scFv-Fc antibodies (VH1-18/V ⁇ 3-25) isolated as described in Examples 1-2, and characterized as described above.
  • Table 2 shows the characteristics of IgG antibodies isolated as described in Example 3, and characterized as described above.
  • Table 3 shows the characteristics of humanized scFv antibodies derived from the murine hybridoma antibodies of Example 10, and characterized as described above.
  • Table 4 provides thermal stability of selected antibodies, as determined by differential scanning fluorimetry (DSF).
  • Tm1 Tm2 Variant ID Target Scaffold (° C.) (° C.) 1353-G12 PD1 scFv-Fc 48.2 1353-G08 PD1 scFv-Fc 45.3 1353-G10 PD1 scFv-Fc 48.6 1353-H09 PD1 scFv-Fc 49.4 m1B10 PD1 scFv 55.3 h1E9-1 PD1 scFv 52.5 h1E9-2 PD1 scFv 50.9 h1E9-4 PD1 scFv 55.2 h1E9-5 PD1 scFv 51.7 h4b10-1 PD1 scFv 45.5 59.4 h4b10-2 PD1 scFv 45 61.7 h4b10-3 PD1 scFv 52.1 59.3
  • Variable domains from h1E9-4 scFv (V H : SEQ ID NO: 260; V L : SEQ ID NO: 284), and h1E9-5 scFv (V H : SEQ ID NO: 261; V L : SEQ ID NO: 285) were grafted onto human antibody constant domains to generate human IgG1 antibodies based on these scFvs.
  • V H sequences were grafted onto C H1 -C H2 -C H3 constant domains to yield full-length IgG HCs with C-terminal FlagHis tags (GSGDYKDDDDKGSGHHHHHH; SEQ ID NO: 294) for ease of purification and assay development.
  • the V L sequences were grafted onto CL domains to yield full-length IgG LCs.
  • the sequence for both the h1E9-4 and h1E9-5 HCs, with C-terminal FlagHis tag, is provided in SEQ ID NO: 302.
  • the sequence for the h1E9-4 LC is provided in SEQ ID NO: 304.
  • the sequence for the h1E9-5 LC is provided in SEQ ID NO: 303.
  • the IgGs were expressed in a cell-free reaction, as described in Example 1, and purified using the FlagHis tags.
  • the affinity of the IgGs for PD-1 was measured by surface plasmon resonance (Biacore®) and determined to be essentially equivalent to that of the parent scFvs. Affinity data is provided in Table 5.
  • the CDRs for m1E9 were grafted onto human antibody frameworks V H 3-23, VH3-30, Vk4-1, Vk3-20, Vk2-28, and Vk1-33 by standard methodology (T. Kuramochi, T. Igawa, H. Tsunoda, and K. Hattori, Method in Molecular Biology, Human Monoclonal Antibodies: Methods and Protocols, 1060, 123-137) to yield humanized antibodies h1E9-HC1, h1E9-HC2, h1E9-HC3, h1E9-LC1, h1E9-LC2, h1E9-LC3, and h1E9-LC4.
  • the HC constructs included C-terminal FlagHis tags (GSGDYKDDDDKGSGHHHHHH; SEQ ID NO: 294) for ease of purification and assay development.
  • the resulting h1E9 heavy chains were: h1E9-HC3 (SEQ ID NO:324), h1E9-HC2 (SEQ ID NO:325), and h1E9-HC3 (SEQ ID NO:326).
  • the resulting light chains were: h1E9-LC4 (SEQ ID NO:327), h1E9-LC3 (SEQ ID NO:328), h1E9-LC2 (SEQ ID NO:329), and h1E9-LC1 (SEQ ID NO:330).
  • the humanized heavy chains h1E9-HC1, h1E9-HC2, h1E9-HC3, and h1E9-5 were paired with humanized IgG light chains h1E9-LC1, h1E9-LC2, h1E9-LC3, and h1E9-LC4. These 16 combinations were then assessed for binding to human PD1 in vitro by surface plasmon resonance (Biacore®) and subsequently human and cynomolgus PD1 binding on CHO cells using FACS as described below.
  • Example 15 In Vivo Efficacy of Anti-PD-1 Antibodies on Tumor Establishment and Growth
  • mice MC38 colorectal cancer cells (2 ⁇ 10 6 cells in 0.1 mL PBS) were implanted subcutaneously on the right flank of C57BL/6 mice (Charles River Laboratories). On day 2 post-cell implantation (day 0), mice were treated with anti-PD-1 or control antibody at a dose of 5 mg/kg intraperitoneally. Animals were dosed on dosing days 0, 4, 8, 11, and 14.
  • the treatment groups were as follows:
  • anti-PD-1 human scFv-Fc clone 1353-G08 (see SEQ ID NOs: 251 and 275 for V H and V L sequences, respectively, and SEQ ID NO: 242 for the scFv-Fc);
  • anti-PD-1 human IgG clone PD1-F2v (see SEQ ID NOs: 603 and 293 for V H and V L sequences, respectively, SEQ ID NO: 307 for the HC sequence, and SEQ ID NO: 308 for the LC sequence).
  • Antibodies (2) and (3) were obtained commercially from Bio X Cell.
  • Antibodies (4)-(6) were produced using the cell-free expression methods described in Example 1.
  • Antibody 7 was produced by mammalian cell expression using HEK293 cells and standard techniques.
  • FIG. 2 provides a chart of the tumor volume over the 17-days of treatment with the various antibodies.
  • Anti-PD-1 antibodies were functionally tested for potency in blocking the PD-pathway in restimulating peripheral blood mononuclear cells (PBMC) from cytomegalovirus-positive (CMV+) human donors by measuring IFN-g secretion in cell culture medium.
  • PBMC peripheral blood mononuclear cells
  • CMV+ cytomegalovirus-positive human donors
  • CD14+ monocytes and CD3+ T cells were obtained from peripheral blood mononuclear cells (PBMC) isolated from CMV+ human donors (AllCells, Alameda, Calif.) using MACS Cell Separation kits (Miltenyi Biotec).
  • PBMC peripheral blood mononuclear cells isolated from CMV+ human donors (AllCells, Alameda, Calif.) using MACS Cell Separation kits (Miltenyi Biotec).
  • CD14+ monocytes were differentiated into immature dendritic cells (DC) by culturing cells at 1 ⁇ 10 6 cells/ml for 7 days in presence of GM-CSF and IL-4 (Peprotech) in X-Vivo 15 media (Lonza) containing 2% human AB serum (Sigma-Aldrich), penicillin-streptomycin (Corning Mediatech) and GlutaMAX (Life Technologies).
  • DC dendritic cells
  • DCs were matured by culturing in X-Vivo 15+2% human AB serum media at 1 ⁇ 10 6 cells/ml for 2 days in the presence of GM-CSF, IL-4, TNF- ⁇ , IL-1b, IL-6 (Peprotech) and prostaglandin E2 (Sigma-Aldrich).
  • Anti-PD-1 or control human IgG antibody (50 final volume of 150 ⁇ l per well) were added starting at a final concentration of 400 nM with 5-fold serial dilutions. Cells were co-cultured with peptides and antibodies for 5-6 days. Conditioned media was collected and tested for human IFN-g levels by ELISA (BD Biosciences).
  • anti-PD-1 human IgG 1353-G10 (SEQ ID NOs: 252 and 276) showed significant fold-increase in IFN-g levels (closed circles). The IFN-g levels were substantial compared to Nivolumab IgG (open circles).
  • Anti-PD-1 antibodies were functionally tested for potency in blocking the PD-1 pathway in a peripheral blood mononuclear cell (PBMC) two-way mixed lymphocyte reaction (MLR) assay by measuring interferon gamma (IFN-g) secretion in cell culture medium.
  • PBMC peripheral blood mononuclear cell
  • MLR mixed lymphocyte reaction
  • CD14+ monocytes and CD4+ T cells were obtained from PBMC isolated from human donors using MACS Cell Separation kits.
  • CD14+ monocytes were differentiated into immature DC by culturing cells at 1 ⁇ 10 6 cells/ml cell density for 7 days in presence of GM-CSF and IL-4 in RPMI media containing 10% fetal bovine serum, penicillin-streptomycin and GlutaMAX.
  • DCs were matured by culturing in RPMI+10% FBS media at 1 ⁇ 10 6 cells/ml cell density for 2 days in the presence of GM-CSF, IL-4, TNF-a, IL-1b, IL-6 and prostaglandin E2.
  • DC/CD4+ T cell MLR To set-up the DC/CD4+ T cell MLR, mature DCs were collected and washed. 10,000 DCs and 100,000 CD4+ T cells were plated per well in a 96-well U-bottom plate in a total volume of 100 ⁇ l media. Anti-PD-1 or control human IgG antibody (50 ⁇ l, final volume of 150 ⁇ l per well) were added starting at a final concentration of 400 nM with 5-fold serial dilutions. Cells were co-cultured with peptides and antibodies for 5-6 days. Conditioned media was collected and tested for human IFN-g levels by ELISA.
  • anti-PD-1 human IgG 1353-G10 (SEQ ID NOs: 252 and 276) showed significant fold-increase in IFN-g levels (closed circles). The IFN-g levels were substantial compared to Nivolumab IgG (open circles).
  • Anti-PD-1 antibodies described herein were evaluated for acceleration of graft versus host disease (GVHD) in a mouse model. Since PD-1 negatively regulates immune response, blockade of PD-1 by an effective antibody should accelerate the immune and GVHD response.
  • GVHD graft versus host disease
  • mice 40 female NSG mice aged 7 weeks and weighing approximately 19-22 g were used as human PBMC recipients. Groups were randomized into four groups of ten. On day 0, all animals received 2 ⁇ 10 7 human PBMC injected via the tail vein. Prior to PBMC injection, animals were dosed intraperitoneally (IP) with either control anti-GFP, Nivolumab anti-PD-1 antibody, or 1353-G10 anti-PD1 antibody (SEQ ID NOs: 252 and 276) as detailed in Table 9. Treatment was administered 2 ⁇ per week until study conclusion.
  • IP intraperitoneally
  • anti-PD-1 treatment with human IgG 1353-G10 showed accelerated mouse morbidity by approximately two weeks (median survival of 13 days for 10 mg/kg 1353-G10 versus 27 days for anti-GFP control).
  • the onset of GVHD severity was similar in mice treated with high (10 mg/kg) and low (3 mg/kg) 1353-G10.
  • Body weight loss was also faster with both doses of 1353-G10 compared to control and Nivolumab (data not shown).
  • Median survival with both doses of 1353-G10 was less compared to Nivolumab, indicating greater PD-1 blockade potency for 1353-G10 in vivo.
  • Table 10 provides sequences referred to herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Description

    FIELD
  • Provided herein are antibodies with binding specificity for PD-1 and compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions and kits. Also provided are methods of using anti-PD-1 antibodies for therapeutic and diagnostic purposes.
    • BACKGROUND
  • Programmed cell death protein 1 (PD-1, also known as CD279) is a cell surface protein molecule that belongs to the immunoglobulin superfamily. It is expressed on T and B lymphocytes and macrophages, and plays a role in cell fate and differentiation. See Ishida et al., EMBO J., 1992, 11:3887-3895, incorporated by reference in its entirety. Activation of PD-1 is thought to negatively regulate the immune response. See Blank et al., Cancer Immunol. Immunother., 2007, 56:739-745; and Freeman et al., J. Exp. Med., 2000, 192:1027-1034, each of which is incorporated by reference in its entirety.
  • PD-1 has two known ligands, PD-L1 and PD-L2, which are both members of the B7 family. See Freeman et al., supra; and Latchman et al., Nat. Immunol., 2001, 2:261-268, each of which is incorporated by reference in its entirety. The interaction between PD-1 and these ligands is thought to play a role in a variety of diseases, including cancer (see Ribas and Tumeh, Clin. Cancer Res., 2014, Jun. 26, PMID: 24970841 [Epub ahead of print]), autoimmune disease (see Dai et al., Cell Immunol., 2014, 290:72-79), and infection (see Day et al., Nature, 2006, 443:350-354). Each of the references cited in the preceding sentence is incorporated by reference in its entirety. In particular, the engagement of PD-1 by one of its ligands is thought to inhibit T-cell effector functions in an antigen-specific manner.
  • In view of the role of PD-1 in multiple disease processes, there is a need for improved methods of modulating the interaction of PD-1 with its ligands and the downstream signaling processes activated by PD-1. Moreover, given the role of PD-1 in several diseases, there is also a need for therapeutics that specifically target cells and tissues that express PD-1.
    • SUMMARY
  • Provided herein are antibodies that selectively bind PD-1. In some embodiments, the antibodies bind human PD-1. In some embodiments, the antibodies also bind homologs of human PD-1. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a murine homolog. In some embodiments, the antibodies bind to human PD-1, a cynomolgus monkey homolog, and a murine homolog.
  • In some embodiments, the antibodies comprise at least one CDR sequence defined by a consensus sequence provided in this disclosure. In some embodiments, the antibodies comprise an illustrative CDR, VH, or VL sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions.
  • Also provided are compositions and kits comprising the antibodies. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.
  • This disclosure also provides methods of using the anti-PD-1 antibodies provided herein. In some embodiments, the method is a method of treatment. In some embodiments, the method is a diagnostic method. In some embodiments, the method is an analytical method. In some embodiments, the method is a method of purifying and/or quantifying PD-1.
  • In some embodiments, the antibodies are used to treat a disease or condition. In some aspects, the disease or condition is selected from a cancer, autoimmune disease, and infection.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 provides a comparison of the Kabat and Chothia numbering systems for CDR-H1. Adapted from Martin A. C. R. (2010). Protein Sequence and Structure Analysis of Antibody Variable Domains. In R. Kontermann & S. Dübel (Eds.), Antibody Engineering vol. 2 (pp. 33-51). Springer-Verlag, Berlin Heidelberg.
  • FIG. 2 provides a chart of tumor volume over 17-days of treatment with various anti-PD-1 antibodies, as described in Example 15.
  • FIG. 3 provides a chart of interferon gamma (IFN-g) secretion in a cytomegalovirus (CMV) recall assay, as described in Example 16.
  • FIG. 4 provides a chart of interferon gamma (IFN-g) secretion in a mixed lymphocyte response (MLR) assay, as described in Example 17.
  • FIG. 5 provides a chart of mouse survival in a model of graft versus host disease, as described in Example 18.
    •  DETAILED DESCRIPTION 1. Definitions
  • Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.
  • As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise.
  • The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value±10%, ±5%, or ±1%. In certain embodiments, the term “about” indicates the designated value±one standard deviation of that value.
  • The term “combinations thereof” includes every possible combination of elements to which the term refers to. For example, a sentence stating that “if α2 is A, then α3 is not D; α5 is not S; or α6 is not S; or combinations thereof” includes the following combinations when α2 is A: (1) α3 is not D; (2) α5 is not S; (3) α6 is not S; (4) α3 is not D; as is not S; and α6 is not S; (5) α3 is not D and α5 is not S; (6) α3 is not D and α6 is not S; and (7) α5 is not S and α6 is not S.
  • The terms “PD-1” and “PD-1 antigen” are used interchangeably herein. Unless specified otherwise, the terms include any variants, isoforms and species homologs of human PD-1 that are naturally expressed by cells, or that are expressed by cells transfected with a PD-1 gene. PD-1 proteins include full-length PD-1 (e.g., human PD-1; GI: 167857792; SEQ ID NO: 1; extracellular domain: Pro21-Gln167), as well as alternative splice variants of PD-1, such as PD-1Δex2, PD-1Δex3, PD-1Δex2,3, and PD-1Δex2,3,4. See Nielsen et al., Cellular Immunology, 2005, 235:109-116, incorporated by reference in its entirety. In some embodiments, PD-1 proteins include murine PD-1 (e.g., SEQ ID NO: 299; extracellular domain: Leu25-Gln167). In some embodiments, PD-1 proteins include cynomolgus PD-1 (e.g., SEQ ID NO: 300; extracellular domain: Pro21-Gln167).
  • The term “immunoglobulin” refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, Pa. Briefly, each heavy chain typically comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, CH1, CH2, and CH3. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
  • The term “antibody” describes a type of immunoglobulin molecule and is used herein in its broadest sense. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), and antibody fragments. Antibodies comprise at least one antigen-binding domain. One example of an antigen-binding domain is an antigen binding domain formed by a VH-VL dimer. A “PD-1 antibody,” “anti-PD-1 antibody,” “PD-1 Ab,” “PD-1-specific antibody” or “anti-PD-1 Ab” is an antibody, as described herein, which binds specifically to the antigen PD-1. In some embodiments, the antibody binds the extracellular domain of PD-1.
  • The VH and VL regions may be further subdivided into regions of hypervariability (“hypervariable regions (HVRs);” also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved. The more conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The CDRs are involved in antigen binding, and confer antigen specificity and binding affinity to the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, Md., incorporated by reference in its entirety.
  • The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
  • The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
  • The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated by reference in its entirety.
  • Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes. FIG. 1 provides a comparison of the Kabat and Chothia numbering schemes for CDR-H1. See Martin (2010), supra.
  • Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat/Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge, the numbering scheme is specified as either Kabat or Chothia.
  • TABLE 1
    Residues in CDRs according to Kabat
    and Chothia numbering schemes.
    CDR Kabat Chothia
    L1 L24-L34 L24-L34
    L2 L50-L56 L50-L56
    L3 L89-L97 L89-L97
    H1 (Kabat Numbering) H31-H35B H26-H32 or H34*
    H1 (Chothia Numbering) H31-H35 H26-H32
    H2 H50-H65 H52-H56
    H3 H95-H102 H95-H102
    *The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR, as illustrated in FIG. 1.
  • The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
  • An “antibody fragment” comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab′)2 fragments, Fab′ fragments, scFv (sFv) fragments, and scFv-Fc fragments.
  • “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.
  • “Fab” fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (Cm) of the heavy chain. Fab fragments may be generated, for example, by papain digestion of a full-length antibody.
  • “F(ab′)2” fragments contain two Fab′ fragments joined, near the hinge region, by disulfide bonds. F(ab′)2 fragments may be generated, for example, by pepsin digestion of an intact antibody. The F(ab′) fragments can be dissociated, for example, by treatment with ß-mercaptoethanol.
  • “Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise a VII domain and a VL domain in a single polypeptide chain. The VH and VL are generally linked by a peptide linker. See Plückthun A. (1994). Antibodies from Escherichia coli. In Rosenberg M. & Moore G. P. (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety. “scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminal of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL-VH). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain is an IgG1 Fc domain (e.g., SEQ ID NO: 295). In some embodiments, the linker is (G4S)3 (see SEQ ID NO: 298).
  • The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and/or to reduce its immunogenicity in a subject.
  • The term “chimeric antibody” refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
  • “Humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.
  • A “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.
  • An “isolated antibody” is one that has been separated and/or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated antibody is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody's natural environment is not present. In some aspects, an isolated antibody is prepared by at least one purification step.
  • In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by weight of an antibody, the remainder of the weight comprising the weight of other solutes dissolved in the solvent.
  • “Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument.
  • With regard to the binding of an antibody to a target molecule, the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that is similar to the target, such as an excess of non-labeled target. In that case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by the excess non-labeled target.
  • The term “kd” (sec−1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.
  • The term “ka” (M−1×sec−1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.
  • The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD=kd/ka.
  • The term “KA” (M−1), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA=ka/kd.
  • An “affinity matured” antibody is one with one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen, compared to a parent antibody which does not possess the alteration(s). In one embodiment, an affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies may be produced using a variety of methods known in the art. For example, Marks et al. (Bio/Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by, for example, Barbas et al. (Proc. Nat. Acad. Sci. USA., 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.
  • When used herein in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (e.g., PD-1). In one exemplary assay, PD-1 is coated on a plate and allowed to bind a first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces binding of the second antibody, then the antibodies compete. The term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of the order in which they are added. In some embodiments, one antibody reduces binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
  • The term “epitope” means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and/or sugar side chains and may have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to PD-1 variants with different point-mutations.
  • Percent “identity” between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, or CLUSTAL OMEGA software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • A “conservative substitution” or a “conservative amino acid substitution,” refers to the substitution of one or more amino acids with one or more chemically or functionally similar amino acids. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as “conservatively modified variants.” Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. By way of example, the following groups of amino acids are considered conservative substitutions for one another.
  •
    Acidic Residues D and E
    Basic Residues K, R, and H
    Hydrophilic Uncharged Residues S, T, N, and Q
    Aliphatic Uncharged Residues G, A, V, L, and I
    Non-polar Uncharged Residues C, M, and P
    Aromatic Residues F, Y, and W
    Alcohol Group-Containing Residues S and T
    Aliphatic Residues I, L, V, and M
    Cycloalkenyl-associated Residues F, H, W, and Y
    Hydrophobic Residues A, C, F, G, H, I, L,
    M, R, T, V, W, and Y
    Negatively Charged Residues D and E
    Polar Residues C, D, E, H, K, N, Q, R, S, and T
    Positively Charged Residues H, K, and R
    Small Residues A, C, D, G, N, P, S, T, and V
    Very Small Residues A, G, and S
    Residues Involved in A, C, D, E, G, H, K,
    Turn Formation N, Q, R, S, P, and T
    Flexible Residues Q, T, K, S, G, P, D, E, and R
    Group 1 A, S, and T
    Group 2 D and E
    Group 3 N and Q
    Group 4 R and K
    Group 5 I, L, and M
    Group 6 F, Y, and W
    Group A A and G
    Group B D and E
    Group C N and Q
    Group D R, K, and H
    Group E I, L, M, V
    Group F F, Y, and W
    Group G S and T
    Group H C and M

    Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, N.Y. An antibody generated by making one or more conservative substitutions of amino acid residues in a parent antibody is referred to as a “conservatively modified variant.”
  • The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).
  • “Treating” or “treatment” of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder that exists in a subject. In another embodiment, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, “treating” or “treatment” includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” includes delaying or preventing the onset of the disease or disorder.
  • As used herein, the term “therapeutically effective amount” or “effective amount” refers to an amount of an antibody or composition that when administered to a subject is effective to treat a disease or disorder.
  • As used herein, the term “subject” means a mammalian subject. Exemplary subjects include, but are not limited to humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, avians, goats and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has cancer, an autoimmune disease or condition, and/or an infection that can be treated with an antibody provided herein. In some embodiments, the subject is a human that is suspected to have cancer, an autoimmune disease or condition, and/or an infection.
    • 2. Antibodies
  • Provided herein are antibodies that selectively bind human PD-1. In some aspects, the antibody selectively binds to the extracellular domain of human PD-1. In some aspects, the antibody selectively binds to one or more of full-length human PD-1, PD-1Δex2, PD-1Δex3, PD-1Δex2,3, and PD-1Δex2,3,4. See Nielsen et al., Cellular Immunology, 2005, 235:109-116, incorporated by reference in its entirety.
  • In some embodiments, the antibody binds to homologs of human PD-1. In some aspects, the antibody binds to a homolog of human PD-1 from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats and sheep. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a murine homolog.
  • In some embodiments, the antibody has one or more CDRs having particular lengths, in terms of the number of amino acid residues. In some embodiments, the Chothia CDR-H1 of the antibody is 6, 7, 8, or 9 residues in length. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5, 6, or 7 residues in length. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length. In some embodiments, the Kabat CDR-H2 of the antibody is 15, 16, 17, or 18 residues in length. In some embodiments, the Kabat/Chothia CDR-H3 of the antibody is 5, 6, 7, 8, 9, 10, 11, or 12 residues in length.
  • In some aspects, the Kabat/Chothia CDR-L1 of the antibody is 9, 10, 11, 12, 13, 14, 15, or 16 residues in length. In some aspects, the Kabat/Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some aspects, the Kabat/Chothia CDR-L3 of the antibody is 8, 9, 10, 11, or 12 residues in length.
  • In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.
  • In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgG1. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgA1. In some aspects, the heavy chain is an IgA2.
  • In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab′)2 fragment. In some aspects, the antibody fragment is a Fab′ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.
  • In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.
  • In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.
  • In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure.
  • In some embodiments, the antibody inhibits the binding of PD-1 to its ligands. In some aspects, the antibody inhibits the binding of PD-1 to PD-L1. In some aspects, the antibody inhibits the binding of PD-1 to PD-L2. In some aspects, the antibody inhibits the binding of PD-1 to PD-L1 and PD-L2.
  • The antibodies provided herein may be useful for the treatment of a variety of diseases and conditions, including cancers, autoimmune diseases, and infections.
  • 2.1. CDR-H3 Sequences
  • In some embodiments, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 309. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 310. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 311. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 312. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 313. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 314. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 315.
  • In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 132-136. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 132. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 133. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 134. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 135. In some aspects, the CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 136.
  • 2.2. VH Sequences Comprising Illustrative CDRs
  • In some embodiments, the antibody comprises a VH sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in this disclosure, and variants thereof.
  • 2.2.1. VH Sequences Comprising Illustrative Kabat CDRs
  • In some embodiments, the antibody comprises a VH sequence comprising one or more Kabat CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-H sequences provided in this disclosure, and variants thereof.
  • 2.2.1.1. Kabat CDR-H3
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. In some aspects, the antibody comprises a VII sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 309. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 310. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 311. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 312. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 313. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 314. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 315.
  • 2.2.1.2. Kabat CDR-H2
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331. In some aspects, the antibody comprises a VII sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 91. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. In some aspects, the antibody comprises a VII sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 331.
  • 2.2.1.3. Kabat CDR-H1
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 31. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 32. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 33. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 34 In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 35. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 36. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 37. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 38. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 39. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 40. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 41. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 42. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 43. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 44. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 45. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 46. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 47. In some aspects, the antibody comprises a VII sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 48. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 49.
  • 2.2.1.4. Kabat CDR-H3+Kabat CDR-H2
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331. In some aspects, the Kabat CDR-H3 sequence and the Kabat CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H3 and Kabat CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • 2.2.1.5. Kabat CDR-H3+Kabat CDR-H1
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49. In some aspects, the Kabat CDR-H3 sequence and the Kabat CDR-H1 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H3 and Kabat CDR-H1 are both from a single illustrative VII sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • 2.2.1.6. Kabat CDR-H1+Kabat CDR-H2
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49 and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331. In some aspects, the Kabat CDR-H1 sequence and the Kabat CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1 and Kabat CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 246-264. 2.2.1.7. Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3
  • In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 31-49, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 84-102 or 331, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 sequence are all from a single illustrative VII sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • 2.2.1.8. Variants of VH Sequences Comprising Illustrative Kabat CDRs
  • In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
  • In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.2.1.9. Excluded VH Sequences Comprising Kabat CDRs
  • In some embodiments, the VH sequences provided herein do not comprise certain Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequences.
  • In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 108-112 or 132-136. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 108. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 109. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 110. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 111. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 112. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 132. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 133. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 134. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 135. In some aspects, the Kabat CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 136.
  • In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 55-59 or 103-107. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 55. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 56. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 57. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 58. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 59. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 103. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 104. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 105. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 106. In some aspects, the Kabat CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 107.
  • In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 2-6 or 50-54. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 2. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 3. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 4. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 5. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 6. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 50. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 51. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 52. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 53. In some aspects, the Kabat CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 54.
  • 2.2.2. VH Sequences Comprising Illustrative Chothia CDRs
  • In some embodiments, the antibody comprises a VH sequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in this disclosure, and variants thereof.
  • 2.2.2.1. Chothia CDR-H3
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a VII sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 309. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 310. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 311. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 312. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 313. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 314. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 315.
  • 2.2.2.2. Chothia CDR-H2
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 60. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 61. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 62. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 63. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 64. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 65. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 66. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 67. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 68. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 69. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 70. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 71. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 72. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 73. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 74. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 75. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 76. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 78.
  • 2.2.2.3. Chothia CDR-H1
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 7. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 8. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 9. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 10 In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 11. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 12. In some aspects, the antibody comprises a VII sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 13. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 14. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 15. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 16. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 17. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 18. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 19. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 20. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 21. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 22. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 23. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 24. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 25.
  • 2.2.2.4. Chothia CDR-H3+Chothia CDR-H2
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78. In some aspects, the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H3 and Chothia CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • 2.2.2.5. Chothia CDR-H3+Chothia CDR-H1
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315, and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25. In some aspects, the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H3 and Chothia CDR-H1 are both from a single illustrative VII sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • 2.2.2.6. Chothia CDR-H1+Chothia CDR-H2
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25 and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78. In some aspects, the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1 and Chothia CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 246-264.
  • 2.2.2.7. Chothia CDR-H1+Chothia CDR-H2+Chothia CDR-H3
  • In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 7-25, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 60-78, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 113-131 and 309-315. In some aspects, the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 246-264 and 316-322.
  • 2.2.2.8. Variants of VH Sequences Comprising Illustrative Chothia CDRs
  • In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
  • In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.2.2.9. Excluded VH Sequences Comprising Chothia CDRs
  • In some embodiments, the VH sequences provided herein do not comprise certain Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequences.
  • In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 108-112 or 132-136. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 108. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 109. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 110. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 111. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 112. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 132. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 133. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 134. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 135. In some aspects, the Chothia CDR-H3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 136.
  • In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 79-83. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 79. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 80. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 81. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 82. In some aspects, the Chothia CDR-H2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 83.
  • In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 26-30. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 26. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 27. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 28. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 29. In some aspects, the Chothia CDR-H1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 30.
  • 2.3. VH Sequences
  • In some embodiments, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 246-264 and 316-322. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 246. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 247. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 248. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 249. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 250. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 251. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 252. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 253. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 254. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 255 (with or without a serine prepended to the sequence). In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 256. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 257. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 258. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 259. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 260. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 261. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 262. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 263. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 264. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 316. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 317. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 318. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 319. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 320. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 321. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 322.
  • 2.3.1. Variants of VH Sequences
  • In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in this disclosure.
  • In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
  • In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.3.2. Excluded VH Sequences
  • In some embodiments, the VH sequences provided herein do not comprise certain VH sequences.
  • In some aspects, the VH sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 265-269. In some aspects, the VH sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 265. In some aspects, the VH sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 266. In some aspects, the VH sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 267. In some aspects, the VH sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 268. In some aspects, the VH sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 269.
  • 2.4. CDR-L3 Sequences
  • In some embodiments, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 200. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 201. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 202. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 203. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 204. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 205. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 206. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 207. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 208. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 209. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 210. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 211. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 212. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 213. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 214. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 215. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 216. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 217. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 218.
  • In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 195-199 or 219-223. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 195. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 196. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 197. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 198. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 199. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 219. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 220. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 221. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 222. In some aspects the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 223.
  • 2.5. VL Sequences Comprising Illustrative CDRs
  • In some embodiments, the antibody comprises a VL sequence comprising one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-L sequences provided in this disclosure, and variants thereof.
  • 2.5.1. CDR-L3
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 200. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 201. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 202. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 203. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 204. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 205. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 206. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 207. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 208. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 209. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 210. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 211. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 212. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 213. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 214. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 215. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 216. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 217. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 218.
  • 2.5.2. CDR-L2
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 171. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 172. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 173. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 174. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 175. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 176. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 177. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 178. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 179. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 180. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 181. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 182. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 183. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 184. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 185. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 186. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 187. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 188. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 189.
  • 2.5.3. CDR-L1
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 145. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 146. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 147. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 148. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160.
  • 2.5.4. CDR-L3+CDR-L2
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189. In some aspects, the CDR-L3 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L3 and CDR-L2 are both from a single illustrative VL sequence selected from SEQ ID NOs: 270-288.
  • 2.5.5. CDR-L3+CDR-L1
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218 and a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160. In some aspects, the CDR-L3 sequence and the CDR-L1 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L3 and CDR-L1 are both from a single illustrative VL sequence selected from SEQ ID NOs: 270-288.
  • 2.5.6. CDR-L1+CDR-L2
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189. In some aspects, the CDR-L1 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1 and CDR-L2 are both from a single illustrative VL sequence selected from SEQ ID NOs: 270-288.
  • 2.5.7. CDR-L1+CDR-L2+CDR-L3
  • In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 142-160, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 171-189, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1, CDR-L2, and CDR-L3 are all from a single illustrative VL sequence selected from SEQ ID NOs: 270-288.
  • 2.5.8. Variants of VL Sequences Comprising Illustrative CDR-Ls
  • In some embodiments, the VL sequences provided herein comprise a variant of an illustrative CDR-L3, CDR-L2, and/or CDR-L1 sequence provided in this disclosure.
  • In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.5.9. Excluded VL Sequences Comprising CDR-Ls
  • In some embodiments, the VL sequences provided herein do not comprise certain CDR-L3, CDR-L2, and/or CDR-L1 sequences.
  • In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 195. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 196. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 197. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 198. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 199. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 219. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 220. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 221. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 222. In some aspects, the CDR-L3 sequence does not comprise, consist of, or consist essentially of SEQ ID NOs: 223.
  • In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 166-170 or 190-194. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 190. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 166. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 167. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 168. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 169. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 170. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 191. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 192. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 193. In some aspects, the CDR-L2 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 194.
  • In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 137-141 or 161-165. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 137. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 138. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 139. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 140. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 141. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 161. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 162. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 163. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 164. In some aspects, the CDR-L1 sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 165.
  • 2.6. VL Sequences
  • In some embodiments, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 270-288. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 270. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 281. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 282. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 283. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 284. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 285. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 286. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 287. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 288.
  • 2.6.1. Variants of VL Sequences
  • In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VL sequence provided in this disclosure.
  • In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity with any of the illustrative VL sequences provided in this disclosure.
  • In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.6.2. Excluded VL Sequences
  • In some embodiments, the VL sequences provided herein do not comprise certain VL sequences.
  • In some aspects, the VL sequence does not comprise, consist of, or consist essentially of a sequence selected from SEQ ID NOs: 289-293. In some aspects, the VL sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 289. In some aspects, the VL sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 290. In some aspects, the VL sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 291. In some aspects, the VL sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 292. In some aspects, the VL sequence does not comprise, consist of, or consist essentially of SEQ ID NO: 293.
  • 2.7. Pairs
  • 2.7.1. CDR-H3-CDR-L3 Pairs
  • In some embodiments, the antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is part of a VII and the CDR-L3 sequence is part of a VL.
  • In some aspects, the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 113-131 and 309-315, and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 200-218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 113, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 114, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 115, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 116, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 117, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 118, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 119, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 120, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 121, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 122, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 123, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 124, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 125, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 126, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 127, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 128, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 129, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 130, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 131, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 309, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 310, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 311, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 312, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 313, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 314, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • In some aspects, the CDR-H3 sequence is SEQ ID NO: 315, and the CDR-L3 sequence is selected from SEQ ID NOs: 200-218. In some aspects, the CDR-L3 sequence is SEQ ID NO: 200. In some aspects, the CDR-L3 sequence is SEQ ID NO: 201. In some aspects, the CDR-L3 sequence is SEQ ID NO: 202. In some aspects, the CDR-L3 sequence is SEQ ID NO: 203. In some aspects, the CDR-L3 sequence is SEQ ID NO: 204. In some aspects, the CDR-L3 sequence is SEQ ID NO: 205. In some aspects, the CDR-L3 sequence is SEQ ID NO: 206. In some aspects, the CDR-L3 sequence is SEQ ID NO: 207. In some aspects, the CDR-L3 sequence is SEQ ID NO: 208. In some aspects, the CDR-L3 sequence is SEQ ID NO: 209. In some aspects, the CDR-L3 sequence is SEQ ID NO: 210. In some aspects, the CDR-L3 sequence is SEQ ID NO: 211. In some aspects, the CDR-L3 sequence is SEQ ID NO: 212. In some aspects, the CDR-L3 sequence is SEQ ID NO: 213. In some aspects, the CDR-L3 sequence is SEQ ID NO: 214. In some aspects, the CDR-L3 sequence is SEQ ID NO: 215. In some aspects, the CDR-L3 sequence is SEQ ID NO: 216. In some aspects, the CDR-L3 sequence is SEQ ID NO: 217. In some aspects, the CDR-L3 sequence is SEQ ID NO: 218.
  • 2.7.1.1. Variants of CDR-H3-CDR-L3 Pairs
  • In some embodiments, the CDR-H3-CDR-L3 pairs provided herein comprise a variant of an illustrative CDR-H3 and/or CDR-L1 sequence provided in this disclosure.
  • In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.7.1.2. Excluded CDR-H3-CDR-L3 Pairs
  • In some embodiments, the CDR-H3-CDR-L3 pairs provided herein do not comprise certain CDR-H3-CDR-L3 pairs.
  • In some aspects, the CDR-H3 sequence is not selected from SEQ ID NOs: 108-112 or 132-136, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 108, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 109, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 110, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 111, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 112, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 132, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 133, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 134, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 135, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • In some aspects, the CDR-H3 sequence is not SEQ ID NO: 136, and the CDR-L3 sequence is not selected from SEQ ID NOs: 195-199 or 219-223. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 195. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 196. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 197. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 198. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 199. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 219. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 220. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 221. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 222. In some aspects, the CDR-L3 sequence is not SEQ ID NO: 223.
  • 2.7.2. VH-VL Pairs
  • In some embodiments, the antibody comprises a VH sequence and a VL sequence.
  • In some aspects, the VH sequence is a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 246-264 and 316-322, and the VL sequence is a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 270-288.
  • In some aspects, the VH sequence is SEQ ID NO: 246, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 247, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 248, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 249, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 250, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 251, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 252, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 253, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 254, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 255 (with or without a serine prepended to the sequence), and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 256, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 257, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 258, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 259, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 260, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 261, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 262, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 263, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 264, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 316, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 317, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 318, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 319, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 320, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 321, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • In some aspects, the VH sequence is SEQ ID NO: 322, and the VL sequence is selected from SEQ ID NOs: 270-288. In some aspects, the VL sequence is SEQ ID NO: 270. In some aspects, the VL sequence is SEQ ID NO: 271. In some aspects, the VL sequence is SEQ ID NO: 272. In some aspects, the VL sequence is SEQ ID NO: 273. In some aspects, the VL sequence is SEQ ID NO: 274. In some aspects, the VL sequence is SEQ ID NO: 275. In some aspects, the VL sequence is SEQ ID NO: 276. In some aspects, the VL sequence is SEQ ID NO: 277. In some aspects, the VL sequence is SEQ ID NO: 278. In some aspects, the VL sequence is SEQ ID NO: 279. In some aspects, the VL sequence is SEQ ID NO: 280. In some aspects, the VL sequence is SEQ ID NO: 281. In some aspects, the VL sequence is SEQ ID NO: 282. In some aspects, the VL sequence is SEQ ID NO: 283. In some aspects, the VL sequence is SEQ ID NO: 284. In some aspects, the VL sequence is SEQ ID NO: 285. In some aspects, the VL sequence is SEQ ID NO: 286. In some aspects, the VL sequence is SEQ ID NO: 287. In some aspects, the VL sequence is SEQ ID NO: 288.
  • 2.7.2.1. Variants of VH-VL Pairs
  • In some embodiments, the VH-VL pairs provided herein comprise a variant of an illustrative VH and/or VL sequence provided in this disclosure.
  • In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity with any of the illustrative VH sequences provided in this disclosure.
  • In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity with any of the illustrative VL sequences provided in this disclosure.
  • In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure, 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
  • 2.7.2.2. Excluded VH-VL Pairs
  • In some embodiments, the VH-VL pairs provided herein do not comprise certain VH-VL pairs.
  • In some aspects, the VH sequence is not selected from SEQ ID NOs: 265-269, and the VL sequence is not selected from SEQ ID NOs: 289-293.
  • In some aspects, the VH sequence is not SEQ ID NO: 265, and the VL sequence is not selected from SEQ ID NO: 289-293. In some aspects, the VL sequence is not SEQ ID NO: 289. In some aspects, the VL sequence is not SEQ ID NO: 290. In some aspects, the VL sequence is not SEQ ID NO: 291. In some aspects, the VL sequence is not SEQ ID NO: 292. In some aspects, the VL sequence is not SEQ ID NO: 293.
  • In some aspects, the VH sequence is not SEQ ID NO: 266, and the VL sequence is not selected from SEQ ID NO: 289-293. In some aspects, the VL sequence is not SEQ ID NO: 289. In some aspects, the VL sequence is not SEQ ID NO: 290. In some aspects, the VL sequence is not SEQ ID NO: 291. In some aspects, the VL sequence is not SEQ ID NO: 292. In some aspects, the VL sequence is not SEQ ID NO: 293.
  • In some aspects, the VH sequence is not SEQ ID NO: 267, and the VL sequence is not selected from SEQ ID NO: 289-293. In some aspects, the VL sequence is not SEQ ID NO: 289. In some aspects, the VL sequence is not SEQ ID NO: 290. In some aspects, the VL sequence is not SEQ ID NO: 291. In some aspects, the VL sequence is not SEQ ID NO: 292. In some aspects, the VL sequence is not SEQ ID NO: 293.
  • In some aspects, the VH sequence is not SEQ ID NO: 268, and the VL sequence is not selected from SEQ ID NO: 289-293. In some aspects, the VL sequence is not SEQ ID NO: 289. In some aspects, the VL sequence is not SEQ ID NO: 290. In some aspects, the VL sequence is not SEQ ID NO: 291. In some aspects, the VL sequence is not SEQ ID NO: 292. In some aspects, the VL sequence is not SEQ ID NO: 293.
  • In some aspects, the VH sequence is not SEQ ID NO: 269, and the VL sequence is not selected from SEQ ID NO: 289-293. In some aspects, the VL sequence is not SEQ ID NO: 289. In some aspects, the VL sequence is not SEQ ID NO: 290. In some aspects, the VL sequence is not SEQ ID NO: 291. In some aspects, the VL sequence is not SEQ ID NO: 292. In some aspects, the VL sequence is not SEQ ID NO: 293.
  • 2.8. Consensus Sequences
  • In some embodiments, provided herein are anti-PD-1 antibodies comprising one or more sequences defined by consensus sequences. Each consensus sequence is based, at least in part, on one or more alignments of two or more useful anti-PD-1 CDR sequences provided in this disclosure. Based on such alignments, a person of skill in the art would recognize that different amino acid residues may useful in certain positions of the CDRs. Accordingly, each consensus sequence encompasses two or more useful anti-PD-1 CDR sequences.
  • 2.8.1. CDR-H3 Consensus Sequences
  • In some embodiments, the antibody comprises a CDR-H3 sequence defined by the consensus sequence D-α2-α3-Y-α5-α6-G-S-G-Y, where α2 is A, V, or S; α3 is D or E; α5 is S or G; and α6 is S, L, or T. In some embodiments, as is S, G, or R. Sequencing of individual clones isolated from the output of the antibody selection process revealed that R occurred at position as at nearly the same frequency as G.
  • In some aspects, if α2 is A, then α3 is not D; α5 is not S; or α6 is not S; or combinations thereof.
  • In some aspects, α2 is V or S; α3 is E; as is G; or α6 is L or T; or combinations thereof.
  • In some aspects, α2 is not A; α3 is not D; α5 is not S; or α6 is not S; or combinations thereof.
  • In some embodiments, the antibody comprises a CDR-H3 sequence defined by the consensus sequence ß1-G-Y-ß4-ß5-Y-ß7-β8-F-ß10-ß11, where ß1 is not present or Q; ß4 is G or D; ß5 is N or V; ß7 is L or S; ß8 is Y or W; ß10 is D or A; and ß11 is V or Y.
  • 2.8.2. Chothia CDR-H1 Consensus Sequences
  • In some embodiments, the antibody comprises a Chothia CDR-H1 sequence defined by the consensus sequence G-ε2-ε3-ε4-ε5-ε6-ε7, where ε2 is Y or F; ε3 is T, R or I; ε4 is F or L; ε5 is S, E, T, P, or R; ε6 is T, S, H, Q, R, or W; and ε7 is F, Y, or Q.
  • In some aspects, if ε5 is T, then ε6 is not S.
  • In some aspects, ε5 is S, E, P, or R; or ε6 is T, H, Q, R, or W; or combinations thereof.
  • In some aspects, ε2 is not Y; ε3 is not T or R; ε5 is not T; ε6 is not S; or ε7 is not Y; or combinations thereof.
  • 2.8.3. Kabat CDR-H2 Consensus Sequences
  • In some embodiments, the antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence W-γ2-S-A-γ5-N-G-N-T-γ10-Y-A-Q-K-L-Q-G, where γ2 is I or V; γ5 is Y or H; and γ10 is K or N.
  • In some aspects, γ2 is not I; γ5 is not Y; or γ10 is not N; or combinations thereof.
  • In some embodiments, the antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence δ1-I-S-G-δ5-G-δ7-δ8-T-Y-Y-δ12-D-S-V-δ16-G, where δ1 is T or A; δ5 is S or G; δ7 is S or G; δ8 is S, D or N; δ12 is A, P or S; and δ16 is K or Q.
  • In some aspects, if δ1 is A, then δ5 is not S; δ7 is not G; δ8 is not S; δ12 is not A; or δ16 is not K; or combinations thereof.
  • In some aspects, δ1 is T; δ5 is G; δ7 is S; δ8 is D or N; or δ12 is P or S; or combinations thereof.
  • In some aspects, δ1 is not A; δ5 is not S; δ7 is not G; δ8 is not S; δ12 is not A; or δ16 is not K; or combinations thereof.
  • 2.8.4. Kabat CDR-H1 Consensus Sequences
  • In some embodiments, the antibody comprises a Kabat CDR-H1 sequence defined by the consensus sequence Θ1-Θ2-G-Θ4-S, where Θ1 is T, R, W, Q, H, or S; Θ2 is Y, F, or Q; and Θ4 is M or I.
  • In some aspects, Θ1 is T, R, W, Q, or H; Θ2 is F or Q; or Θ4 is M; or combinations thereof.
  • In some aspects, Θ1 is not S; Θ2 is not Y; or Θ4 is not I; or combinations thereof.
  • 2.8.5. CDR-L3 Consensus Sequences
  • In some embodiments, the antibody comprises a CDR-L3 sequence defined by the consensus sequence Q-Q-π3-π4-π5-π6-P-π8-T, where π3 is N, S, or W; π4 is Y, K, or I; π5 is N, E, or S; π6 is S, V, D, or T; and π8 is Y or W.
  • In some aspects, if π4 is Y, then π3 is not S; π5 is not S; π6 is not T; or π8 is not W; or combinations thereof.
  • In some aspects, π3 is N or W; π4 is K or I; π5 is N or E; π6 is S, V, or D; or π8 is Y; or combinations thereof.
  • In some aspects, π3 is not S; π4 is not Y; π5 is not S; π6 is not T; or π8 is not W; or combinations thereof.
  • 2.8.6. CDR-L1 Consensus Sequences
  • In some embodiments, the antibody comprises a CDR-L1 sequence defined by the consensus sequence S-G-D-A-L-μ6-μ7-Q-Y-μ10-Y, where μ6 is P, T, or S; μ7 is M, T, E, or K; and μ10 is G or A.
  • In some aspects, if μ6 is P, then μ7 is not K, μ10 is not A, or combinations thereof.
  • In some aspects, μ6 is T or S; μ7 is M, T, or E; or μ10 is G; or combinations thereof.
  • In some aspects, μ6 is not P; μ7 is not K; or μ10 is not A; or combinations thereof.
  • In some embodiments, the antibody comprises a CDR-L1 sequence defined by the consensus sequence R-A-S-E-Σ5-V-D-Σ8-Σ9-G-Σ11-S-F-M-Σ15, where Σ5 is S or N; Σ8 is N or D; Σ9 is S or Y; Σ11 is I or V; and Σ15 is S or N.
    • 3. Germline
  • In some embodiments, the antibody that specifically binds PD-1 is an antibody comprising a variable region that is encoded by a particular germline gene, or a variant thereof. The illustrative antibodies provided herein comprise variable regions that are encoded by the heavy chain variable region germline genes VH1-18, VH3-21, VH3-7, and VH3-15, or variants thereof; and the light chain variable region germline genes Vλ3-25, Vκ1-9, Vκ3-11, Vκ3-20, and Vκ4-1, or variants thereof. One of skill in the art would recognize that the CDR sequences provided herein may also be useful when combined with variable regions encoded by other variable region germline genes, or variants thereof. In particular, the CDR sequences provided herein may be useful when combined with variable regions encoded by variable region germline genes, or variants thereof, that are structurally similar to the variable region germline genes recited above. For example, in some embodiments, a CDR-H sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the VH1 or VH3 family, or a variant thereof. In some embodiments, a CDR-L sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the Vλ3, Vκ1, Vκ3, and Vκ4 families, or a variant thereof.
    • 4. Affinity
  • In some embodiments, the affinity of the antibody for PD-1, as indicated by KD, is less than about 10−5 M, less than about 10−6 M, less than about 10−7 M, less than about 10−8 M, less than about 10−9 M, less than about 10−10 M, less than about 10−11 M, or less than about 10−12 M. In some embodiments, the affinity of the antibody is between about 10−7 M and 10−11 M. In some embodiments, the affinity of the antibody is between about 10−7 M and 10−10 M. In some embodiments, the affinity of the antibody is between about 10−7 M and 10−9 M. In some embodiments, the affinity of the antibody is between about 10−7 M and 10−8 M. In some embodiments, the affinity of the antibody is between about 10−8 M and 10−11 M. In some embodiments, the affinity of the antibody is between about 10−8 M and 10−10 M. In some embodiments, the affinity of the antibody is between about 10−9 M and 10−11 M. In some embodiments, the affinity of the antibody is between about 10−10 M and 10−11M.
  • In some embodiments, the affinity of the antibody for human PD-1 is between about 3.85×10−8 M and 2.52×10−10 M. In some embodiment, the affinity of the antibody for human PD-1 is about 2.55×10−8 M, about 1.52×10−8 M, about 9.52×10−9 M, about 1.09×10−8 M, about 4.50×10−9 M, about 1.90×10−9 M, about 4.76×10−9 M, about 4.5×10−9 M, about 1.04×10−8 M, about 9.90×10−9 M, about 9.13×10−10 M, about 2.52×10−10 M, about 2.58×10−9 M, about 3.85×10−8 M, about 3.66×10−9 M, about 3.15×10−9 M, about 5.14×10−9 M, about 2.47×10−9M, about 2.79×10−9M, about 1.20×10−9M, or about 1.28×10−8 M
  • In some embodiments, the affinity of the antibody for human PD-1 expressed on the surface of a cell is between about 3.2 and about 0.2 nM. In some embodiment, the affinity of the antibody for human PD-1 expressed on the surface of a cell is about 0.2 nM, about 0.4 nM, about 0.9 nM, about 1 nM, about 0.3 nM, about 0.7 nM, about 0.2 nM, about 0.8 nM, about 3.2 nM, about 2.9 nM, about 1.39 nM, or about 1.34 nM.
  • In some embodiments, the affinity of the antibody for murine PD-1 is between about 6.09×10−8 M and 9.08×10−9 M. In some embodiment, the affinity of the antibody for murine PD-1 is about 6.09×10−8 M, about 6.22×10−8 M, or about 9.08×10−9 M.
  • In some embodiments, the affinity of the antibody for cynomolgus PD-1 is between about 2.43×10−8 M and 1.95×10−10 M. In some embodiment, the affinity of the antibody for cynomolgus PD-1 is about 2.43×10−8 M, about 1.55×10−8 M, about 2.22×10−8 M, about 2.56×10−9M, about 2.54×10−9M, about 5.61×10−10 M, or about 1.95×10−10 M
  • In some embodiments the antibody has a ka of at least about 104 M−1×sec−1. In some embodiments the antibody has a ka of at least about 105 M−1×sec−1. In some embodiments the antibody has a ka of at least about 106 M−1×sec−1. In some embodiments the antibody has a ka of between about 104 M−1×sec−1 and about 105 M−1×sec−1. In some embodiments the antibody has a ka of between about 105 M−1×sec−1 and about 106 M−1×sec−1.
  • In some embodiments the antibody has a ka when associating with human PD-1 of between about 4.74×104 M−1×sec−1 and about 1.23×106 M−1×sec−1. In some embodiments the antibody has a ka when associating with human PD-1 of about 4.88×105 M−1×sec−1, about 1.23×106 M−1×sec−1, about 7.37×105 M−1×sec−1, about 6.87×105 M−1×sec−1, about 5.63×105 M−1×sec−1, about 5.16×105 M−1×sec−1, about 2.48×105 M−1×sec−1, about 7.98×105 M−1×sec−1, about 1.82×105 M−1×sec−1, about 4.74×104 M−1×sec−1, about 1.85×105 M−1×sec−1, about 2.00×105 M−1×sec−1, about 8.12×104 M−1×sec−1, about 1.21×106 M−1×sec−1, about 1.16×106 M−1×sec−1, about 5.13×105 M−1×sec−1, or about 1.86×105 M−1×sec−1.
  • In some embodiments the antibody has a kd of about 10−5 sec−1 or less. In some embodiments the antibody has a kd of about 104 sec−1 or less. In some embodiments the antibody has a kd of about 10−3 sec−1 or less. In some embodiments the antibody has a kd of between about 10−2 sec−1 and about 10−5 sec−1. In some embodiments the antibody has a kd of between about 10−2 sec−1 and about 10−4 sec−1. In some embodiments the antibody has a kd of between about 10−3 sec−1 and about 10−5 sec−1.
  • In some embodiments the antibody has a kd when dissociating from human PD-1 of between about 1.87×10−2 sec−1 and about 4.17×10−4 sec−1. In some embodiments the antibody has a kd when dissociating from human PD-1 of about 1.24×10−2 sec−1, about 1.87×10−2 sec−1, about 7.01×10−3 sec−1, about 7.74×10−3 sec−1, about 2.54×10−3 sec−1, about 9.80×10−4 sec−1, about 1.18×10−3 sec−1, about 3.59×10−3 sec−1, about 4.68×10−4 sec−1, about 1.82×10−3 sec−1, about 6.79×10−4 sec−1, about 6.28×10−4 sec−1, about 4.17×10−4 sec−1, about 2.99×10−3 sec−1, about 3.24×10−3 sec−1, about 6.17×10−4 sec−1, or about 2.39×10−3 sec−1.
  • In some aspects, the KD, ka, and kd are determined at 25° C. In some embodiments, the KD, ka, and kd are determined by surface plasmon resonance. In some embodiments, the KD, ka, and kd are determined according to the methods described in Examples 4 and 6.
    • 5. Inhibition of PD-L1 and PD-L2 Binding
  • In some embodiments, the antibody inhibits binding of one or more of PD-L1 and PD-L2 to PD-1.
  • In some embodiments, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1 to about 7 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1.99, about 2.53, about 5.86, or about 5.96 nM.
  • In some embodiments, the antibody inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.01 to about 1 nM. In some aspects, the antibody inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.01, about 0.18, about 0.56, or about 0.58 nM.
  • In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 5.96 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.56 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 5.86 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.58 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1.99 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.01 nM. In some aspects, the antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 2.53 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.18 nM.
    • 6. PD-1 Assays
  • In some embodiments, the anti-PD-1 antibodies induce the secretion of interferon gamma when added to a peripheral blood mononuclear cell (PBMC) two-way mixed lymphocyte reaction (MLR) assay, as described in Examples 8 and 16.
  • In some embodiments, the anti-PD-1 antibodies induce the secretion of interferon gamma when added to a PBMC cytomegalovirus recall assay, as described in Example 16.
  • In some embodiments, the anti-PD-1 antibodies accelerate the onset of graft versus host disease, as shown in Example 18.
    • 7. Glycosylation Variants
  • In certain embodiments, an antibody may be altered to increase, decrease or eliminate the extent to which it is glycosylated. Glycosylation of polypeptides is typically either “N-linked” or “O-linked.”
  • “N-linked” glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site.
  • “O-linked” glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
  • Addition or deletion of N-linked glycosylation sites to the antibody may be accomplished by altering the amino acid sequence such that one or more of the above-described tripeptide sequences is created or removed. Addition or deletion of O-linked glycosylation sites may be accomplished by addition, deletion, or substitution of one or more serine or threonine residues in or to (as the case may be) the sequence of an antibody.
    • 8. Fc Variants
  • In certain embodiments, amino acid modifications may be introduced into the Fc region of an antibody provided herein to generate an Fc region variant. In certain embodiments, the Fc region variant possesses some, but not all, effector functions. Such antibodies may be useful, for example, in applications in which the half-life of the antibody in vivo is important, yet certain effector functions are unnecessary or deleterious. Examples of effector functions include complement-dependent cytotoxicity (CDC) and antibody-directed complement-mediated cytotoxicity (ADCC). Numerous substitutions or substitutions or deletions with altered effector function are known in the art.
  • An alteration in in CDC and/or ADCC activity can be confirmed using in vitro and/or in vivo assays. For example, Fc receptor (FcR) binding assays can be conducted to measure FcγR binding. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Ann. Rev. Immunol., 1991, 9:457-492.
  • Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are provided in U.S. Pat. Nos. 5,500,362 and 5,821,337; Hellstrom et al., Proc. Natl. Acad. Sci. USA., 1986, 83:7059-7063; Hellstrom et al., Proc. Natl. Acad. Sci. USA., 1985, 82:1499-1502; and Bruggemann et al., J. Exp. Med., 1987, 166:1351-1361. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, using an animal model such as that disclosed in Clynes et al. Proc. Natl. Acad. Sci. USA., 1998, 95:652-656.
  • C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. Examples of C1q binding assays include those described in WO 2006/029879 and WO 2005/100402.
  • Complement activation assays include those described, for example, in Gazzano-Santoro et al., J. Immunol. Methods, 1996, 202:163-171; Cragg et al., Blood, 2003, 101:1045-1052; and Cragg and Glennie, Blood, 2004, 103:2738-2743.
  • FcRn binding and in vivo clearance (half-life determination) can also be measured, for example, using the methods described in Petkova et al., Intl. Immunol., 2006, 18:1759-1769.
    • 9. Preparation of Antibodies
  • 9.1. Antigen Preparation
  • The PD-1 antigen to be used for production of antibodies may be intact PD-1 or a fragment of PD-1. The intact PD-1, or fragment of PD-1, may be in the form of an isolated protein or expressed by a cell. Other forms of PD-1 useful for generating antibodies will be apparent to those skilled in the art.
  • 9.2. Monoclonal Antibodies
  • Monoclonal antibodies may be obtained, for example, using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-497, and/or by recombinant DNA methods (see e.g., U.S. Pat. No. 4,816,567). Monoclonal antibodies may also be obtained, for example, using phage or yeast-based libraries. See e.g., U.S. Pat. Nos. 8,258,082 and 8,691,730.
  • In the hybridoma method, a mouse or other appropriate host animal is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell. See Goding J. W., Monoclonal Antibodies: Principles and Practice 3rd ed. (1986) Academic Press, San Diego, Calif.
  • The hybridoma cells are seeded and grown in a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • Useful myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive media conditions, such as the presence or absence of HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and MC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, Calif.), and SP-2 or X63-Ag8-653 cells (available from the American Type Culture Collection, Rockville, Md.). Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. See e.g., Kozbor, J. Immunol., 1984, 133:3001.
  • After the identification of hybridoma cells that produce antibodies of the desired specificity, affinity, and/or biological activity, selected clones may be subcloned by limiting dilution procedures and grown by standard methods. See Goding, supra. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • DNA encoding the monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). Thus, the hybridoma cells can serve as a useful source of DNA encoding antibodies with the desired properties. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as bacteria (e.g., E. coli), yeast (e.g., Saccharomyces or Pichia sp.), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody, to produce the monoclonal antibodies.
  • 9.3. Humanized Antibodies
  • Humanized antibodies may be generated by replacing most, or all, of the structural portions of a monoclonal antibody with corresponding human antibody sequences. Consequently, a hybrid molecule is generated in which only the antigen-specific variable, or CDR, is composed of non-human sequence. Methods to obtain humanized antibodies include those described in, for example, Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. USA., 1998, 95:8910-8915; Steinberger et al., J. Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl. Acad. Sci. USA., 1989, 86:10029-10033; and U.S. Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6,180,370.
  • 9.4. Human Antibodies
  • Human antibodies can be generated by a variety of techniques known in the art, for example by using transgenic animals (e.g., humanized mice). See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA., 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258; Bruggermann et al., Year in Immuno., 1993, 7:33; and U.S. Pat. Nos. 5,591,669, 5,589,369 and 5,545,807. Human antibodies can also be derived from phage-display libraries (see e.g., Hoogenboom et al., J. Mol. Biol., 1991, 227:381-388; Marks et al., J. Mol. Biol., 1991, 222:581-597; and U.S. Pat. Nos. 5,565,332 and 5,573,905). Human antibodies may also be generated by in vitro activated B cells (see e.g., U.S. Pat. Nos. 5,567,610 and 5,229,275). Human antibodies may also be derived from yeast-based libraries (see e.g., U.S. Pat. No. 8,691,730).
    • 10. Vectors, Host Cells, and Recombinant Methods
  • The invention also provides isolated nucleic acids encoding anti-PD-1 antibodies, vectors and host cells comprising the nucleic acids, and recombinant techniques for the production of the antibodies.
  • For recombinant production of the antibody, the nucleic acid encoding it may be isolated and inserted into a replicable vector for further cloning (i.e., amplification of the DNA) or expression. In some aspects, the nucleic acid may be produced by homologous recombination, for example as described in U.S. Pat. No. 5,204,244.
  • Many different vectors are known in the art. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, for example as described in U.S. Pat. No. 5,534,615.
  • Illustrative examples of suitable host cells are provided below, these host cells are not meant to be limiting.
  • Suitable host cells include any prokaryotic (e.g., bacterial), lower eukaryotic (e.g., yeast), or higher eukaryotic (e.g., mammalian) cells. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia (E. coli), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella (S. typhimurium), Serratia (S. marcescans), Shigella, Bacilli (B. subtilis and B. licheniformis), Pseudomonas (P. aeruginosa), and Streptomyces. One useful E. coli cloning host is E. coli 294, although other strains such as E. coli B, E. coli X1776, and E. coli W3110 are suitable.
  • In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are also suitable cloning or expression hosts for anti-PD-1 antibody-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species, and strains are available and useful, such as Schizosaccharomyces pombe, Kluyveromyces (K. lactis, K. fragilis, K. bulgaricus K. wickeramii, K. waltii, K. drosophilarum, K. thermotolerans, and K. marxianus), Yarrowia, Pichia pastoris, Candida (C. albicans), Trichoderma reesia, Neurospora crassa, Schwanniomyces (S. occidentalis), and filamentous fungi such as, for example Penicillium, Tolypocladium, and Aspergillus (A. nidulans and A. niger).
  • Useful mammalian host cells include COS-7 cells, HEK293 cells; baby hamster kidney (BHK) cells; Chinese hamster ovary (CHO); mouse sertoli cells; African green monkey kidney cells (VERO-76), and the like.
  • The host cells used to produce the anti-PD-1 antibody of this invention may be cultured in a variety of media. Commercially available media such as, for example, Ham's F10, Minimal Essential Medium (MEM), RPMI-1640, and Dulbecco's Modified Eagle's Medium (DMEM) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal. Biochem., 1980, 102:255; and U.S. Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, and 5,122,469, or WO 90/03430 and WO 87/00195 may be used.
  • Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics, trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. For example, Carter et al. (Bio/Technology, 1992, 10:163-167) describes a procedure for isolating antibodies which are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation.
  • In some embodiments, the antibody is produced in a cell-free system. In some aspects, the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety. In some aspects, the cell-free system utilizes a cell-free extract from a eukaryotic cell or from a prokaryotic cell. In some aspects, the prokaryotic cell is E. coli. Cell-free expression of the antibody may be useful, for example, where the antibody accumulates in a cell as an insoluble aggregate, or where yields from periplasmic expression are low.
  • Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon® or Millipore® Pellcon® ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a particularly useful purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human γ1, γ2, or γ4 heavy chains (Lindmark et al., J. Immunol. Meth., 1983, 62:1-13). Protein G is useful for all mouse isotypes and for human γ3 (Guss et al., EMBO J., 1986, 5:1567-1575).
  • The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a CH3 domain, the BakerBond ABX® resin is useful for purification.
  • Other techniques for protein purification, such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin Sepharose®, chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available, and can be applied by one of skill in the art.
  • Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5 to about 4.5, generally performed at low salt concentrations (e.g., from about 0 to about 0.25 M salt).
    • 11. Pharmaceutical Compositions and Methods of Administration
  • Any of the antibodies provided herein can be provided in any appropriate pharmaceutical composition and be administered by any suitable route of administration. Suitable routes of administration include, but are not limited to, the inhalation, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary, and subcutaneous routes.
  • The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
  • In some embodiments, the pharmaceutical composition comprises an anti-foaming agent. Any suitable anti-foaming agent may be used. In some aspects, the anti-foaming agent is selected from an alcohol, an ether, an oil, a wax, a silicone, a surfactant, and combinations thereof. In some aspects, the anti-foaming agent is selected from a mineral oil, a vegetable oil, ethylene bis stearamide, a paraffin wax, an ester wax, a fatty alcohol wax, a long chain fatty alcohol, a fatty acid soap, a fatty acid ester, a silicon glycol, a fluorosilicone, a polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2-ethyl-hexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof.
  • In some embodiments, the pharmaceutical composition comprises a cosolvent. Illustrative examples of cosolvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, and propylene glycol.
  • In some embodiments, the pharmaceutical composition comprises a buffer. Illustrative examples of buffers include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, and monosodium glutamate.
  • In some embodiments, the pharmaceutical composition comprises a carrier or filler. Illustrative examples of carriers or fillers include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, and guar gum.
  • In some embodiments, the pharmaceutical composition comprises a surfactant. Illustrative examples of surfactants include d-alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, and vitamin E polyethylene(glycol) succinate.
  • In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include calcium phosphate (tribasic), hydroxymethyl cellulose, hydroxypropyl cellulose, and magnesium oxide.
  • Other excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, and sugars. Specific examples of each of these agents are described, for example, in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, incorporated by reference in its entirety.
  • In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, the solvent is saline solution, such as a sterile isotonic saline solution or dextrose solution. In some aspects, the solvent is water for injection.
  • In some embodiments, the pharmaceutical compositions are in a particulate form, such as a microparticle or a nanoparticle. Microparticles and nanoparticles may be formed from any suitable material, such as a polymer or a lipid. In some aspects, the microparticles or nanoparticles are micelles, liposomes, or polymersomes. In certain embodiments, a composition provided herein is a pharmaceutical composition or a single unit dosage form. Pharmaceutical compositions and single unit dosage forms provided herein comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic antibodies.
  • Further encompassed herein are anhydrous pharmaceutical compositions and dosage forms comprising an antibody, since water can facilitate the degradation of some antibodies.
  • Anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine can be anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • An anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • 11.1. Parenteral Dosage Forms
  • In certain embodiments, provided are parenteral dosage forms. Parenteral dosage forms can be administered to subjects by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses subjects' natural defenses against contaminants, parenteral dosage forms are typically, sterile or capable of being sterilized prior to administration to a subject. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • Excipients that increase the solubility of one or more of the antibodies disclosed herein can also be incorporated into the parenteral dosage forms.
  • 11.2. Dosage and Unit Dosage Forms
  • In human therapeutics, the doctor will determine the posology which he considers most appropriate according to a preventive or curative treatment and according to the age, weight, condition and other factors specific to the subject to be treated.
  • The amount of the antibody or composition which will be effective in the prevention or treatment of a disorder or one or more symptoms thereof will vary with the nature and severity of the disease or condition, and the route by which the antibody is administered. The frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • In certain embodiments, exemplary doses of a composition include milligram or microgram amounts of the antibody per kilogram of subject or sample weight (e.g., about 10 micrograms per kilogram to about 50 milligrams per kilogram, about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 microgram per kilogram to about 10 milligrams per kilogram). In certain embodiment, the dosage of the antibody provided herein, based on weight of the antibody, administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, or 15 mg/kg or more of a subject's body weight. In another embodiment, the dosage of the composition or a composition provided herein administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is 0.1 mg to 200 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 10 mg, 0.1 mg to 7.5 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 mg to 7.5 mg, 0.25 mg to 5 mg, 0.25 mg to 2.5 mg, 0.5 mg to 20 mg, 0.5 to 15 mg, 0.5 to 12 mg, 0.5 to 10 mg, 0.5 mg to 7.5 mg, 0.5 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 7.5 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.
  • The dose can be administered according to a suitable schedule, for example, once, two times, three times, or for times weekly. It may be necessary to use dosages of the antibody outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with subject response.
  • Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the antibodies provided herein are also encompassed by the herein described dosage amounts and dose frequency schedules. Further, when a subject is administered multiple dosages of a composition provided herein, not all of the dosages need be the same. For example, the dosage administered to the subject may be increased to improve the prophylactic or therapeutic effect of the composition or it may be decreased to reduce one or more side effects that a particular subject is experiencing.
  • In certain embodiments, treatment or prevention can be initiated with one or more loading doses of an antibody or composition provided herein followed by one or more maintenance doses.
  • In certain embodiments, a dose of an antibody or composition provided herein can be administered to achieve a steady-state concentration of the antibody in blood or serum of the subject. The steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age.
  • In certain embodiments, administration of the same composition may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months. In other embodiments, administration of the same prophylactic or therapeutic agent may be repeated and the administration may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.
    • 12. Therapeutic Applications
  • For therapeutic applications, the antibodies of the invention are administered to a mammal, generally a human, in a pharmaceutically acceptable dosage form such as those known in the art and those discussed above. For example, the antibodies of the invention may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, or intratumoral routes. The antibodies also are suitably administered by peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. The intraperitoneal route may be particularly useful, for example, in the treatment of ovarian tumors.
  • The antibodies provided herein may be useful for the treatment of any disease or condition involving PD-1, such as cancer, autoimmune disease, and infection.
  • Any suitable cancer may be treated with the antibodies provided herein. Illustrative suitable cancers include, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone cancer, breast cancer, bronchial tumor, Burkitt Lymphoma, carcinoma of unknown primary origin, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, fibrous histiocytoma, Ewing sarcoma, eye cancer, germ cell tumor, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, glioma, head and neck cancer, hairy cell leukemia, hepatocellular cancer, histiocytosis, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ, lung cancer, lymphoma, macroglobulinemia, malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytomas, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumor, stomach cancer, T-cell lymphoma, teratoid tumor, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms tumor.
  • Any suitable autoimmune disease may be treated with the antibodies provided herein. Illustrative suitable autoimmune diseases, or diseases with an autoimmune component, include, for example, acute disseminated encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticarial, axonal & neuronal neuropathies, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, Celiac disease, Chagas disease, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST disease, essential mixed cryoglobulinemia, demyelinating neuropathies, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly called Wegener's Granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, immunoregulatory lipoproteins, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus (SLE), Lyme disease (chronic), Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's), neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, type I, II, & III autoimmune polyglandular syndromes, polymyalgia rheumatic, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, rimary sclerosing cholangitis, psoriasis, psoriatic arthritis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynauds phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren's syndrome, sperm & testicular autoimmunity, stiff person syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis/giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, and Wegener's granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).
  • Any suitable infection may be treated with the antibodies provided herein. Illustrative suitable infections include, for example, hepatitis A virus, hepatitis B virus, hepatitis C virus (HCV), human immunodeficiency virus (HIV), and other viral infections.
    • 13. Diagnostic Applications
  • In some embodiments, the antibodies provided herein are used in diagnostic applications. For example, an ant-PD-1 antibody may be useful in assays for PD-1 protein. In some aspects the antibody can be used to detect the expression of PD-1 in various cells and tissues. These assays may be useful, for example, evaluating cancer and autoimmune disease.
  • In some diagnostic applications, the antibody may be labeled with a detectable moiety. Suitable detectable moieties include, but are not limited to radioisotopes, fluorescent labels, and enzyme-substrate labels. In another embodiment of the invention, the anti-PD-1 antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which specifically binds to the anti-PD-1 antibody.
    • 14. Affinity Purification Reagents
  • The antibodies of the invention may be used as affinity purification agents. In this process, the antibodies may be immobilized on a solid phase such a resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing the PD-1 protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PD-1 protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the PD-1 protein from the antibody.
    • 15. Kits
  • In some embodiments, an anti-PD-1 antibody provided herein is provided in the form of a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing a procedure. In some embodiments, the procedure is a diagnostic assay. In other embodiments, the procedure is a therapeutic procedure.
  • In some embodiments, the kit further comprises a solvent for the reconstitution of the anti-PD-1 antibody. In some embodiments, the anti-PD-1 antibody is provided in the form of a pharmaceutical composition.
    • EXAMPLES Example 1: Generation and Primary Screening of Anti-PD-1 Antibodies
  • Antibody Fab or scFv libraries were constructed using a standard overlap extension PCR protocol with mutagenic primers targeting CDRs. See Heckman and Pease, Nat. Protoc., 2007, 2:924-932, incorporated by reference in its entirety. Selections for novel antibodies were performed using standard ribosome display protocols. See Dreir and Plückthun, Methods Mol. Biol., 2011, Clifton, N.J., 687:283-306, incorporated by reference in its entirety. Specifically, scFv-based selection formats were performed according to published protocols. See Hanes and Plückthun, Proc. Natl. Acad. Sci. USA., 1997, 94:4937-4942, incorporated by reference in its entirety. After multiple rounds of selection, the DNA from RT-PCR output was cloned into an optimized vector for cell-free expression using standard molecular biology techniques. See Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety. All constructs were HIS- and FLAG-tagged to streamline purification and testing during screening.
  • Libraries of antibody variants isolated by the selections were transformed into E. coli and grown on agar plates with antibiotic (kanamycin). Individual colonies were picked and grown in liquid broth (TB+kanamycin), and used as a template for DNA amplification via rolling circle amplification (RCA). The variants were then expressed in a cell-free protein synthesis reaction as described in Zawada et al. (Biotechnol. Bioeng., 2011, 108:1570-1578, incorporated by reference in its entirety).
  • Briefly, cell-free extracts were treated with 50 μM iodoacetamide for 30 minutes at room temperature (RT; 20° C.) and added to a premix containing cell-free reaction components (see Groff et al., mAbs, 2014, 6:671-678, incorporated by reference in its entirety) and 10% (v/v) RCA DNA template (approximately 10 μg/mL DNA) for variants of interest. Cell free reactions, at a final volume of 604, were incubated at 30° C. for 12 h on a shaker at 650 rpm in 96-well plates. Four hundred to one-thousand-five-hundred colonies were screened, depending on the predicted diversity of the libraries used in the different selection campaigns. Following synthesis, each reaction was diluted 1:50 into PBST (PBS at pH 7.4 with 0.2% Tween-20+0.2% BSA) and the variants expressed in each reaction were tested for functional activity via ELISA-based binding to recombinant human PD-1 (ACROBiosystems, Inc., Catalog No. PD1-H5221 or SINO Biological Inc. Catalog No. 10377-H08H).
  • Standard ELISA-based methods were employed. Specifically, 384-well plates were coated with 2 μg/mL recombinant PD-1 diluted in bicarbonate buffer, and then blocked with BSA. Antibody variants of interest were allowed to bind to the PD-1-coated plates, and detected with secondary antibodies (e.g., HRP-conjugated anti-human Fc or anti-FLAG) and then detected with chemiluminescent substrate (Pierce ELISA SuperSignal™ Substrate). Plates were analyzed on a Molecular Devices SpectraMax® M5 plate reader. Top hits were selected based on ELISA signal or signal/noise ratio and sequenced. Based on functional activity and sequence analysis, a subset of variants was selected for further scale-up and characterization.
    • Example 2: Secondary Screening of Antibody Variants
  • The top leads from the initial round of screening were cultured and plasmids encoding the antibody genes of interest were isolated using a QIAprep 96 Turbo® Miniprep Kit (Qiagen) according to the manufacturer's instructions. DNA was added to 4 mL of cell-free reaction medium to achieve a final concentration of 10 μg/mL. The cell-free reaction medium was then incubated overnight for 12 hr at 30° C., at 650 rpm.
  • The expressed variants from clarified cell-free reactions were purified via immobilized metal ion affinity chromatography (IMAC) using a semi-automated high throughput batch purification method. Briefly, purifications were performed in a 96-well plate format where 50 μL/well of IMAC resin (Ni Sepharose® High Performance, GE Healthcare) was equilibrated in IMAC binding buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole), incubated with 1 mL cell-free reaction for 15 minutes, followed by two washes in IMAC binding buffer. His-tagged antibody variants were then eluted using 200 μL IMAC elution buffer (50 mM Tris pH 8.0, 300 mM NaCl, 500 mM imidazole), and buffer exchanged into PBS using a 96-well Zeba™ plate (7 kDa MWCO, Thermo Fisher). Purified antibodies were quantified via high throughput capillary electrophoresis using the LabChip GXII® (Perkin Elmer) against a trastuzumab standard curve, according to the manufacturer's instructions.
    • Example 3: Hybridoma Generation
  • Balb/C mice were immunized with the extracellular domain of human PD-1 fused with human Fc (R&D Systems, supra) using standard immunization methods. The spleens and/or lymph nodes of the mice were harvested and fused with P3X cells to generate the hybridomas (Aragen Biosciences, Morgan Hill, Calif.), similar to what has been previously described. See Chronopoulou et al., Methods Mol. Biol., 2014, 1131:47-70; and Kim et al., Methods Mol. Biol., 2014, 1131:33-45, each of which is incorporated by reference in its entirety.
  • Total RNA was extracted from hybridoma cells using an RNeasy® Mini Kit (Qiagen) and converted to cDNA using a SMARTer™ RACE cDNA Amplification Kit (Clontech). Positive clones were identified by gel electrophoresis, cloned using a TOPO® kit (Invitrogen), and sequenced using standard Sanger methods.
  • Mouse single-chain antibodies were constructed by using total gene synthesis using codons optimized for E. coli. The genes encoding the antibodies were cloned into a standard cell-free expression vector. See Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety.
  • The CDRs from m1E9 were grafted onto human antibody frameworks VH3-21, VH3-7, Vκ1-9, and Vκ3-11 by standard methodology to yield humanized antibodies h1E9-1, h1E9-2, h1E9-4, and h1E9-5. See Kuramochi et al., Methods Mole. Biol., 2014, 1060:123-137, incorporated by reference in its entirety. The same method was used to graft the CDRs from m4B10 onto human antibody frameworks VH3-15, Vκ3-11, Vκ3-20, and Vκ4-1 to yield humanized antibodies h4B10-1, h4B10-2, and h4B10-3.
    • Example 4: Kinetic Analysis of Selected Antibody Variants
  • Human PD-1 (ACROBiosystems, Inc., Catalog No. PD1-H5221), cynomolgus PD-1 (ACROBiosystems, Inc., Catalog No. PD1-H5254), and murine PD-1 (R&D Systems Inc., Catalog No. 1021-PD-100) were used, as indicated, for kinetic analysis.
  • Monoclonal anti-FLAG M2 IgG (Sigma-Aldrich #F9291) was immobilized onto a CMS chip (GE Life Sciences) using amine coupling chemistry (from Amine Coupling Kit, GE Life Sciences). The immobilization steps were carried out at a flow rate of 25 μl/min in 1×HBS-EP+ buffer (GE Life Sciences; 10× Stock diluted before use). The sensor surfaces were activated for 7 min with a mixture of NHS (0.05 M) and EDC (0.2 M). The Anti-FLAG M2 IgG was injected over all 4 flow cells at a concentration of 25 μg/ml in 10 mM sodium acetate, pH 4.5, for 7 min. Ethanolamine (1 M, pH 8.5) was injected for 7 min to block any remaining activated groups. An average of 12,000 response units (RU) of capture antibody was immobilized on each flow cell.
  • Off-rate and kinetic binding experiments were performed at 25° C. using 1×HBS-EP+ buffer. Test and control antibodies were injected over the Anti-FLAG surface at concentrations of 5-10 μg/mL for 12 seconds at a flow rate of 10 μl/min on flow cells 2, 3 and 4, followed by a buffer wash for 30 seconds at the same flow rate. Kinetic characterization of antibody samples was carried out with a single concentration of antigen (for off-rate ranking) or a 1:2 dilution series of antigen (for kinetic characterization) and 1 injection of 0 nM antigen (i.e., buffer alone). After capturing ligand (anti-PD-1 antibody) on the anti-FLAG surface, the analyte (huPD1-His) was bound at 50, 25, 12.5, 6.25 and 0 nM for 180 seconds, followed by a 600 second dissociation phase at a flow rate of 50 μl/min. Between each ligand capture and analyte binding cycle, regeneration was carried out using 2 injections of 10 mM glycine pH 2.0 for 30 seconds at 30 μL/min, followed by a 30 second buffer wash step.
  • The data was fit with the Biacore T200 Evaluation software, using a 1:1 Langmuir binding model. KD (affinity, nM) was determined as a ratio of the kinetic rate constants calculated from the fits of the association and dissociation phases.
    • Example 5: PD-1-PD-L1 Competition ELISA
  • Anti-PD1 antibodies were tested for their ability to block a PD-1/PD-L1 interaction. PD-1 (ACROBiosystems, Inc.) was adsorbed on 384-well white Maxisorp® plates (Nunc) at 2 μg/mL in sodium bicarbonate buffer (pH 8.9) and incubated at 30° C. for 1 hour or overnight at 4° C. The plate was washed 3 times with PBS pH 7.4 with 0.05% Tween20 and blocked with 2% bovine serum albumin (BSA) in PBS pH 7.4+0.1% Tween20 for 1 hour at 30° C.
  • The blocking solution was aspirated, and a dilution series of antibody was mixed with 100 nM PD-L1-Fc (ACROBiosystems, Inc.) in 0.2% BSA in PBS pH 7.4+0.1% Tween20 (diluent buffer) and incubated at 30° C. for 1 hour. The plate was washed, and 10 nM anti-PD-L1 antibody (BioLegend, clone 29E.2A3) in diluent buffer was added to all wells. After a 1 hour incubation at 30° C., the plate was washed and incubated with HRP-conjugated anti-mouse Fc (Jackson Laboratories), followed by detection with SuperSignal™ Pico Chemiluminescent Substrate (Thermo Pierce). Luminescence was detected on a SpectraMax® M5 plate reader (Molecular Devices).
    • Example 6: Cell Binding Experiments
  • Antibodies with expression levels >250 nM and mouse IgGs from hybridomas were tested in a fluorescence-activated cell sorting (FACS) cell-binding assay. Chinese Hamster Ovary (or CHO) Cells stably expressing the human target molecule PD-1 on the cell surface (CHO-PD1) were used to screen for binding. Parental CHO cells were used as a negative control to determine background-binding levels. Parental CHO cells and CHO-PD1 cells were cultured in RPMI w/10% FCS penicillin/streptomycin (Pen/Strep) and glutamine (or Gln) and split every 3-4 days at 105 cells/mL.
  • A mix of parental CHO cells and CHO-PD1 cells was prepared as follows: Parental CHO cells were washed 2× in PBS then incubated in PBS containing 1 μM CellTrace™ Oregon Green488® (Life Technologies) at 37° C. for 30 minutes. Cells were then washed 2× with RPMI w/10% fetal calf serum (FCS), washed 2× with FACS buffer (PBS w/2% FCS), suspended thoroughly in ice-cold FACS buffer at a final concentration of 2×106 cells/mL and kept on ice. CHO-PD1 cells were similarly washed with FACS buffer and kept on ice at 2×106 cells/mL. Parental CHO cells and CHO-PD1 cells were then mixed to obtain a 1:1 cell suspension and seeded at 100 μL per well on 96 well polypropylene plates. Plates were spun at 1500 rpm for 5 minutes and cell pellets were suspended in 50 μL FACS buffer containing 6-12 point dilutions of anti-PD-1 variants starting from concentrations of −100-200 nM antibody, dispensed using BioMek FX (Beckman Coulter). Cells were then incubated on ice for 1 hr, washed with FACS buffer and incubated for 1 hr on ice with 50 μL FACS buffer containing 2.5 μg/ml R-phycoerythrin-conjugated goat anti-Human IgG (Jackson ImmunoResearch) or AF647-conjugated goat anti-mouse IgG (Life Technologies) dispensed using BioMek FX (Beckman Coulter). Cells were then washed 2× with FACS buffer and fixed for 10 minutes in 200 μL PBS with 2% paraformaldehyde (PFA) prior to fluorescence detection. Samples were acquired using a Becton Dickinson LSRII FACS. Mean Fluorescence Intensity of PD-1 antibody binding was analyzed using FlowJo® software (Tree Star, Inc.).
    • Example 7: Cell-Based Ligand Competition Experiments
  • Variants that showed cell-binding activity were tested in a fluorescence-activated cell sorting (FACS) cell-based competition assay. CHO cells stably expressing the human target molecule PD-1 on the cell surface (CHO-PD1) were used to screen for antibodies that compete with hFc-tagged recombinant human PD-L1 or PD-L2 proteins (R&D systems) for binding to PD-L1 expressed on the cell surface.
  • CHO-PD1 cells were cultured in RPMI with 10% FCS Pen/Strep and Gln and split every 3-4 days at 105 cells/ml. Cells were washed 2× with FACS buffer (PBS w/2% FCS), thoroughly in ice-cold FACS buffer at a final concentration of 1×106 cells/ml and seeded at 1004 per well on 96 well polypropylene plates. Plates were spun at 1500 rpm for 5 minutes and cell pellets were suspended in 50 μL FACS buffer containing 8 point 1:3 dilutions (2× concentrated) of anti-PD-1 antibody variants, starting from high concentration of −200 nM. 50 μL FACS buffer containing a fixed amount of either 6 μg/ml rhPDL2-Fc or 50 μg/ml rhPDL1-Fc proteins were then added to the cells. Cell were then incubated on ice for 1 hr, washed with FACS buffer and incubated for 1 hr on ice with 50 μl FACS buffer containing 2.5 μg/ml R-phycoerythrin-conjugated anti-human IgG (Jackson ImmunoResearch). Cells were then washed 2× with FACS buffer and fixed for 10 minutes in 200 μl PBS with 2% PFA prior to acquisition. Samples were acquired using a Becton Dickinson LSRII FACS. Mean Fluorescence Intensity of rhPDL1 or rhPDL2 protein binding was analyzed using FlowJo® software (Tree Star, Inc.).
    • Example 8: Evaluating the Effect of Anti-PD-1 Antibodies on Interferon Gamma Production in a Mixed Lymphocyte Reaction
  • Anti-PD-1 antibodies were functionally tested for potency in blocking the PD-1 pathway in a peripheral blood mononuclear cell (PBMC) two-way mixed lymphocyte reaction (MLR) assay by measuring interferon gamma (IFN-g) secretion in cell culture medium. 1×105 human PBMC from 2 allogeneic donors were co-cultured in RPMI media+10% FBS in a total volume of 150 μl in a 96-well U-bottom plate. Anti-PD-1 antibodies were added at specific concentrations to each well. Isotype control antibody, non-PD-1 targeting antibody, or nothing were used as a negative controls. Cells were cultured for 5 days at 37° C. At day 5, conditioned media was collected and levels of IFN-g were measured using DuoSet® ELISA kits (R&D Systems).
    • Example 9: Characteristics of Antibodies Isolated from Primary and Secondary Screen
  • Table 1 shows the characteristics of scFv-Fc antibodies (VH1-18/Vλ3-25) isolated as described in Examples 1-2, and characterized as described above.
  • TABLE 1
    Characteristics of antibodies isolated as described in Examples 1-2, and
    characterized as described above.
    Cell
    Binding,
    KD Murine Cynomolgus MLR
    ka (1/Ms) kd (1/s) KD (M) (nM) PD-1 PD-1 Activity
    Human Human Human PD-L1 Human Binding, Binding, KD (IFNg
    Clone ID PD-1 PD-1 PD-1 Competition PD-1 KD (M) (M) release)
    1353-A09 4.88E+05 1.24E−02 2.55E−08 yes, ++ 0.2 Not Not tested Not
    (SEQ ID NO: 238) tested tested
    1353-C07 1.23E+06 1.87E−02 1.52E−08 yes 0.4 Not Not tested Not
    (SEQ ID NO: 239) tested tested
    1353-E07 7.37E+05 7.01E−03 9.52E−09 yes 0.9 Not Not tested Not
    (SEQ ID NO: 240) tested tested
    1353-F09 6.87E+05 7.47E−03 1.09E−08 yes 1 Not Not tested Not
    (SEQ ID NO: 241) tested tested
    1353-G08 5.63E+05 2.54E−03 4.50E−09 yes, +++ 0.3 6.09E−08 2.43E−08 Not
    (SEQ ID NO: 242) tested
    1353-G10 5.16E+05 9.80E−04 1.90E−09 yes, ++ 0.7 6.22E−08 1.55E−08 positive
    (SEQ ID NO: 243)
    1353-H08 2.48E+05 1.18E−03 4.76E−09 yes, +++ 0.2 Not Not tested Not
    (SEQ ID NO: 244) tested tested
    1353-H09 7.98E+05 3.59E−03 4.50E−09 yes, ++ 0.8 9.08E−09 2.22E−08 positive
    (SEQ ID NO: 245)
    • Example 10: Characteristics of Murine Hybridoma Antibodies
  • Table 2 shows the characteristics of IgG antibodies isolated as described in Example 3, and characterized as described above.
  • TABLE 2
    Characteristics of murine hybridoma antibodies, characterized as described above.
    PD-L1 PD-L2 Biacore Biacore
    Cell, Competition, Competition, Human Cynomolgus MLR,
    EC501 IC502 Binding, IC50 4 IC50 4 PD1 KD KD IFNg
    Clone ID (nM) (nM) KD 3 (nM) (nM) (nM) (M) (M) secretion
    1B10 1.71 9.47 3.2 5.96 0.56 1.04E−08 2.56E−09 positive
    VH: SEQ
    ID NO:
    255, with
    serine
    prepended
    to the
    sequence
    VL: SEQ
    ID NO:
    279
    1E9 0.33 0.89 2.9 5.86 0.58 9.90E−09 2.54E−09 positive
    VH: SEQ
    ID NO:
    256
    VL: SEQ
    ID NO:
    280
    4B10 0.47 1.43 1.39 1.99 0.01 9.13E−10 5.61E−10 positive
    VH: SEQ
    ID NO:
    257
    VL: SEQ
    ID NO:
    281
    10B4 0.59 1.32 1.34 2.53 0.18 2.52E−10 1.95E−10 positive
    VH: SEQ
    ID NO:
    258
    VL: SEQ
    ID NO:
    282
    1Binding of human PD-1 (ACROBiosystems, Inc., Cat. No. PD1-H5221) via ELISA.
    2Competition against PD-L1 (ACROBiosystems, Inc., Cat No. PD1-H5258)
    3CHO cell line overexpressing human PD-1.
    4Cell-based competition. i.e., Inhibition of PD-L1 or PD-L2 binding to CHO cells overexpressing human PD-1 is inhibited by IgG.
    • Example 11: Characteristics of Humanized Antibodies
  • Table 3 shows the characteristics of humanized scFv antibodies derived from the murine hybridoma antibodies of Example 10, and characterized as described above.
  • TABLE 3
    Characteristics of humanized antibodies,
    characterized as described above.
    ka (1/Ms) kd (1/s) KD (M)
    Clone Human PD-1 Human PD-1 Human PD-1
    h1E9-1 (VH3-21-Vκ1-9) 1.82E+05 4.68E−04 2.58E−09
    scFv
    (SEQ ID NO: 227)
    h1E9-2 (VH3-21-Vκ3-11) 4.74E+04 1.82E−03 3.85E−08
    scFv
    (SEQ ID NO: 228)
    h1E9-4 (VH3-7-Vκ1-9) 1.85E+05 6.79E−04 3.66E−09
    scFv
    (SEQ ID NO: 229)
    h1E9-5 (VH3-7-Vκ3-11) 2.00E+05 6.28E−04 3.15E−09
    scFv
    (SEQ ID NO: 230)
    m4B10 scFv 8.12E+04 4.17E−04 5.14E−09
    (SEQ ID NO: 237)
    h4B10-1 (VH3-15-Vκ3- 1.21E+06 2.99E−03 2.47E−09
    11) scFv
    (SEQ ID NO: 231)
    h4B10-2 (VH3-15-Vκ3- 1.16E+06 3.24E−03 2.79E−09
    20) scFv
    (SEQ ID NO: 232)
    h4B10-3 (VH3-15-Vκ4-1) 5.13E+05 6.17E−04 1.20E−09
    scFv
    (SEQ ID NO: 233)
    m1B10 scFv 1.86E+05 2.39E−03 1.28E−08
    (SEQ ID NO: 235)
    • Example 12: Thermal Stability Data
  • Table 4 provides thermal stability of selected antibodies, as determined by differential scanning fluorimetry (DSF).
  • TABLE 4
    Thermal stability of selected antibodies,
    as determined by DSF.
    Tm1 Tm2
    Variant ID Target Scaffold (° C.) (° C.)
    1353-G12 PD1 scFv-Fc 48.2
    1353-G08 PD1 scFv-Fc 45.3
    1353-G10 PD1 scFv-Fc 48.6
    1353-H09 PD1 scFv-Fc 49.4
    m1B10 PD1 scFv 55.3
    h1E9-1 PD1 scFv 52.5
    h1E9-2 PD1 scFv 50.9
    h1E9-4 PD1 scFv 55.2
    h1E9-5 PD1 scFv 51.7
    h4b10-1 PD1 scFv 45.5 59.4
    h4b10-2 PD1 scFv 45 61.7
    h4b10-3 PD1 scFv 52.1 59.3
    • Example 13: Construction and Evaluation of h1E9-4 and h1E9-5 IgGs
  • Variable domains from h1E9-4 scFv (VH: SEQ ID NO: 260; VL: SEQ ID NO: 284), and h1E9-5 scFv (VH: SEQ ID NO: 261; VL: SEQ ID NO: 285) were grafted onto human antibody constant domains to generate human IgG1 antibodies based on these scFvs.
  • Specifically, the VH sequences were grafted onto CH1-CH2-CH3 constant domains to yield full-length IgG HCs with C-terminal FlagHis tags (GSGDYKDDDDKGSGHHHHHH; SEQ ID NO: 294) for ease of purification and assay development. The VL sequences were grafted onto CL domains to yield full-length IgG LCs. The sequence for both the h1E9-4 and h1E9-5 HCs, with C-terminal FlagHis tag, is provided in SEQ ID NO: 302. The sequence for the h1E9-4 LC is provided in SEQ ID NO: 304. The sequence for the h1E9-5 LC is provided in SEQ ID NO: 303.
  • The IgGs were expressed in a cell-free reaction, as described in Example 1, and purified using the FlagHis tags. The affinity of the IgGs for PD-1 was measured by surface plasmon resonance (Biacore®) and determined to be essentially equivalent to that of the parent scFvs. Affinity data is provided in Table 5.
  • TABLE 5
    Affinity of h1E9-4 and h1E9-5 IgGs for PD-1 antigen.
    Sample Ligand ka (1/Ms) kd (1/s) KD (M)
    PD-1- h1E9-4 IgG 3.56E+04 4.42E−04 1.24E−08
    his
    PD-1- h1E9-5 IgG 2.43E+04 4.71E−04 1.94E−08
    his
    • Example 14: Construction and Evaluation of h1E9 Humanized IgGs
  • The CDRs for m1E9 were grafted onto human antibody frameworks VH3-23, VH3-30, Vk4-1, Vk3-20, Vk2-28, and Vk1-33 by standard methodology (T. Kuramochi, T. Igawa, H. Tsunoda, and K. Hattori, Method in Molecular Biology, Human Monoclonal Antibodies: Methods and Protocols, 1060, 123-137) to yield humanized antibodies h1E9-HC1, h1E9-HC2, h1E9-HC3, h1E9-LC1, h1E9-LC2, h1E9-LC3, and h1E9-LC4. The HC constructs included C-terminal FlagHis tags (GSGDYKDDDDKGSGHHHHHH; SEQ ID NO: 294) for ease of purification and assay development. The resulting h1E9 heavy chains were: h1E9-HC3 (SEQ ID NO:324), h1E9-HC2 (SEQ ID NO:325), and h1E9-HC3 (SEQ ID NO:326). The resulting light chains were: h1E9-LC4 (SEQ ID NO:327), h1E9-LC3 (SEQ ID NO:328), h1E9-LC2 (SEQ ID NO:329), and h1E9-LC1 (SEQ ID NO:330).
  • The humanized heavy chains h1E9-HC1, h1E9-HC2, h1E9-HC3, and h1E9-5 were paired with humanized IgG light chains h1E9-LC1, h1E9-LC2, h1E9-LC3, and h1E9-LC4. These 16 combinations were then assessed for binding to human PD1 in vitro by surface plasmon resonance (Biacore®) and subsequently human and cynomolgus PD1 binding on CHO cells using FACS as described below.
  • Surface plasmon resonance (Biacore data is provided in Table 6.
  • TABLE 6
    Affinity of h1E9 humanized IgGs for PD-1 antigen.
    Sample Ligand SEQ ID NOS KD (M)
    PD-1-his h1E9-HC1 × h1E9-LC1 326 330 5.08E−09
    PD-1-his h1E9-HC1 × h1E9-LC2 326 329 1.90E−08
    PD-1-his h1E9-HC1 × h1E9-LC3 326 328 6.38E−09
    PD-1-his h1E9-HC1 × h1E9-LC4 326 327 6.33E−09
    PD-1-his h1E9-HC2 × h1E9-LC1 325 330 3.11E−09
    PD-1-his h1E9-HC2 × h1E9-LC2 325 329 1.23E−08
    PD-1-his h1E9-HC2 × h1E9-LC3 325 328 1.09E−08
    PD-1-his h1E9-HC2 × h1E9-LC4 325 327 4.96E−09
    PD-1-his h1E9-HC3 × h1E9-LC1 324 330 3.60E−09
    PD-1-his h1E9-HC3 × h1E9-LC2 324 329 3.19E−09
    PD-1-his h1E9-HC3 × h1E9-LC3 324 328 1.69E−08
    PD-1-his h1E9-HC3 × h1E9-LC4 324 327 9.40E−09
    PD-1-his h1E9-5-IgG-HC-FLAG-HIS × 261 330 3.70E−09
    h1E9-LC1
    PD-1-his h1E9-5-IgG-HC-FLAG-HIS × 261 329 1.62E−08
    h1E9-LC2
    PD-1-his h1E9-5-IgG-HC-FLAG-HIS × 261 328 1.63E−08
    h1E9-LC3
    PD-1-his h1E9-5-IgG-HC-FLAG-HIS × 261 327 7.31E−09
    h1E9-LC4
  • The affinity of the IgGs for cell-surface expressed human PD-1 were measured according to Example 6, above. Affinity data is provided in Table 7.
  • TABLE 7
    Affinity of h1E9 humanized IgGs for Cell-Surface Human PD-1 antigen
    (nM).
    h1E9-HC1 h1E9-HC2 h1E9-HC3 h1E9-5 HC
    SEQ ID SEQ ID SEQ ID SEQ ID
    NO: 326 NO: 325 NO: 324 NO: 261
    h1E9-LC1 SEQ ID 6 7 8 9
    NO: 330
    h1E9-LC2 SEQ ID 12 11 19 16
    NO: 329
    h1E9-LC3 SEQ ID 12 9 12 11
    NO: 328
    h1E9-LC4 SEQ ID 8 4 9 14
    NO: 327
  • The affinity of the IgGs for cell-surface expressed cynomolgus PD-1 were measured according to Example 6, above. Affinity data is provided in Table 8.
  • TABLE 8
    Affinity of h1E9 humanized IgGs for Cell-Surface Cynomolgus PD-1
    antigen (nM).
    h1E9-HC1 h1E9-HC2 h1E9-HC3 h1E9-5 HC
    SEQ ID SEQ ID SEQ ID SEQ ID
    NO: 326 NO: 325 NO: 324 NO: 261
    h1E9-LC1 SEQ ID 7 6 4 4
    NO: 330
    h1E9-LC2 SEQ ID 19 9 11 11
    NO: 329
    h1E9-LC3 SEQ ID 15 9 8 9
    NO: 328
    h1E9-LC4 SEQ ID 11 6 5 12
    NO: 327
    • Example 15: In Vivo Efficacy of Anti-PD-1 Antibodies on Tumor Establishment and Growth
  • MC38 colorectal cancer cells (2×106 cells in 0.1 mL PBS) were implanted subcutaneously on the right flank of C57BL/6 mice (Charles River Laboratories). On day 2 post-cell implantation (day 0), mice were treated with anti-PD-1 or control antibody at a dose of 5 mg/kg intraperitoneally. Animals were dosed on dosing days 0, 4, 8, 11, and 14.
  • The treatment groups were as follows:
  • (1) PBS vehicle;
  • (2) control rat IgG2a, clone 2A3;
  • (3) anti-PD-1 rat IgG2a, clone RMP1-14;
  • (4) anti-PD-1 human scFv-Fc, clone PD1-F2 (see SEQ ID NOs: 306 and 293 for VH and VL sequences, respectively, and SEQ ID NO: 305 for the scFv-Fc);
  • (5) anti-PD-1 human scFv-Fc, clone 1353-G08 (see SEQ ID NOs: 251 and 275 for VH and VL sequences, respectively, and SEQ ID NO: 242 for the scFv-Fc);
  • (6) anti-PD-1 human scFv-Fc, clone 1353-G10 (see SEQ ID NOs: 252 and 276 for VH and VL sequences, respectively, and SEQ ID NO: 243 for the scFv-Fc); and
  • (7) anti-PD-1 human IgG, clone PD1-F2v (see SEQ ID NOs: 603 and 293 for VH and VL sequences, respectively, SEQ ID NO: 307 for the HC sequence, and SEQ ID NO: 308 for the LC sequence).
  • Antibodies (2) and (3) were obtained commercially from Bio X Cell. Antibodies (4)-(6) were produced using the cell-free expression methods described in Example 1. Antibody 7 was produced by mammalian cell expression using HEK293 cells and standard techniques.
  • Tumors were measured using an electronic caliper and tumor volumes were calculated using the formula, volume=(width2×length)/2. Statistical analysis was performed via a two-tailed Mann-Whitney test at day 17 post-treatment.
  • At day 17 post-treatment, all anti-PD-1 antibodies with strong mouse PD-1 reactivity (i.e., antibodies RMP1-14, PD1-F2, and 1353-G08) resulted in a significant delay in tumor establishment and growth (p<0.01) compared to the PBS and control rat IgG2a treatment groups. In contrast, antibody 1353-G10, which binds human PD-1 but has weaker reactivity with mouse PD-1, showed no significant effect on tumor establishment and growth (p>0.05).
  • FIG. 2 provides a chart of the tumor volume over the 17-days of treatment with the various antibodies.
    • Example 16: Cytomegalovirus (CMV) Recall Assay
  • Anti-PD-1 antibodies were functionally tested for potency in blocking the PD-pathway in restimulating peripheral blood mononuclear cells (PBMC) from cytomegalovirus-positive (CMV+) human donors by measuring IFN-g secretion in cell culture medium.
  • CD14+ monocytes and CD3+ T cells were obtained from peripheral blood mononuclear cells (PBMC) isolated from CMV+ human donors (AllCells, Alameda, Calif.) using MACS Cell Separation kits (Miltenyi Biotec).
  • CD14+ monocytes were differentiated into immature dendritic cells (DC) by culturing cells at 1×106 cells/ml for 7 days in presence of GM-CSF and IL-4 (Peprotech) in X-Vivo 15 media (Lonza) containing 2% human AB serum (Sigma-Aldrich), penicillin-streptomycin (Corning Mediatech) and GlutaMAX (Life Technologies). Following differentiation, DCs were matured by culturing in X-Vivo 15+2% human AB serum media at 1×106 cells/ml for 2 days in the presence of GM-CSF, IL-4, TNF-α, IL-1b, IL-6 (Peprotech) and prostaglandin E2 (Sigma-Aldrich).
  • To set-up the CMV recall assay, mature DCs were collected and washed. 10,000 DCs and 100,000 pan CD3+ T cells were plated per well in a 96-well U-bottom plate in a total volume of 100 μl media containing peptide pools for the CMV IE-1 and CMV pp65 proteins (Miltenyi Biotec).
  • Anti-PD-1 or control human IgG antibody (50 final volume of 150 μl per well) were added starting at a final concentration of 400 nM with 5-fold serial dilutions. Cells were co-cultured with peptides and antibodies for 5-6 days. Conditioned media was collected and tested for human IFN-g levels by ELISA (BD Biosciences).
  • As shown in FIG. 3, anti-PD-1 human IgG 1353-G10 (SEQ ID NOs: 252 and 276) showed significant fold-increase in IFN-g levels (closed circles). The IFN-g levels were substantial compared to Nivolumab IgG (open circles).
    • Example 17: DC/CD4+ T Cell Mixed Lymphocyte Reaction (MLR) Assay
  • Anti-PD-1 antibodies were functionally tested for potency in blocking the PD-1 pathway in a peripheral blood mononuclear cell (PBMC) two-way mixed lymphocyte reaction (MLR) assay by measuring interferon gamma (IFN-g) secretion in cell culture medium.
  • CD14+ monocytes and CD4+ T cells were obtained from PBMC isolated from human donors using MACS Cell Separation kits. CD14+ monocytes were differentiated into immature DC by culturing cells at 1×106 cells/ml cell density for 7 days in presence of GM-CSF and IL-4 in RPMI media containing 10% fetal bovine serum, penicillin-streptomycin and GlutaMAX.
  • Following differentiation, DCs were matured by culturing in RPMI+10% FBS media at 1×106 cells/ml cell density for 2 days in the presence of GM-CSF, IL-4, TNF-a, IL-1b, IL-6 and prostaglandin E2.
  • To set-up the DC/CD4+ T cell MLR, mature DCs were collected and washed. 10,000 DCs and 100,000 CD4+ T cells were plated per well in a 96-well U-bottom plate in a total volume of 100 μl media. Anti-PD-1 or control human IgG antibody (50 μl, final volume of 150 μl per well) were added starting at a final concentration of 400 nM with 5-fold serial dilutions. Cells were co-cultured with peptides and antibodies for 5-6 days. Conditioned media was collected and tested for human IFN-g levels by ELISA.
  • As shown in FIG. 4, anti-PD-1 human IgG 1353-G10 (SEQ ID NOs: 252 and 276) showed significant fold-increase in IFN-g levels (closed circles). The IFN-g levels were substantial compared to Nivolumab IgG (open circles).
    • Example 18: Effect of PD-1 Blockade on Graft Versus Host Disease (GVHD) Response
  • Anti-PD-1 antibodies described herein were evaluated for acceleration of graft versus host disease (GVHD) in a mouse model. Since PD-1 negatively regulates immune response, blockade of PD-1 by an effective antibody should accelerate the immune and GVHD response.
  • 40 female NSG mice aged 7 weeks and weighing approximately 19-22 g were used as human PBMC recipients. Groups were randomized into four groups of ten. On day 0, all animals received 2×107 human PBMC injected via the tail vein. Prior to PBMC injection, animals were dosed intraperitoneally (IP) with either control anti-GFP, Nivolumab anti-PD-1 antibody, or 1353-G10 anti-PD1 antibody (SEQ ID NOs: 252 and 276) as detailed in Table 9. Treatment was administered 2× per week until study conclusion.
  • TABLE 9
    Treatment groups
    huPBMC Total
    con- Test Dosing number
    Group centration article Dose frequency of doses Route N
    1 2 × 107 Control 10 2×/week 10 IP 10
    Anti-GFP mg/kg
    2 2 × 107 Anti-PD1 10 2×/week 10 IP 10
    Nivolumab mg/kg
    3 2 × 107 Anti-PD1 10 2×/week 10 IP 10
    1353-G10 mg/kg
    4 2 × 107 Anti-PD1  3 2×/week 10 IP 10
    1353-G10 mg/kg
  • Animals were weighed and observed at least two times per week for 5 weeks. Monitoring increased to daily when 10% body weight loss (compared to initial mouse weight) occurred. Animals were euthanized with CO2 at the end of five weeks (end of study), when they exhibited weight loss greater than 20%, or were unable to right themselves, cold to the touch, and moribund (severe hair ruffling, body weight loss, hunched posture, or decreased activity).
  • Upon sacrifice (after 5 weeks) or pre-mature euthanasia (due to body weight loss or moribundity), the spleen, liver, and serum were collected for further analyses. The liver and spleen were placed in formalin for 24 hours then transferred to 70% ethanol for storage. The serum was flash frozen and stored at −80° C. All procedures were conducted according to the guidelines of the Sutro Institutional Animal Care and Use Committee (IACUC) and Sutro IACUC protocol SU-001-2013
  • As shown in FIG. 5, anti-PD-1 treatment with human IgG 1353-G10 (SEQ ID NOs: 252 and 276) showed accelerated mouse morbidity by approximately two weeks (median survival of 13 days for 10 mg/kg 1353-G10 versus 27 days for anti-GFP control). The onset of GVHD severity was similar in mice treated with high (10 mg/kg) and low (3 mg/kg) 1353-G10. Body weight loss was also faster with both doses of 1353-G10 compared to control and Nivolumab (data not shown). Median survival with both doses of 1353-G10 was less compared to Nivolumab, indicating greater PD-1 blockade potency for 1353-G10 in vivo.
    • Example 19: Sequences
  • Table 10 provides sequences referred to herein.
  • TABLE 10
    Sequences.
    SEQ ID
    NO Molecule Region Scheme Sequence
    1 hPD-1 MQIPQAPWPVVWAVLQLGWRPGWFLDSPDR
    PWNPPTFSPALLVVTEGDNATFTCSFSNTS
    ESFVLNWYRMSPSNQTDKLAAFPEDRSQPG
    QDCRFRVTQLPNGRDFHMSVVRARRNDSGT
    YLCGAISLAPKAQIKESLRAELRVTERRAE
    VPTAHPSPSPRPAGQFQTLVVGVVGGLLGS
    LVLLVWVLAVICSRAARGTIGARRTGQPLK
    EDPSAVPVFSVDYGELDFQWREKTPEPPVP
    CVPEQTEYATIVFPSGMGTSSPARRGSADG
    PRSAQPLRPEDGHCSWPL
    2 PD1-17 CDR-H1 SGGSIRSTRWWS
    3 PD1-28 CDR-H1 SYGIS
    4 PD1-33 CDR-H1 SYYIH
    5 PD1-35 CDR-H1 SGAYYWS
    6 PD1-F2 CDR-H1 SSYWMS
    7 10B4 CDR-H1 Chothia GYIFSSY
    8 1353-A09 CDR-H1 Chothia GYRFTWY
    9 1353-C07 CDR-H1 Chothia GYRFSTF
    10 1353-E07 CDR-H1 Chothia GYRFETY
    11 1353-F09 CDR-H1 Chothia GYRFRQY
    12 1353-G08 CDR-H1 Chothia GYRFTRY
    13 1353-G10 CDR-H1 Chothia GYRFPHY
    14 1353-H08 CDR-H1 Chothia GYRFTRQ
    15 1353-H09 CDR-H1 Chothia GYRFPHY
    16 1B10 CDR-H1 Chothia GHSITSDY
    17 1E9 CDR-H1 Chothia GFTFSTF
    18 4B10 CDR-H1 Chothia GFTFSTY
    19 h1E9-1 CDR-H1 Chothia GFTFSTF
    20 h1E9-2 CDR-H1 Chothia GFTFSTF
    21 h1E9-4 CDR-H1 Chothia GFTFSTF
    22 h1E9-5 CDR-H1 Chothia GFTFSTF
    23 h4B10-1 CDR-H1 Chothia GFTFSTY
    24 h4B10-2 CDR-H1 Chothia GFTFSTY
    25 h4B10-3 CDR-H1 Chothia GFTFSTY
    26 PD1-17 CDR-H1 Chothia GGSIGSGGSIRSTR
    27 PD1-28 CDR-H1 Chothia GYRFTSY
    28 PD1-33 CDR-H1 Chothia GYTLTSY
    29 PD1-35 CDR-H1 Chothia GGSISSGAY
    30 PD1-F2 CDR-H1 Chothia GFTFSSYWCD
    31 10B4 CDR-H1 Kabat SYWIG
    32 1353-A09 CDR-H1 Kabat WYGIS
    33 1353-C07 CDR-H1 Kabat TFGIS
    34 1353-E07 CDR-H1 Kabat TYGIS
    35 1353-F09 CDR-H1 Kabat QYGIS
    36 1353-G08 CDR-H1 Kabat RYGIS
    37 1353-G10 CDR-H1 Kabat HYGIS
    38 1353-H08 CDR-H1 Kabat RQGIS
    39 1353-H09 CDR-H1 Kabat HYGIS
    40 1B10 CDR-H1 Kabat SDYAWN
    41 1E9 CDR-H1 Kabat TFGMS
    42 4B10 CDR-H1 Kabat TYGMS
    43 h1E9-1 CDR-H1 Kabat TFGMS
    44 h1E9-2 CDR-H1 Kabat TFGMS
    45 h1E9-4 CDR-H1 Kabat TFGMS
    46 h1E9-5 CDR-H1 Kabat TFGMS
    47 h4B10-1 CDR-H1 Kabat TYGMS
    48 h4B10-2 CDR-H1 Kabat TYGMS
    49 h4B10-3 CDR-H1 Kabat TYGMS
    50 PD1-17 CDR-H1 Kabat SGGSIRSTRWWS
    51 PD1-28 CDR-H1 Kabat SYGIS
    52 PD1-33 CDR-H1 Kabat SYYIH
    53 PD1-35 CDR-H1 Kabat SGAYYWS
    54 PD1-F2 CDR-H1 Kabat SYWCDRMS
    55 PD1-17 CDR-H2 EIYHSGSTNYNPSLKS
    56 PD1-28 CDR-H2 WISAYNGNTNYAQKLQG
    57 PD1-33 CDR-H2 IINPRGATISYAQKFQG
    58 PD1-35 CDR-H2 YIYYNGNTYYNPSLRS
    59 PD1-F2 CDR-H2 AISGSGGSTYYADSVKG
    60 10B4 CDR-H2 Chothia FPGSGS
    61 1353-A09 CDR-H2 Chothia SAYNGN
    62 1353-C07 CDR-H2 Chothia SAYNGN
    63 1353-E07 CDR-H2 Chothia SAYNGN
    64 1353-F09 CDR-H2 Chothia SAYNGN
    65 1353-G08 CDR-H2 Chothia SAHNGN
    66 1353-G10 CDR-H2 Chothia SAYNGN
    67 1353-H08 CDR-H2 Chothia SAYNGN
    68 1353-H09 CDR-H2 Chothia SAYNGN
    69 1B10 CDR-H2 Chothia SYSGR
    70 1E9 CDR-H2 Chothia SGGGSD
    71 4B10 CDR-H2 Chothia SGGGSN
    72 h1E9-1 CDR-H2 Chothia SGGGSD
    73 h1E9-2 CDR-H2 Chothia SGGGSD
    74 h1E9-4 CDR-H2 Chothia SGGGSD
    75 h1E9-5 CDR-H2 Chothia SGGGSD
    76 h4B10-1 CDR-H2 Chothia SGGGSN
    77 h4B10-2 CDR-H2 Chothia SGGGSN
    78 h4B10-3 CDR-H2 Chothia SGGGSN
    79 PD1-17 CDR-H2 Chothia YHSGS
    80 PD1-28 CDR-H2 Chothia SAYNGN
    81 PD1-33 CDR-H2 Chothia NPRGAT
    82 PD1-35 CDR-H2 Chothia YYNGN
    83 PD1-F2 CDR-H2 Chothia SGSGGS
    84 10B4 CDR-H2 Kabat KIFPGSGSADYNENFKG
    85 1353-A09 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    86 1353-C07 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    87 1353-E07 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    88 1353-F09 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    89 1353-G08 CDR-H2 Kabat WVSAHNGNTNYAQKLQG
    90 1353-G10 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    91 1353-H08 CDR-H2 Kabat WISAYNGNTKYAQKLQG
    92 1353-H09 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    93 1B10 CDR-H2 Kabat YISYSGRTSYNPSLTS
    94 1E9 CDR-H2 Kabat TISGGGSDTYYPDSVQG
    95 4B10 CDR-H2 Kabat TISGGGSNTYYSDSVKG
    96 h1E9-1 CDR-H2 Kabat TISGGGSDTYYPDSVQG
    97 h1E9-2 CDR-H2 Kabat TISGGGSDTYYPDSVQG
    98 h1E9-4 CDR-H2 Kabat TISGGGSDTYYPDSVQG
    99 h1E9-5 CDR-H2 Kabat TISGGGSDTYYPDSVQG
    100 h4B10-1 CDR-H2 Kabat TISGGGSNTYYSDSVKG
    101 h4B10-2 CDR-H2 Kabat TISGGGSNTYYSDSVKG
    102 h4B10-3 CDR-H2 Kabat TISGGGSNTYYSDSVKG
    103 PD1-17 CDR-H2 Kabat EIYHSGSTNYNPSLKS
    104 PD1-28 CDR-H2 Kabat WISAYNGNTNYAQKLQG
    105 PD1-33 CDR-H2 Kabat IINPRGATISYAQKFQG
    106 PD1-35 CDR-H2 Kabat YIYYNGNTYYNPSLRS
    107 PD1-F2 CDR-H2 Kabat AISGSGGSTYYADSVKG
    108 PD1-17 CDR-H3 QDYGDSGDWYFDL
    109 PD1-28 CDR-H3 DADYSSGSGY
    110 PD1-33 CDR-H3 AGIYGFDFDY
    111 PD1-35 CDR-H3 ASDYVWGGYRYMDAFDI
    112 PD1-F2 CDR-H3 ENWGSYFDL
    113 10B4 CDR-H3 GYGNYLYFDV
    114 1353-A09 CDR-H3 DSEYSSGSGY
    115 1353-C07 CDR-H3 DVDYSSGSGY
    116 1353-E07 CDR-H3 DAEYSLGSGY
    117 1353-F09 CDR-H3 DAEYGSGSGY
    118 1353-G08 CDR-H3 DADYGSGSGY
    119 1353-G10 CDR-H3 DVDYGTGSGY
    120 1353-H08 CDR-H3 DVDYGSGSGY
    121 1353-H09 CDR-H3 DAEYGSGSGY
    122 1B10 CDR-H3 GYALDY
    123 1E9 CDR-H3 QGYDVYSWFAY
    124 4B10 CDR-H3 QRDSAWFAS
    125 h1E9-1 CDR-H3 QGYDVYSWFAY
    126 h1E9-2 CDR-H3 QGYDVYSWFAY
    127 h1E9-4 CDR-H3 QGYDVYSWFAY
    128 h1E9-5 CDR-H3 QGYDVYSWFAY
    129 h4B10-1 CDR-H3 QRDSAWFAS
    130 h4B10-2 CDR-H3 QRDSAWFAS
    131 h4B10-3 CDR-H3 QRDSAWFAS
    132 PD1-17 CDR-H3 QDYGDSGDWYFDL
    133 PD1-28 CDR-H3 DADYSSGSGY
    134 PD1-33 CDR-H3 AGIYGFDFDY
    135 PD1-35 CDR-H3 ASDYVWGGYRYMDAFDI
    136 PD1-F2 CDR-H3 ENWGSYFDL
    137 PD1-17 CDR-L1 TRSSGSIASNSVQ
    138 PD1-28 CDR-L1 SGDALPKQYAY
    139 PD1-33 CDR-L1 TGTSNDVGGYNYVS
    140 PD1-35 CDR-L1 SGSNSNIGSNSVN
    141 PD1-F2 CDR-L1 RASQGISSWLA
    142 10B4 CDR-L1 KASQSVSDDVA
    143 1353-A09 CDR-L1 SGDALTTQYAY
    144 1353-C07 CDR-L1 SGDALSEQYAY
    145 1353-E07 CDR-L1 SGDALPKQYAY
    146 1353-F09 CDR-L1 SGDALPKQYAY
    147 1353-G08 CDR-L1 SGDALPMQYGY
    148 1353-G10 CDR-L1 SGDALPKQYAY
    149 1353-H08 CDR-L1 SGDALPKQYAY
    150 1353-H09 CDR-L1 SGDALPKQYAY
    151 1B10 CDR-L1 RTSSSVNYMH
    152 1E9 CDR-L1 RASESVDNSGISFMS
    153 4B10 CDR-L1 RASENVDDYGVSFMN
    154 h1E9-1 CDR-L1 RASESVDNSGISFMS
    155 h1E9-2 CDR-L1 RASESVDNSGISFMS
    156 h1E9-4 CDR-L1 RASESVDNSGISFMS
    157 h1E9-5 CDR-L1 RASESVDNSGISFMS
    158 h4B10-1 CDR-L1 RASENVDDYGVSFMN
    159 h4B10-2 CDR-L1 RASENVDDYGVSFMN
    160 h4B10-3 CDR-L1 RASENVDDYGVSFMN
    161 PD1-17 CDR-L1 TRSSGSIASNSVQ
    162 PD1-28 CDR-L1 SGDALPKQYAY
    163 PD1-33 CDR-L1 TGTSNDVGGYNYVS
    164 PD1-35 CDR-L1 SGSNSNIGSNSVN
    165 PD1-F2 CDR-L1 RASQGISSWLA
    166 PD1-17 CDR-L2 EDNQRPS
    167 PD1-28 CDR-L2 KDTERPS
    168 PD1-33 CDR-L2 DVTNRPS
    169 PD1-35 CDR-L2 GNNQRPS
    170 PD1-F2 CDR-L2 KASTLES
    171 10B4 CDR-L2 YAFKRYI
    172 1353-A09 CDR-L2 KDTERPS
    173 1353-C07 CDR-L2 KDTERPS
    174 1353-E07 CDR-L2 KDTERPS
    175 1353-F09 CDR-L2 KDTERPS
    176 1353-G08 CDR-L2 KDTERPS
    177 1353-G10 CDR-L2 KDTERPS
    178 1353-H08 CDR-L2 KDTERPS
    179 1353-H09 CDR-L2 KDTERPS
    180 1B10 CDR-L2 ATSKLAS
    181 1E9 CDR-L2 TASNQGS
    182 4B10 CDR-L2 PASNQGS
    183 h1E9-1 CDR-L2 TASNQGS
    184 h1E9-2 CDR-L2 TASNQGS
    185 h1E9-4 CDR-L2 TASNQGS
    186 h1E9-5 CDR-L2 TASNQGS
    187 h4B10-1 CDR-L2 PASNQGS
    188 h4B10-2 CDR-L2 PASNQGS
    189 h4B10-3 CDR-L2 PASNQGS
    190 PD1-17 CDR-L2 EDNQRPS
    191 PD1-28 CDR-L2 KDTERPS
    192 PD1-33 CDR-L2 DVTNRPS
    193 PD1-35 CDR-L2 GNNQRPS
    194 PD1-F2 CDR-L2 KASTLES
    195 PD1-17 CDR-L3 QSSDSSAVV
    196 PD1-28 CDR-L3 QSADNSITYRV
    197 PD1-33 CDR-L3 SSYTIVTNFEVL
    198 PD1-35 CDR-L3 AAWDDSLNGPV
    199 PD1-F2 CDR-L3 QQSYSTPWT
    200 10B4 CDR-L3 QQNYNSPYT
    201 1353-A09 CDR-L3 QSADNSITYRV
    202 1353-C07 CDR-L3 QSADNSITYRV
    203 1353-E07 CDR-L3 QSADNSITYRV
    204 1353-F09 CDR-L3 QSADNSITYRV
    205 1353-G08 CDR-L3 QSADNSITYRV
    206 1353-G10 CDR-L3 QSADNSITYRV
    207 1353-H08 CDR-L3 QSADNSITYRV
    208 1353-H09 CDR-L3 QSADNSITYRV
    209 1B10 CDR-L3 QQWISDPWT
    210 1E9 CDR-L3 QQSKEVPWT
    211 4B10 CDR-L3 QQSKEVPWT
    212 h1E9-1 CDR-L3 QQSKEVPWT
    213 h1E9-2 CDR-L3 QQSKEVPWT
    214 h1E9-4 CDR-L3 QQSKEVPWT
    215 h1E9-5 CDR-L3 QQSKEVPWT
    216 h4B10-1 CDR-L3 QQSKEVPWT
    217 h4B10-2 CDR-L3 QQSKEVPWT
    218 h4B10-3 CDR-L3 QQSKEVPWT
    219 PD1-17 CDR-L3 QSSDSSAVV
    220 PD1-28 CDR-L3 QSADNSITYRV
    221 PD1-33 CDR-L3 SSYTIVTNFEVL
    222 PD1-35 CDR-L3 AAWDDSLNGPV
    223 PD1-F2 CDR-L3 QQSYSTPWT
    224 HC ASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    Constant DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
    GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
    NTKVDKKVEPKSCDKTHTCPPCPAPELLGG
    PSVFLEPPKPKDTLMISRTPEVTCVVVDVS
    HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
    STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
    LPAPIEKTISKAKGQPREPQVYTLPPSREE
    MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
    ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
    QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    225 Kappa LC HMTVAAPSVFIFPPSDEQLKSGTASVVCLL
    NNFYPREAKVQWKVDNALQSGNSQESVTEQ
    DSKDSTYSLSSTLTLSKADYEKHKVYACEV
    THQGLSSPVTKSFNRGEC
    226 Lambda GQPKAAPSVTLFPPSSEELQANKATLVCLI
    LD SDFYPGAVTVAWKADSSPVKAGVETTTPSK
    QSNNKYAASSYLSLTPEQWKSHRSYSCQVT
    HEGSTVEKTVAPTECS
    227 h1E9-1 scFv MEVQLVESGGGLVKPGGSLRLSCAASGFTF
    STFGMSWVRQAPGKGLEWVSTISGGGSDTY
    YPDSVQGRFTISRDNAKNSLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SGGGGSGGGGSGGGGSDIQLTQSPSFLSAS
    VGDRVTITCRASESVDNSGISFMSWYQQKP
    GKAPKLLIYTASNQGSGVPSRFSGSGSGTE
    FTLTISSLQPEDFATYYCQQSKEVPWTFGQ
    GTKVEIKGSGDYKDDDDKGSGHHHHHH
    228 h1E9-2 scFv MEVQLVESGGGLVKPGGSLRLSCAASGFTF
    STFGMSWVRQAPGKGLEWVSTISGGGSDTY
    YPDSVQGRFTISRDNAKNSLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SGGGGSGGGGSGGGGSEIVLTQSPATLSLS
    PGERATLSCRASESVDNSGISFMSWYQQKP
    GQAPRLLIYTASNQGSGIPARFSGSGSGTD
    FTLTISSLEPEDFAVYYCQQSKEVPWTFGQ
    GTKVEIKGSGDYKDDDDKGSGHHHHHH
    229 h1E9-4 scFv MEVQLVESGGGLVQPGGSLRLSCAASGFTF
    STFGMSWVRQAPGKGLEWVATISGGGSDTY
    YPDSVQGRFTISRDNAKNSLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SGGGGSGGGGSGGGGSDIQLTQSPSFLSAS
    VGDRVTITCRASESVDNSGISFMSWYQQKP
    GKAPKLLIYTASNQGSGVPSRFSGSGSGTE
    FTLTISSLQPEDFATYYCQQSKEVPWTFGQ
    GTKVEIKGSGDYKDDDDKGSGHHHHHH
    230 h1E9-5 scFv MEVQLVESGGGLVQPGGSLRLSCAASGFTF
    STFGMSWVRQAPGKGLEWVATISGGGSDTY
    YPDSVQGRFTISRDNAKNSLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SGGGGSGGGGSGGGGSEIVLTQSPATLSLS
    PGERATLSCRASESVDNSGISFMSWYQQKP
    GQAPRLLIYTASNQGSGIPARFSGSGSGTD
    FTLTISSLEPEDFAVYYCQQSKEVPWTFGQ
    GTKVEIKGSGDYKDDDDKGSGHHHHHH
    231 h4B10-1 scFv MEVQLVESGGGLVKPGGSLRLSCAASGFTF
    TSYGMSWVRQAPGKGLEWVATISGGGSNTY
    YSDSVKGRFTISRDDSKNTLYLQMNSLKTE
    DTAVYYCARQRDSAWFASWGQGTLVTVSSG
    GGGSGGGGSGGGGSEIVLTQSPATLSLSPG
    ERATLSCRASENVDDYGVSFMNWYQQKPGQ
    APRLLIYPASNQGSGIPARFSGSGSGTDFT
    LTISSLEPEDFAVYYCQQSKEVPWTFGQGT
    KVEIKGSGDYKDDDDKGSGHHHHHH
    232 h4B10-2 scFv MEVQLVESGGGLVKPGGSLRLSCAASGFTF
    STYGMSWVRQAPGKGLEWVATISGGGSNTY
    YSDSVKGRFTISRDDSKNTLYLQMNSLKTE
    DTAVYYCARQRDSAWFASWGQGTLVTVSSG
    GGGSGGGGSGGGGSEIVLTQSPGTLSLSPG
    ERATLSCRASENVDDYGVSFMNWYQQKPGQ
    APRLLIYPASNQGSGIPDRFSGSGSGTDFT
    LTISRLEPEDFAVYYCQQSKEVPWTFGQGT
    KVEIKGSGDYKDDDDKGSGHHHHHH
    233 h4B10-3 scFv MEVQLVESGGGLVKPGGSLRLSCAASGFTF
    STYGMSWVRQAPGKGLEWVATISGGGSNTY
    YSDSVKGRFTISRDDSKNTLYLQMNSLKTE
    DTAVYYCARQRDSAWFASWGQGTLVTVSSG
    GGGSGGGGSGGGGSDIVMTQSPDSLAVSLG
    ERATINCRASENVDDYGVSFMNWYQQKPGQ
    PPKLLIYPASNQGSGVPDRFSGSGSGTDFT
    LTISSLQAEDVAVYYCQQSKEVPWTFGGGT
    KLEIKGSGDYKDDDDKGSGHHHHHH
    234 m10B4 scFv MQVQLQQSGAELMKPGASVKMSCKTTGYIF
    SSYWIGWVKQRPGHGLEWIGKIFPGSGSAD
    YNENFKGKATFTVDTSSNTAYMQLSSLTSE
    DSAVYYCARGYGNYLYFDVWGAGTTVTVSS
    GGGGSGGGGSGGGGSNIVMTQTPKFLLVSA
    GDRITITCKASQSVSDDVAWYQQKPGQSPK
    LLISYAFKRYIGVPDRFTGSGYGTDFTFTI
    STVQAEDLAVYFCQQNYNSPYTFGGGTKLE
    LKGSGDYKDDDDKGSGHHHHHH
    235 m1B10 scFv MSDVQLQESGPGLVKPSQSLSLTCTVTGHS
    ITSDYAWNWIRQFPGNKLEWMGYISYSGRT
    SYNPSLTSRISITRDTSKNQFFLQLNSVTT
    EDTATYYCARGYALDYWGQGTSVTVSSGGG
    GSGGGGSGGGGSQIVLSQSPAILSASPGEK
    VTMTCRTSSSVNYMHWFQQKPGSSPKPWIY
    ATSKLASGVPARFSGSGSGTSYSLTISRVE
    AEDAATYFCQQWISDPWTFGGGTKLEIKGS
    GDYKDDDDKGSGHHHHHH
    236 m1E9 scFv MEVKLVESGGGLVSPGGSLKLSCAASGFTF
    STFGMSWVRQTPEKRLEWVATISGGGSDTY
    YPDSVQGRFIISRYNAKNNLYLQMNSLRPE
    DTALYYCARQGYDVYSWFAYWGQGTLVTVS
    AGGGGSGGGGSGGGGSDIILTQSPASLAVS
    LGQRAAISCRASESVDNSGISFMSWFQQKP
    GQPPKLLIYTASNQGSGVPARFSGSGSGTE
    FSLNIHPMEEDDTAMYFCQQSKEVPWTFGG
    GTKLEIRGSGDYKDDDDKGSGHHHHHH
    237 m4B10 scFv MEVKLVESGGGLVKPGGSLKLSCAASGFTF
    STYGMSWVRQTPEKRLQWVATISGGGSNTY
    YSDSVKGRFTISRDNAKNNLYLQMSSLRSE
    DTALYYCARQRDSAWFASWGQGTLVTVSAG
    GGGSGGGGSGGGGSDIVLTQSPASLAVSLG
    QRATISCRASENVDDYGVSFMNWFQQKPGQ
    PPKLLIYPASNQGSGVPARFSGSGSGTDFS
    LNIHPMEEDDTAMYFCQQSKEVPWTEGGGT
    KLEIKGSGDYKDDDDKGSGHHHHHH
    238 1353-A09 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    TWYGISWVRQAPGQGLEWMGWISAYNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDSEYSSGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALTTQYAYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLFPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFE
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    239 1353-C07 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    STFGISWVRQAPGQGLEWMGWISAYNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDVDYSSGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALSEQYAYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    240 1353-E07 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    ETYGISWVRQAPGQGLEWMGWISAYNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDAEYSLGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALPKQYAYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    YLSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    241 1353-F09 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    RQYGISWVRQAPGQGLEWMGWISAYNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDAEYGSGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALPKQYAYWYQQKPGQAPVM
    VLYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    242 1353-G08 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    TRYGISWVRQAPGQGLEWMGWVSAHNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDADYGSGSGYWGQGTLVTVSS
    GGGVSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALPMQYGYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    243 1353-G10 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    PHYGISWVRQAPGQGLEWMGWISAYNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDVDYGTGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALPKQYAYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    244 1353-H08 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    TRQGISWVRQAPGQGLEWMGWISAYNGNTK
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDVDYGSGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALPKQYAYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    CPPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    245 1353-H09 scFv-Fc MEVQLVQSGAEVKKPGASVKVSCKASGYRF
    PHYGISWVRQAPGQGLEWMGWISAYNGNTN
    YAQKLQGRVTMTTDTSTNTAYMELRSLRSD
    DTAVYYCARDAEYGSGSGYWGQGTLVTVSS
    GGGGSGGGGSGGGGSSYELTQPPSVSVSPG
    QTARTTCSGDALPKQYAYWYQQKPGQAPVM
    VIYKDTERPSGIPERFSGSSSGTKVTLTIS
    GVQAEDEADYYCQSADNSITYRVFGGGTKV
    TVLAAGSDQEPKKLAAGSDQEPKSSDKTHT
    PCPCSAPELLGGSSVFLEPPKPKDTLMISR
    TPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
    NAKTKPREEQYNSTYRVVSVLTVLHQDWLN
    GKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSRDELTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFF
    LYSKLTVDKSRWQQGNVFSCSVMHEALHNH
    YTQKSLSLSPGKGSGDYKDDDDKGSGHHHH
    HH
    246 10B4 VH QVQLQQSGAELMKPGASVKMSCKTTGYIFS
    SYWIGWVKQRPGHGLEWIGKIFPGSGSADY
    NENFKGKATFTVDTSSNTAYMQLSSLTSED
    SAVYYCARGYGNYLYFDVWGAGTTVTVSS
    247 1353-A09 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    WYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDSEYSSGSGYWGQGTLVTVSS
    248 1353-C07 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFS
    TFGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDVDYSSGSGYWGQGTLVTVSS
    249 1353-E07 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFE
    TYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDAEYSLGSGYWGQGTLVTVSS
    250 1353-F09 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFR
    QYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDAEYGSGSGYWGQGTLVTVSS
    251 1353-G08 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    RYGISWVRQAPGQGLEWMGWVSAHNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDADYGSGSGYWGQGTLVTVSS
    252 1353-G10 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFP
    HYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDVDYGTGSGYWGQGTLVTVSS
    253 1353-H08 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    RQGISWVRQAPGQGLEWMGWISAYNGNTKY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDVDYGSGSGYWGQGTLVTVSS
    254 1353-H09 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFP
    HYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDAEYGSGSGYWGQGTLVTVSS
    255 1B10 VH DVQLQESGPGLVKPSQSLSLTCTVTGHSIT
    SDYAWNWIRQFPGNKLEWMGYISYSGRTSY
    NPSLTSRISITRDTSKNQFFLQLNSVTTED
    TATYYCARGYALDYWGQGTSVTVSS
    256 1E9 VH EVKLVESGGGLVSPGGSLKLSCAASGFTFS
    TFGMSWVRQTPEKRLEWVATISGGGSDTYY
    PDSVQGRFIISRYNAKNNLYLQMNSLRPED
    TALYYCARQGYDVYSWFAYWGQGTLVTVSA
    257 4B10 VH EVKLVESGGGLVKPGGSLKLSCAASGFTFS
    TYGMSWVRQTPEKRLQWVATISGGGSNTYY
    SDSVKGRFTISRDNAKNNLYLQMSSLRSED
    TALYYCARQRDSAWFASWGQGTLVTVSA
    258 h1E9-1 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS
    TFGMSWVRQAPGKGLEWVSTISGGGSDTYY
    PDSVQGRFTISRDNAKNSLYLQMNSLRAED
    TAVYYCARQGYDVYSWFAYWGQGTLVTVSS
    259 h1E9-2 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS
    TFGMSWVRQAPGKGLEWVSTISGGGSDTYY
    PDSVQGRFTISRDNAKNSLYLQMNSLRAED
    TAVYYCARQGYDVYSWFAYWGQGTLVTVSS
    260 h1E9-4 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFS
    TFGMSWVRQAPGKGLEWVATISGGGSDTYY
    PDSVQGRFTISRDNAKNSLYLQMNSLRAED
    TAVYYCARQGYDVYSWFAYWGQGTLVTVSS
    261 h1E9-5 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFS
    TFGMSWVRQAPGKGLEWVATISGGGSDTYY
    PDSVQGRFTISRDNAKNSLYLQMNSLRAED
    TAVYYCARQGYDVYSWFAYWGQGTLVTVSS
    262 h4B10-1 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS
    TYGMSWVRQAPGKGLEWVATISGGGSNTYY
    SDSVKGRFTISRDDSKNTLYLQMNSLKTED
    TAVYYCARQRDSAWFASWGQGTLVTVSS
    263 h4B10-2 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS
    TYGMSWVRQAPGKGLEWVATISGGGSNTYY
    SDSVKGRFTISRDDSKNTLYLQMNSLKTED
    TAVYYCARQRDSAWFASWGQGTLVTVSS
    264 h4B10-3 VH EVQLVESGGGLVKPGGSLRLSCAASGFTFS
    TYGMSWVRQAPGKGLEWVATISGGGSNTYY
    SDSVKGRFTISRDDSKNTLYLQMNSLKTED
    TAVYYCARQRDSAWFASWGQGTLVTVSS
    265 PD1-17 VH QVQLQESGPGVVKPSGTLSLTCAISGGSIG
    SGGSIRSTRWWSWVRQSPGKGLEWIGEIYH
    SGSTNYNPSLKSRVTISLDKSRNHFSLRLN
    SVTAADTAVYYCARQDYGDSGDWYFDLWGK
    GTMVTVSS
    266 PD1-28 VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    SYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDADYSSGSGYWGQGTLVTVSS
    267 PD1-33 VH QVQLVQSGAEVKKPGASVRVSCKASGYTLT
    SYYIHWVRQAPGQGLEWMGIINPRGATISY
    AQKFQGRVTMTRDTSTSTVYMELRNLKSED
    TALYYCATAGIYGFDFDYWGRGTLVTVSS
    268 PD1-35 VH QVQLQESGPGLVKPSQTLSLTCTVSGGSIS
    SGAYYWSWIRQHPGKGLEWIGYIYYNGNTY
    YNPSLRSLVTISVDASKNQFSLKLSSVTAA
    DTAVYYCARASDYVWGGYRYMDAFDIWGRG
    TLITVSS
    269 PD1-F2 VH EVQLVQSGGGVVQPGRSLRLSCAASGFTFS
    SYWCDRMSWVRQAPGKGLEWVSAISGSGGS
    TYYADSVKGRFTISRDNSKNTLYLQMNSLR
    AEDTAVYYCAKENWGSYFDLWGQGTTVTVS
    S
    270 10B4 VL NIVMTQTPKFLLVSAGDRITITCKASQSVS
    DDVAWYQQKPGQSPKLLISYAFKRYIGVPD
    RFTGSGYGTDFTFTISTVQAEDLAVYFCQQ
    NYNSPYTFGGGTKLELKR
    271 1353-A09 VL SYELTQPPSVSVSPGQTARITCSGDALTTQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    272 1353-C07 VL SYELTQPPSVSVSPGQTARITCSGDALSEQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    273 1353-E07 VL SYELTQPPSVSVSPGQTARITCSGDALPKQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    274 1353-F09 VL SYELTQPPSVSVSPGQTARITCSGDALPKQ
    YAYWYQQKPGQAPVMVLYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    275 1353-G08 VL SYELTQPPSVSVSPGQTARITCSGDALPMQ
    YGYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    276 1353-G10 VL SYELTQPPSVSVSPGQTARITCSGDALPKQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    277 1353-H08 VL SYELTQPPSVSVSPGQTARITCSGDALPKQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    278 1353-H09 VL SYELTQPPSVSVSPGQTARITCSGDALPKQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    279 1B10 VL QIVLSQSPAILSASPGEKVTMTCRTSSSVN
    YMHWFQQKPGSSPKPWIYATSKLASGVPAR
    FSGSGSGTSYSLTISRVEAEDAATYFCQQW
    ISDPWTFGGGTKLEIK
    280 1E9 VL DIILTQSPASLAVSLGQRAAISCRASESVD
    NSGISFMSWFQQKPGQPPKLLIYTASNQGS
    GVPARFSGSGSGTEFSLNIHPMEEDDTAMY
    FCQQSKEVPWTFGGGTKLEIR
    281 4B10 VL DIVLTQSPASLAVSLGQRATISCRASENVD
    DYGVSFMNWFQQKPGQPPKLLIYPASNQGS
    GVPARFSGSGSGTDFSLNIHPMEEDDTAMY
    FCQQSKEVPWTFGGGTKLEIK
    282 h1E9-1 VL DIQLTQSPSFLSASVGDRVTITCRASESVD
    NSGISFMSWYQQKPGKAPKLLIYTASNQGS
    GVPSRFSGSGSGTEFTLTISSLQPEDFATY
    YCQQSKEVPWTFGQGTKVEIK
    283 h1E9-2 VL EIVLTQSPATLSLSPGERATLSCRASESVD
    NSGISFMSWYQQKPGQAPRLLIYTASNQGS
    GIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQSKEVPWTFGQGTKVEIK
    284 h1E9-4 VL DIQLTQSPSFLSASVGDRVTITCRASESVD
    NSGISFMSWYQQKPGKAPKLLIYTASNQGS
    GVPSRFSGSGSGTEFTLTISSLQPEDFATY
    YCQQSKEVPWTFGQGTKVEIK
    285 h1E9-5 VL EIVLTQSPATLSLSPGERATLSCRASESVD
    NSGISFMSWYQQKPGQAPRLLIYTASNQGS
    GIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQSKEVPWTFGQGTKVEIK
    286 h4B10-1 VL EIVLTQSPATLSLSPGERATLSCRASENVD
    DYGVSFMNWYQQKPGQAPRLLTYPASNQGS
    GIPARFSGSGSGTDFTLTISSLEPEDFAVY
    YCQQSKEVPWTFGQGTKVEIK
    287 h4B10-2 VL EIVLTQSPGTLSLSPGERATLSCRASENVD
    DYGVSFMNWYQQKPGQAPRLLTYPASNQGS
    GIPDRFSGSGSGTDFTLTISRLEPEDFAVY
    YCQQSKEVPWTFGQGTKVEIK
    288 h4B10-3 VL DIVMTQSPDSLAVSLGERATINCRASENVD
    DYGVSFMNWYQQKPGQPPKLLTYPASNQGS
    GVPDRFSGSGSGTDFTLTISSLQAEDVAVY
    YCQQSKEVPWTFGGGTKLEIK
    289 PD1-17 VL NFMLTQPHSVSESPGKTVTISCTRSSGSIA
    SNSVQWYQQRPGSSPTTVIYEDNQRPSGVP
    DRFSGSIDSSSNSASLTVSGLKTEDEADYY
    CQSSDSSAVVFGSGTKLTVL
    290 PD1-28 VL SYELTQPPSVSVSPGQTARITCSGDALPKQ
    YAYWYQQKPGQAPVMVIYKDTERPSGIPER
    FSGSSSGTKVTLTISGVQAEDEADYYCQSA
    DNSITYRVFGGGTKVTVL
    291 PD1-33 VL QSALTQPASVSGSPGQSITISCTGTSNDVG
    GYNYVSWYQHHPGKAPKLIIYDVTNRPSGV
    SDRFSGSKSGNTASLTISGLLAEDEGDYYC
    SSYTIVTNFEVLEGGGTKLTV
    292 PD1-35 VL QSVLTQPPSASGTPGQRVTISCSGSNSNIG
    SNSVNWYQQLPGTAPKLLIYGNNQRPSGVP
    DRFSGSKSGTSASLAISGLQSENEADYYCA
    AWDDSLNGPVFGRGTKVTVL
    293 PD1-F2 VL DIVMTQSPSTLSASVGDRVTITCRASQGIS
    SWLAWYQQKPGRAPKVLIYKASTLESGVPS
    RFSGSGSGTDFTLTISSLQPEDFATYYCQQ
    SYSTPWTFGQGTKLEIK
    294 FlagHis GSGDYKDDDDKGSGHHHHHH
    Tag
    295 IgG1 Fc AAGSDQEPKSSDKTHTCPPCSAPELLGGSS
    from VFLFPPKPKDTLMISRTPEVTCVVVDVSHE
    scFv-Fc DPEVKFNWYVDGVEVHNAKTKPREEQYNST
    YRVVSVLTVLHQDWLNGKEYKCKVSNKALP
    APIEKTISKAKGQPREPQVYTLPPSRDELT
    KNQVSLTCLVKGFYPSDIAVEWESNGQPEN
    NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
    GNVFSCSVMHEALHNHYTQKSLSLSPGKGS
    GDYKDDDDKGSG
    296 HC ASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    Constant DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
    GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
    NTKVDKKVEPKSCDKTHTCPPCPAPELLGG
    PSVFLFPPKPKDTLMISRTPEVTCVVVDVS
    HEDPEVKFNWYVDGVEVHNAKTKPREEQYN
    STYRVVSVLTVLHQDWLNGKEYKCKVSNKA
    LPAPIEKTISKAKGQPREPQVYTLPPSREE
    MTKNQVSLTCLVKGFYPSDIAVEWESNGQP
    ENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
    QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    297 LC RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
    Constant NFYPREAKVQWKVDNALQSGNSQESVTEQD
    SKDSTYSLSSTLTLSKADYEKHKVYACEVT
    HQGLSSPVTKSFNRGEC
    298 Linker GGGGSGGGGSGGGGS
    299 murine MWVRQVPWSFTWAVLQLSWQSGWLLEVPNG
    PD-1 PWRSLTFYPAWLTVSEGANATFTCSLSNWS
    EDLMLNWNRLSPSNQTEKQAAFCNGLSQPV
    QDARFQITQLPNRHDEHMNILDTRRNDSGI
    YLCGAISLHPKAKIEESPGAELVVTERILE
    TSTRYPSPSPKPEGRFQGMVIGIMSALVGI
    PVLLLLAWALAVFCSTSMSEARGAGSKDDT
    LKEEPSAAPVPSVAYEELDFQGREKTPELP
    TACVHTEYATIVFTEGLGASAMGRRGSADG
    LQGPRPPRHEDGHCSWPL
    300 cyno MWVRQVPWSFTWAVLQLSWQSGWLLEVPNG
    PD-1 PWRSLTFYPAWLTVSEGANATFTCSLSNWS
    EDLMLNWNRLSPSNQTEKQAAFCNGLSQPV
    QDARFQITQLPNRHDEHMNILDTRRNDSGI
    YLCGAISLHPKAKIEESPGAELVVTERILE
    TSTRYPSPSPKPEGRFQGMVIGIMSALVGI
    PVLLLLAWALAVFCSTSMSEARGAGSKDDT
    LKEEPSAAPVPSVAYEELDFQGREKTPELP
    TACVHTEYATIVFTEGLGASAMGRRGSADG
    LQGPRPPRHEDGHCSWPL
    301 Linker AAGSDQEPK
    302 h1E9-4 & HC- MEVQLVESGGGLVQPGGSLRLSCAASGFTF
    h1E9-5 FlagHis STFGMSWVRQAPGKGLEWVATISGGGSDTY
    YPDSVQGRFTISRDNAKNSLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQS
    SGLYSLSSVVTVPSSSLGTQTYICNVNHKP
    SNTKVDKKVEPKSCDKTHTCPPCPAPELLG
    GPSVFLEPPKPKDTLMISRTPEVTCVVVDV
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQY
    NSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
    ALPAPIEKTISKAKGQPREPQVYTLPPSRE
    EMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
    PENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    KGSGDYKDDDDKGSGHHHHHH
    303 h1E9-5 LC MEIVLTQSPATLSLSPGERATLSCRASESV
    DNSGISFMSWYQQKPGQAPRLLIYTASNQG
    SGIPARFSGSGSGTDFTLTISSLEPEDFAV
    YYCQQSKEVPWTFGQGTKVEIKRTVAAPSV
    FIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSL
    SSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    304 h1E9-4 LC MDIQLTQSPSFLSASVGDRVTITCRASESV
    DNSGISFMSWYQQKPGKAPKLLIYTASNQG
    SGVPSRFSGSGSGTEFTLTISSLQPEDFAT
    YYCQQSKEVPWTFGQGTKVEIKRTVAAPSV
    FIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSL
    SSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    305 PD1-F2v- scFv-Fc MGAHSEVQLVQSGGGVVQPGRSLRLSCAAS
    scFvFcFlag GFTFSSYWMSWVRQAPGKGLEWVSAISGSG
    His GSTYYADSVKGRFTISRDNSKNTLYLQMNS
    LRAEDTAVYYCAKENWGSYFDLWGQGTTVT
    VSSGGGGSGGGGSGGGGSGVHSDIVMTQSP
    STLSASVGDRVTITCRASQGISSWLAWYQQ
    KPGRAPKVLTYKASTLESGVPSRFSGSGSG
    TDFTLTISSLQPEDFATYYCQQSYSTPWTF
    GQGTKLEIKAAGSDQEPKSSDKTHTCPPCS
    APELLGGSSVFLEPPKPKDTLMISRTPEVT
    CVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
    PREEQYNSTYRVVSVLTVLHQDWLNGKEYK
    CKVSNKALPAPIEKTISKAKGQPREPQVYT
    LPPSRDELTKNQVSLTCLVKGFYPSDIAVE
    WESNGQPENNYKTTPPVLDSDGSFFLYSKL
    TVDKSRWQQGNVFSCSVMHEALHNHYTQKS
    LSLSPGKGSGDYKDDDDKGSGHHHHHH
    306 PD1-F2v VH EVQLVQSGGGVVQPGRSLRLSCAASGFTES
    SYWMSWVRQAPGKGLEWVSAISGSGGSTYY
    ADSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCAKENWGSYFDLWGQGTTVTVSS
    307 PD1-F2v HC GAHSEVQLVQSGGGVVQPGRSLRLSCAASG
    FTESSYWMSWVRQAPGKGLEWVSAISGSGG
    STYYADSVKGRFTISRDNSKNTLYLQMNSL
    RAEDTAVYYCAKENWGSYFDLWGQGTTVTV
    SSASTKGPSVFPLAPSSKSTSGGTAALGCL
    VKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
    SSGLYSLSSVVTVPSSSLGTQTYICNVNHK
    PSNTKVDKKVEPKSCDKTHTCPPCPAPELL
    GGPSVFLFPPKPKDTLMISRTPEVTCVVVD
    VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
    YNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
    KALPAPIEKTISKAKGQPREPQVYTLPPSR
    EEMTKNQVSLTCLVKGFYPSDIAVEWESNG
    QPENNYKTTPPVLDSDGSFFLYSKLTVDKS
    RWQQGNVFSCSVMHEALHNHYTQKSLSLSP
    GK
    308 PD1-F2v LC GVHSDIVMTQSPSTLSASVGDRVTITCRAS
    QGISSWLAWYQQKPGRAPKVLIYKASTLES
    GVPSRFSGSGSGTDFTLTISSLQPEDFATY
    YCQQSYSTPWTFGQGTKLEIKRHMTVAAPS
    VFIFPPSDEQLKSGTASVVCLLNNFYPREA
    KVQWKVDNALQSGNSQESVTEQDSKDSTYS
    LSSTLTLSKADYEKHKVYACEVTHQGLSSP
    VTKSFNRGEC
    309 1353-E07- CDR-H3 DAEYRLGSGY
    R5
    310 1353-A09- CDR-H3 DSEYRSGSGY
    R5
    311 1353-F09- CDR-H3 DAEYRSGSGY
    R5
    312 1353-G08- CDR-H3 DADYRSGSGY
    R5
    313 1353-G10- CDR-H3 DVDYRTGSGY
    R5
    314 1353-C07- CDR-H3 DVDYRSGSGY
    R5
    315 1353-H08- CDR-H3 DVDYRSGSGY
    R5
    316 1353-E07- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFE
    R5 TYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDAEYRLGSGYWGQGTLVTVSS
    317 1353-A09- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    R5 WYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDSEYRSGSGYWGQGTLVTVSS
    318 1353-F09- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFR
    R5 QYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDAEYRSGSGYWGQGTLVTVSS
    319 1353-G08- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    R5 RYGISWVRQAPGQGLEWMGWVSAHNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDADYRSGSGYWGQGTLVTVSS
    320 1353-G10- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFP
    R5 HYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDVDYRTGSGYWGQGTLVTVSS
    321 1353-C07- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFS
    R5 TFGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDVDYRSGSGYWGQGTLVTVSS
    322 1353-H08- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFT
    R5 RQGISWVRQAPGQGLEWMGWISAYNGNTKY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDVDYRSGSGYWGQGTLVTVSS
    323 1353-H09- VH EVQLVQSGAEVKKPGASVKVSCKASGYRFP
    R5 HYGISWVRQAPGQGLEWMGWISAYNGNTNY
    AQKLQGRVTMTTDTSTNTAYMELRSLRSDD
    TAVYYCARDAEYRSGSGYWGQGTLVTVSS
    324 H1E9-HC3 HC- MEVQLVESGGGLVQPGGSLRLSCAASGFTF
    FlagHis STFGMSWVRQAPGKGLEWVATISGGGSDTY
    YPDSVKGRFTISRDNAKNSLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQS
    SGLYSLSSVVTVPSSSLGTQTYICNVNHKP
    SNTKVDKKVEPKSCDKTHTCPPCPAPELLG
    GPSVFLFPPKPKDTLMISRTPEVTCVVVDV
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQY
    NSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
    ALPAPIEKTISKAKGQPREPQVYTLPPSRE
    EMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
    PENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    KGSGDYKDDDDKGSGHHHHHH
    325 H1E9-HC2 HC- MQVQLVESGGGVVQPGRSLRLSCAASGFTF
    FlagHis STFGMSWVRQAPGKGLEWVATISGGGSDTY
    YPDSVKGRFTISRDNSKNTLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQS
    SGLYSLSSVVTVPSSSLGTQTYICNVNHKP
    SNTKVDKKVEPKSCDKTHTCPPCPAPELLG
    GPSVFLFPPKPKDTLMISRTPEVTCVVVDV
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQY
    NSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
    ALPAPIEKTISKAKGQPREPQVYTLPPSRE
    EMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
    PENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    KGSGDYKDDDDKGSGHHHHHH
    326 H1E9-HC1 HC- MEVQLLESGGGLVQPGGSLRLSCAASGFTF
    FlagHis STFGMSWVRQAPGKGLEWVATISGGGSDTY
    YPDSVKGRFTISRDNSKNTLYLQMNSLRAE
    DTAVYYCARQGYDVYSWFAYWGQGTLVTVS
    SASTKGPSVFPLAPSSKSTSGGTAALGCLV
    KDYFPEPVTVSWNSGALTSGVHTFPAVLQS
    SGLYSLSSVVTVPSSSLGTQTYICNVNHKP
    SNTKVDKKVEPKSCDKTHTCPPCPAPELLG
    GPSVFLFPPKPKDTLMISRTPEVTCVVVDV
    SHEDPEVKFNWYVDGVEVHNAKTKPREEQY
    NSTYRVVSVLTVLHQDWLNGKEYKCKVSNK
    ALPAPIEKTISKAKGQPREPQVYTLPPSRE
    EMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
    PENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    KGSGDYKDDDDKGSGHHHHHH
    327 H1E9-LC4 LC MDIVLTQSPDSLAVSLGERATINCRASESV
    DNSGISFMSWYQQKPGQPPKLLIYTASNQG
    SGVPDRFSGSGSGTDFTLTISSLQAEDVAV
    YYCQQSKEVPWTFGQGTKVEIKRTVAAPSV
    FIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSL
    SSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    328 H1E9-LC3 LC MEIVLTQSPGTLSLSPGERATLSCRASESV
    DNSGISFMSWYQQKPGQAPRLLIYTASNQG
    SGIPDRFSGSGSGTDFTLTISRLEPEDFAV
    YYCQQSKEVPWTFGQGTKVEIKRTVAAPSV
    FIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSL
    SSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    329 H1E9-LC2 LC MDIVLTQSPLSLPVTPGEPASISCRASESV
    DNSGISFMSWYLQKPGQSPQLLIYTASNQG
    SGVPDRFSGSGSGTDFTLKISRVEAEDVGV
    YYCQQSKEVPWTFGQGTKVEIKRTVAAPSV
    FIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSL
    SSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    330 H1E9-LC1 LC MDIQLTQSPSSLSASVGDRVTITCRASESV
    DNSGISFMSWYQQKPGKAPKLLIYTASNQG
    SGVPSRFSGSGSGTDFTFTISSLQPEDIAT
    YYCQQSKEVPWTFGQGTKVEIKRTVAAPSV
    FIFPPSDEQLKSGTASVVCLLNNFYPREAK
    VQWKVDNALQSGNSQESVTEQDSKDSTYSL
    SSTLTLSKADYEKHKVYACEVTHQGLSSPV
    TKSFNRGEC
    331 CDR-H2 Kabat TISGGGSDTYYPDSVQG
    • EQUIVALENTS
  • The disclosure set forth above may encompass multiple distinct inventions with independent utility. Although each of these inventions has been disclosed in its preferred form(s), the specific embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. The subject matter of the inventions includes all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and/or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious. Inventions embodied in other combinations and subcombinations of features, functions, elements, and/or properties may be claimed in this application, in applications claiming priority from this application, or in related applications. Such claims, whether directed to a different invention or to the same invention, and whether broader, narrower, equal, or different in scope in comparison to the original claims, also are regarded as included within the subject matter of the inventions of the present disclosure.

Claims (23)

1.-20. (canceled)
21.-67. (canceled)
68. A method of treating disease in a subject, comprising administering an effective amount of an antibody conjugate, or a pharmaceutical composition comprising the same, wherein the antibody conjugate comprises an antibody or antibody fragment of the IgG class comprising:
three heavy chain CDRs of the VH region SEQ ID NO: 252, or a variant thereof, and hree light chain CDRs of the VL region SEQ ID NO: 276, or a variant thereof.
69. A method of diagnosing a disease in a subject, comprising administering an effective amount of an antibody conjugate, or a pharmaceutical composition comprising the same, wherein the antibody conjugate comprises an antibody or antibody fragment of the IgG class comprising:
three heavy chain CDRs of the VH region SEQ ID NO: 252, or a variant thereof, and three light chain CDRs of the VL region SEQ ID NO: 276, or a variant thereof.
70. The method of claim 68, wherein the disease is cancer, an autoimmune disease or condition, infection, or any combination thereof.
71. The method of claim 68, wherein the pharmaceutical composition comprises the antibody or antibody fragment of claim 68 and a pharmaceutically acceptable carrier.
72. The method of claim 68, wherein the pharmaceutical composition is substantially pure.
73. The method of claim 72, wherein the pharmaceutical composition comprises an antibody that is at least 95% by mass of the total antibody or antibody fragment mass of said composition.
74. The method of claim 68, wherein the pharmaceutical composition is administered intramuscularly, intradermally, intraperitoneally, intravenously, subcutaneously administration, or any combination thereof.
75. The method of claim 68, wherein the antibody or antibody fragment comprises:
a CDR-H1 comprising SEQ ID NO: 13; a CDR-H2 comprising SEQ ID NO: 66; a CDR-H3 comprising SEQ ID NO: 119; a CDR-L1 comprising SEQ ID NO: 148; a CDR-L2 comprising SEQ ID NO: 177; and a CDR-L3 comprising SEQ ID NO: 206; or
b. a CDR-H1 comprising SEQ ID NO: 37; a CDR-H2 comprising SEQ ID NO: 90; a CDR-H3 comprising SEQ ID NO: 119; a CDR-L1 comprising SEQ ID NO: 148; a CDR-L2 comprising SEQ ID NO: 177; and a CDR-L3 comprising SEQ ID NO: 206.
76. The method of claim 68, wherein the variant of the VH and VL regions have 20 or fewer amino acid substitutions, and wherein the substitutions are conservative amino acid substitutions.
77. The method of claim 68, wherein the antibody or antibody fragment further comprises at least one constant region domain.
78. The antibody of claim 77, wherein the constant region domain comprises a sequence selected from SEQ ID NOs: 224-226 and 297.
79. The method of claim 68, wherein the antibody or antibody fragment is a monoclonal antibody.
80. The method of claim 68, wherein the antibody or antibody fragment is aglycosylated.
81. The method of claim 68, wherein the antibody fragment is selected from an Fv fragment, a Fab fragment, a F(ab′)2 fragment, a Fab′ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.
82. The antibody fragment of claim 81, wherein the antibody fragment is an scFv fragment.
83. The antibody fragment of claim 81, wherein the antibody fragment is an scFv-Fc fragment.
84. The antibody fragment of claim 83, wherein the scFv-Fc fragment comprises a sequence selected from SEQ ID NO: 243 with AAGSDQEPK (SEQ ID NO: 301) removed from the sequence.
85. The method of claim 68, wherein the antibody or antibody fragment has a ka of about 4.74×104 M−1×sec−1 to about 1.23×106 M−1×sec−1 when associating with human PD-1 at a temperature of 25° C.
86. The method of claim 68, wherein the antibody or antibody fragment has a kd of about 1.87×10−2 sec−1 to about 4.17×10−4 sec−1 when dissociating from human PD-1 at a temperature of 25° C.
87. The method of claim 68, wherein the antibody or antibody fragment has a KD of about 3.85×10−8 M to about 2.52×10−10 M when bound to human PD-1 at a temperature of 25° C.
88. The method of claim 68, wherein the antibody or antibody fragment specifically binds one or more of murine PD-1 and cynomolgus PD-1.
US17/068,477 2014-10-27 2020-10-12 Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies Abandoned US20210107981A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/068,477 US20210107981A1 (en) 2014-11-11 2020-10-12 Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
US18/110,114 US20230203165A1 (en) 2014-10-27 2023-02-15 Selective Picture-Based Encryption of Video Streams

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462078115P 2014-11-11 2014-11-11
PCT/US2015/060033 WO2016077397A2 (en) 2014-11-11 2015-11-10 Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
US201715525943A 2017-05-10 2017-05-10
US17/068,477 US20210107981A1 (en) 2014-11-11 2020-10-12 Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US14/525,197 Continuation US10841626B2 (en) 2014-10-27 2014-10-27 Selective picture-based encryption of video streams
US15/525,943 Continuation US10822414B2 (en) 2014-11-11 2015-11-10 Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
PCT/US2015/060033 Continuation WO2016077397A2 (en) 2014-11-11 2015-11-10 Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/110,114 Continuation US20230203165A1 (en) 2014-10-27 2023-02-15 Selective Picture-Based Encryption of Video Streams

Publications (1)

Publication Number Publication Date
US20210107981A1 true US20210107981A1 (en) 2021-04-15

Family

ID=54602076

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/525,943 Active 2036-07-13 US10822414B2 (en) 2014-11-11 2015-11-10 Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
US17/068,477 Abandoned US20210107981A1 (en) 2014-10-27 2020-10-12 Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/525,943 Active 2036-07-13 US10822414B2 (en) 2014-11-11 2015-11-10 Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies

Country Status (3)

Country Link
US (2) US10822414B2 (en)
EP (1) EP3218409A2 (en)
WO (1) WO2016077397A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119659C2 (en) 2013-12-12 2019-07-25 Шанхай Хенжуй Фармасьютикал Ко., Лтд. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
MX2018000621A (en) 2015-07-13 2018-05-11 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof.
AU2016293674B2 (en) 2015-07-16 2019-11-21 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
CR20220194A (en) 2015-07-30 2022-06-16 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017031242A1 (en) 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation Pd-1 binding proteins and methods of use thereof
CR20180234A (en) 2015-11-03 2018-09-11 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
KR102424513B1 (en) 2015-12-14 2022-07-25 마크로제닉스, 인크. Bispecific molecules with immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
CN106008714B (en) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti-human PD-1 Humanized monoclonal antibodies and its application
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
JOP20190013A1 (en) * 2016-08-25 2019-01-31 Lilly Co Eli Anti-tim-3 antibodies
KR102391338B1 (en) * 2016-09-16 2022-04-26 상하이 헨리우스 바이오테크, 인크. anti-PD-1 antibody
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
RU2757316C2 (en) 2016-09-21 2021-10-13 СиСТОНЕ ФАРМАСЬЮТИКАЛС New monoclonal antibodies to programmed cell death 1 (pd-1) protein
KR102603681B1 (en) 2016-12-07 2023-11-17 아게누스 인코포레이티드 Antibodies and methods of using them
CN106519034B (en) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 anti-PD-1 antibodies and uses thereof
EP3559044A4 (en) * 2016-12-23 2020-12-02 REMD Biotherapeutics, Inc. Immunotherapy using antibodies that bind programmed death 1 (pd-1)
CN108203464B (en) * 2016-12-25 2021-07-20 南京金斯瑞生物科技有限公司 High-affinity, high-specificity and high-functionality anti-human PD-1 antibody with multiple antigen recognition epitopes
EP3585813A1 (en) 2017-02-22 2020-01-01 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
CN110325209A (en) 2017-02-24 2019-10-11 宏观基因有限公司 CD137 and the bi-specific binding molecule of tumour antigen and application thereof can be combined
WO2018162944A1 (en) 2017-03-04 2018-09-13 Shenzhen Runshin Bioscience Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
WO2018217940A2 (en) 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
US12071477B2 (en) 2017-09-18 2024-08-27 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugated with hemiasterlins
CN111699200B (en) * 2018-01-15 2023-05-26 南京传奇生物科技有限公司 Single domain antibodies and variants thereof against PD-1
WO2019219064A1 (en) * 2018-05-17 2019-11-21 Nanjing Leads Biolabs Co.Ltd Antibody binding pd-1 and use thereof
CA3108460A1 (en) * 2018-07-04 2020-01-09 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
PE20220336A1 (en) 2019-05-03 2022-03-14 Celgene Corp ANTI-BCMA ANTIBODY CONJUGATE, COMPOSITIONS COMPRISING IT, AND METHODS OF MANUFACTURING AND USE THEREOF
WO2020252043A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
EP3983410A1 (en) 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
WO2021063201A1 (en) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 Anti-pd-1 antibody and use thereof
CA3214729A1 (en) 2021-04-08 2022-10-13 Marilena GALLOTTA Combination therapies with cbl-b inhibitor compounds
TW202308702A (en) 2021-04-30 2023-03-01 美商西建公司 Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
CA3151350A1 (en) * 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2014201367B2 (en) * 2007-06-18 2016-01-28 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
KR101814408B1 (en) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies

Also Published As

Publication number Publication date
WO2016077397A2 (en) 2016-05-19
WO2016077397A3 (en) 2016-09-01
US20180142022A1 (en) 2018-05-24
EP3218409A2 (en) 2017-09-20
US10822414B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
US20210107981A1 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
US20220340680A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US20210403558A1 (en) Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
US20220135689A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
US20190330336A1 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
US20220098312A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
US11453720B2 (en) Anti-TIGIT antigen-binding proteins and methods of use thereof
US20240368295A1 (en) Anti-bcma antibodies and treatment methods
US20220106401A1 (en) ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES
US20190233512A1 (en) Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION